The cardioprotective mechanisms of dietary flavonoids by Daubney, J
1 
 
THE CARDIOPROTECTIVE MECHANISMS 
OF DIETARY FLAVONOIDS 
 
 
 
JAMES DAUBNEY 
 
 
 
 
 
A thesis submitted in partial fulfilment of the 
requirements of Nottingham Trent University for the 
degree of Doctor of Philosophy  
 
 
July 2015 
2 
 
 
 
 
 
 
This work is the intellectual property of the author. You may copy up to 5% of this work 
for private study, or personal, non-commercial research. Any re-use of the information 
contained within this document should be fully referenced, quoting the author, title, 
university, degree level and pagination. Queries or requests for any other use, or if a 
more substantial copy is required, should be directed in author. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
 
Proceedings and Publications 
 
Data from this thesis has been published in Basic & Clinical Pharmacology & Toxicology, 
and has been presented at the 6th Annual School of Science and Technology Research 
Conference held by Nottingham Trent University (2012).  
 
• Daubney J, Bonner PL, Hargreaves AJ and Dickenson, JM (2015) Cardioprotective 
and Cardiotoxic Effects of Quercetin and Two of Its In Vivo Metabolites on 
Differentiated H9c2 Cardiomyocytes, Basic & Clinical Pharmacology & Toxicology, 
116, 96–109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
Abstract  
Mitotic rat embryonic cardiomyoblast-derived H9c2 cells are widely used as a model 
cardiomyocyte to study the protective mechanisms of dietary flavonoids, but they lack 
features of fully differentiated cardiomyocytes. Therefore, this present study aimed to 
investigate the cytoprotective and cytotoxic effects of the dietary flavonoids quercetin, 
kaempferol, myricetin and two major quercetin metabolites, quercetin-3-glucoronide and 
3’-O-methylquercetin, on fully differentiated H9c2 cells for the first time. The 
cardiomyocyte-like phenotype of the differentiated H9c2 cells was confirmed by 
monitoring the expression of cardiac specific troponin T, as well as through the 
identification of other cardiac specific cytoskeletal markers using MALDI-TOF MS/MS. The 
cytoprotective effect of quercetin, kaempferol, myricetin, quercetin-3-glucoronide and 3’-
O-methylquercetin against hypoxia and H2O2-induced cell death was assessed by 
monitoring MTT reduction and LDH release. Furthermore the effect of quercetin pre-
treatment on ERK1/2, PKB, JNK and p38 MAPK phosphorylation was monitored using 
western blotting. It was shown that quercetin was the most potent flavonoid at inducing a 
protective effect, and 3’-O-methylquercetin the most potent metabolite. Using western 
blotting it was shown that this protective effect is most likely due to quercetin-mediated 
inhibition of ERK1/2, PKB, JNK and p38 MAPK. Specific inhibitors of these protein kinases 
did not modulate the observed cytoprotective effect, or cause significant protection alone. 
The cytotoxic effects of dietary flavonoids, particularly quercetin, was monitored with MTT 
reduction, LDH release, western blotting to monitor phosphorylation of ERK1/2, PKB, JNK 
and p38 MAPK and activation of caspase-3, and monitoring intracellular ROS generation 
with DCFDA assay. The cytotoxic effect of quercetin was shown to be linked to intracellular 
ROS generation, caspase-3 activation and phosphorylation of ERK1/2, PKB, JNK and p38 
MAPK. MALDI-TOF MS for the first time identified several proteins associated with the 
flavonoid-mediated cytoprotective effect and flavonoid pre-treatment in differentiated 
H9c2 cells. Most were shown to be linked to the regulation of MAPK and PI3K cell signalling 
pathways. This present study for the first time demonstrates the cytoprotective and 
cytotoxic effects of flavonoids on differentiated H9c2 cells, and has identified novel 
proteins associated with the cytoprotective effect.  
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1.0 Introduction 
1.1 Cardiovascular disease 
In the developed world cardiovascular disease is the leading cause of death. In 2011 alone 
cardiovascular disease was responsible for approximately 160,000 deaths in the United 
Kingdom (British heart foundation). Factors such as diet, alcoholism, lack of exercise, 
smoking and longer life expectancy have led to an increased risk of cardiovascular disease 
in developed nations. Cardiovascular disease is also the leading cause of premature death 
of adults in the United Kingdom. Atherosclerotic plaques or thrombi causing a blockage of 
the coronary arteries is the major cause of ischaemic heart disease (coronary heart disease). 
This blockage causes a decrease in blood flow to the myocardium resulting in the 
myocardial tissue experiencing ischaemia. This ischaemia can lead to angina pectoris and 
myocardial infarction. Cardiovascular disease represents a significant burden to health 
authorities worldwide as risk factors and the overall age of the population increases, thus 
plentiful research on protection from ischaemia has been conducted. The potential 
protective effect of flavonoids against ischaemia in general and ischaemic heart disease in 
particular is still being studied. Flavonoids represent an interesting avenue in combating 
ischaemic heart disease, since they are already a ubiquitous component in the human diet, 
and some varieties are already available as dietary supplements. The interactions of 
flavonoids with the complex cellular mechanisms involved in ischaemia and 
cardioprotection could identify potential targets for prophylactic therapy against 
cardiovascular disease, and therefore reduce the overall burden of cardiovascular disease 
on the human population. 
1.2 Ischaemia induced cell death 
Adequate oxygen supply is vital for normal functioning of cardiac tissue. During an 
ischaemic attack the reduced availability of oxygen can lead to impaired contractile ability 
and cell death (de Moissac et al, 2000). This cell death can be divided into two classes, 
namely apoptosis and necrosis. Apoptosis is a “programmed cell death” where the cell 
destroys itself to minimise the leakage of cellular content into the extracellular 
microenvironment. Apoptosis is identified by nuclear condensation, fragmentation of 
chromosomal DNA and packaging the cellular content into apoptotic bodies, as well as 
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zeiosis of the plasma membrane. In vivo these apoptotic bodies are then recognised and 
phagocytosed, thus minimising the inflammatory response of the surrounding tissue. 
Apoptosis can be characterised by the activation of caspases (cysteine-
dependent aspartate-directed proteases), cell death by apoptosis also requires ATP 
(Edinger and Thompson, 2004).  
A number of studies have shown that hypoxia is able to induce apoptosis in a number of 
cell lines. Hypoxia has been shown to induce apoptosis via the activation of cytochrome c, 
which goes on to activate caspases, in Jurcat cells (Malhotra et al, 2001). The study by 
Malhotra, et al (2001) specified the involvement of caspase-3 in hypoxia mediated 
apoptosis in Jurcat cells. In adult rat cardiomyocytes caspase-3 was shown to be activated 
by mitochondrial cytochrome c and specifically target the DNA repair enzyme PARP (poly 
ADP ribose polymerase), which when cleaved results in the fragmentation of DNA and 
apoptosis (de Moissac et al, 2000). It has also been suggested that a caspase-independent 
pathway for apoptosis exists in certain cell lines (Malhotra et al, 2001). Overall there is 
strong evidence that ischaemia induces apoptosis in cardiomyocytes. 
In opposition to the programmed cell death of apoptosis, necrosis has been described as a 
passive form of cell death, as well as it being much less concerned with contamination of 
the extracellular microenvironment with cellular debris. Necrosis results from a 
“bioenergetics catastrophe” where ATP levels are depleted to such a level to become 
incompatible with cellular life (Edinger and Thompson, 2004). Specifically during ischaemia 
the reduced availability of oxygen, other metabolites, and important sources of energy 
such as glucose, that would normally arrive via the blood stream become so depleted as to 
be insufficient for normal oxidative phosphorylation. This triggers anaerobic respiration, 
which reduces the intracellular production of ATP and increases the intracellular 
accumulation of hydrogen ions (H+). This further leads to the intracellular accumulation of 
Sodium ion (Na+) via the inhibition of ATP-dependant sodium/potassium pumps (Na+/K+-
ATPase) and activation of sodium/hydrogen exchangers (NHE). Intracellular Calcium ions 
(Ca2+) are also accumulated by various mechanisms, including activation of Na+/Ca2+ 
exchangers and reduced uptake of Ca2+ by sarcoplasmic reticulum due to decreased ATP in 
myoctyes. Intracellular levels of Ca2+ go on to activate Ca2+-dependant proteases which 
damage cytoskeletal and membrane bound proteins. Cellular osmotic swelling also occurs 
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due to the influx of water and Cl- ions. The weakening of the cytoskeleton and cell 
membrane by the Ca2+-dependant proteases and influx of osmotic swelling leads to 
membrane rupture and necrosis. This particular ischaemic cell death mechanism is mostly 
referred to as necrosis, but has been more specifically named oncotic necrosis (Schaper 
and Kostin, 2005). Rather than being separated it is now believed that apoptosis and 
necrosis represent different outcomes of the same pathway. Initially apoptosis is favoured 
by cardiomyocytes in hypoxia, but when ATP levels are depleted to a low enough level 
necrosis takes over as the dominant form of cell death, since it is not dependent on energy 
derived from ATP (Tatsumi et al, 2003). The proposed pathway of ischaemic attack leading 
to cell death is outlined in Fig 1.1. 
In addition to apoptosis and necrosis a third cell death mechanism has been variously 
described, the theory of non-apoptotic programmed autophagy, or ‘Programmed Necrosis’ 
is gaining scientific momentum. A cell undergoing autophagy (self-digestion) forms a 
double membrane around organelles and cytoplasmic components, which then fuses with 
the lysozyme. This fusion leads to the digestion of the content of the vesicle, which are then 
recycled. It has been suggested that this mechanism can be used by the cell as a method of 
suicide, leading to the complete digestion of itself (Edinger and Thompson, 2004). 
Autophagy is generally thought to be a method of self-preservation, where the cell content 
is recycled during times of famine in certain mammalian cells, as well as in plants species, 
yeasts and nematodes. The debate as to if autophagy represents a viable form of 
programmed cell death is ongoing, but it goes to prove that the apoptosis-independent 
mechanisms of cell death do occur, and therefore provide a potential for therapeutic 
targets (Edinger and Thompson, 2004). 
   
 
 
 
 
 
15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1 Proposed scheme of events from ischaemia to cell death. Reduced oxygen and metabolic substrates 
leads to lack of ATP and intracellular acidosis. Cell swelling and damage leads to necrosis. (NHE: 
sodium/hydrogen exchangers). 
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1.3 Reactive oxygen species and cell signalling 
The intracellular environment in cells under normal condirions is highly reducing. Reactive 
oxygen species (ROS) such as superoxides and peroxides are generated as a by-product of 
mitochondrial metabolism, and are eliminated from the cell via internal cellular 
antioxidants, reductants and other scavengers (Kamata and Hirata, 1999). Despite this 
mechanism some production of the highly reactive OH· occurs, which can lead to damage 
to the cell via the Haber-Weiss and Fenton reactions (Kamata and Hirata, 1999).  These 
reactions can be artificially stimulated by adding H2O2 to the cellular environment. 
Oxidative stress caused by ROS has been shown to activate several cell signalling pathways, 
including Ras, the upstream activator of MEKs and the PI3K/Akt pathway. Furthermore 
oxidative stress can cause the activation of the caspases including caspase-3. Oxidative 
stress has a drastic effect on the intracellular regulation of Ca2+, causing an intracellular 
increase though the modulation of the activity of Ca+2-Na+ exchangers and Ca+2-ATPase 
(Kamata and Hirata, 1999).  
1.4 Pharmacological preconditioning 
 
The effect known as ischaemic preconditioning (IPC) was first described by Murry et al 
(1986). The group was able to successfully precondition in vivo canine hearts to long 
periods of ischaemia by briefly and repeatedly occluding the coronary artery.  This study 
showed that intermittent episodes of ischaemia resulted in a protective effect on the 
myocardium, visible upon histological inspection (Murry et al, 1986). It has since been the 
goal of many studies to recreate this effect pharmacologically. Studies have shown that a 
number of cell signalling pathways are associated with IPC, including MEK1/2, ERK1/2, RAS, 
PI3Kγ and AKT (Hausenloy and Yellon, 2007). It is known now that flavonoids are able to 
act upon these cell signalling molecules in a number of ways, this opens the possibility of 
using flavonoids as a cardioprotective agent. Given the ubiquitous nature of flavonoids in 
the human diet, they present a good prospect for pharmacological preconditioning of the 
heart in humans.    
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1.5 Cardioprotective properties of flavonoids 
 
Flavonoids, in particular quercetin, have been extensively reported to possess many 
pharmacological properties, including anti-proliferation effects on cancer cell lines, as well 
as a strong antioxidant effect. Quercetin also possesses a broad range of effects that 
promote its reported cardioprotective action, including anti-inflammatory, anti-platelet 
aggregation and anti-hypercholesterolemia effects. In the past it was thought the majority 
of quercetins cardioprotective effect was due to its potent antioxidant activity, but it is now 
also becoming evident that quercetin is able to modulate certain cell signalling pathways 
which may have an effect on the post-ischaemic survival of heart cells (Choi et al, 2005).  
   It has been shown that quercetin is able to bind to the ATP-binding sites of a large number 
of proteins which can cause competitive inhibition of these proteins (Williams et al, 2004). 
Proteins that have been shown to be inhibited by quercetin include proteins important to 
cell signalling pathways, such as protein kinase C (PKC), mitogen-activated protein kinase 
(MAPK) family proteins, Phosphoinositide 3-kinase (PI3Kγ) and myosin-light chain kinases 
(MLCK) (Russo et al, 2012). These cell signalling pathways are associated with cell survival, 
growth arrest and apoptosis. 
 
Supplementation with quercetin (730 mg/day) for 28 days has been demonstrated to cause 
a reduction in mean systolic, diastolic and arterial pressure in a cohort of patients suffering 
hypertension (Edwards et al, 2007). Similarly, a study on a cohort of overweight patients 
with high risk of cardiovascular disease showed that supplementation with 150 mg/day  
quercetin  for 42 days caused a reduction in systolic blood pressure, and reduced 
atherogenic-oxidised low density lipoproteins (LDL)(Egert et al, 2009). These studies show 
the diverse range of effects quercetin possesses with lead to cardioprotection. 
This body of work will focus on the effect flavonoids have on heart cells during ischaemic 
attack as a way to investigate the potential benefits of flavonoids on CVD development. 
Generally in vivo a number of other physiological events occur before damage to the heart 
cells develops due to ischaemia. These events, namely the development and progression 
of atherosclerosis, also have the potential to be effected by flavonoids.  
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Atherosclerosis is typified by the development of lesions, called atheromas or 
atherosclerotic plaques, located in the intimal layer of cells in the blood vessels. These 
lesions consist of a fatty core of lipids, mostly cholesterol, capped with a fibrous layer 
consisting of smooth muscle, macrophages, foam cells, collagen and elastins. These lesions 
lead to the mechanical obstruction of blood vessels which can lead to ischaemic attack, 
furthermore the lesion can rupture causing vessel thrombosis and aneurysm formation.  
There have been a number of risk factors identified with regard to developing 
atherosclerosis, these include hyperlipidaemia (hypercholesterolaemia), hypertension, 
tobacco smoking and diabetes (Chambless et al, 2002).  
Atherosclerosis has been characterised as a chronic inflammatory condition where healing 
responses in the endothelium of the artery lead to injury. The development of an 
atherosclerotic lesion follows a series of pathological events, starting with endothelial 
injury which leads to increased endothelial permeability and leukocyte adhesion. 
Lipoproteins, mostly in the form of LDL (low density lipoproteins) then accumulate in the 
vessel wall. Monocytes then migrate into the area and transform into macrophages and 
foam cells. Platelet adhesion, along with the presence of macrophages, then leads to factor 
release which induces smooth muscle cell recruitment. The smooth muscle in response 
proliferates and the ECM (extracellular matrix) production is increased. Finally lipids further 
accumulate leading to the formation of the lesion (Ross, 1999).     
The initial injury to the endothelium of the blood vessel is the keystone in the sequence of 
events that lead to the formation of the atherosclerotic plaque. The thickening of the 
intima can be a result of a range of different injurious stimuli, such as immune complex 
desposition, irradiation, chemical injury or haemodynamic forces. Coupled with high-lipid 
diets, this leads to the formation of the plaque. Furthermore, endothelial dysfunction is a 
key factor in the development of an atherosclerotic plaque, specifically regarding increased 
endothelial permeability and increased leukocyte adhesion. Currently the specific 
pathways and factors leading to this dysfunction are not fully understood, etiologic studies 
suggest hypertension, hyperlipidaemia, toxins from tobacco smoking and infectious agents 
are key factors. However, haemodynamic disturbance and hypercholesterolaemia are 
considered the main contributing factors.  
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The prominence of haemodynamic disturbance in the formation of atherosclerotic plaques 
is demonstrated principally by the observation that lesions tend to form at the branch 
points and the dorsal wall of the abdominal aorta where disturbed flow patterns of blood 
are common (Chatzizisis et al, 2007). 
The evidence implicating hypercholesterolaemia as a dominant factor in atherogenesis 
includes the observation that cholesterol and cholesterol esters form the dominant lipids 
in atherosclerotic plaques. Furthermore, disorders that cause hypercholesterolaemia, such 
as diabetes and hypothyroidism, lead to premature atherosclerosis. The mechanism by 
which hypercholesterolaemia is thought to contribute to atherogenesis is mainly due to 
increasing oxygen free radical production, which leads to tissue injury and decreased 
vasodilatory action due to accelerated nitric oxide decay. Furthermore, lipids that are 
accumulated in the intima are oxidised in the presence of the oxygen free radicals 
generated by macrophages and the endothelium. The oxidised LDLs are then phagocytised 
by macrophages, accumulate and form foam cells. Oxidised LDL also stimulates the release 
of cytokines, chemokines and growth factors that lead to increased amassing of monocytes. 
Endothelial cell dysfunction is further stimulated by oxidised LDL as it has a cytotoxic effect 
on smooth muscle and endothelial cells (Gau et al, 2006).      
Progression of atherosclerotic lesions is also heavily influenced by inflammatory cells and 
pathways. dysfunctional endothelial cells express adhesion molecules that encourage 
immune cells adhere. Once adhered to the endothelium these immune cells are able to 
migrate into the intima, attracted by locally produced chemokines. The differentiation of 
monocytes into macrophages and foam cells is considered protective as this removes 
harmful lipid particles. However oxidised LDL augments the macrophages leading to more 
leukocyte adhesion and chemokine production, leading to mononuclear cell infiltration. 
Activated macrophages also produce ROS that increase LDL oxidation. The recruitment of 
T-lymphocytes to the intima can generate a chronic inflammatory state by producing pro-
inflammatory cytokines when they interact with the macrophages, the exact reason for this 
remains unknown. Furthermore activated leukocytes and the cells of the vascular wall 
release growth factors that lead to smooth muscle proliferation and ECM synthesis 
(Hansson, 2005). 
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Flavonoids, in particular quercetin and its metabolites, have been demonstrated to have 
anti-atherogenic properties in a number of studies. Flavonoids are known to inhibit LDL 
oxidation, inhibit platelet aggregation and adhesion, have a detrimental effect on the 
uptake of lipids into macrophages, induce vasodilation and lower LDL cholesterol (Reed, 
2002). Specifically, quercetin and quercetin-3-glucoronide have  been demonstrated to 
prevent endothelial dysfunction in vitro at 1 μmol/L (Lodi et al, 2009). Similarly, quercetin 
and the glucornidated metabolite was able to prevent ROS release at concentrations less 
than 10 μmol/L in aortic smooth muscle cells in culture (Lodi et al, 2009). Quercetin was 
found to modulate the effect of inflammatory enzymes such as cyclooxygenase, 
lipoxygenases, myeloperoxidase and nitric oxide synthase in rabbits with a 
hypercholesterolemic diets when administered at 25mg/kg body weight (Bhaskar et al, 
2013). Quercetin was also demonstrated to modulate PKC activity induced by superoxide 
production and endothelial dysfunction in rat aortas (Romero et al, 2009).  
Various studies have demonstrated how quercetin and its metabolites effect atherogenesis. 
In the diet, these flavonoids will lead to a decreased risk of atherosclerosis and therefore a 
decreased risk in overall CVD, representing a significant mechanism of cardioprotection. In 
this present study the protective effects of flavonoids were investigated with regard to 
heart cells, to further elaborate on the effects of flavonoids on the progression of CVD in 
general.   
1.6 Flavonoids 
Flavonoids are a diverse family of plant metabolites, which form a ubiquitous part of the 
human diet. Over 4000 types of flavonoids have been identified, and can be found in the 
leaves, bark, fruits, seeds and flowers of many plants (Hiem, et al, 2002). The intake of 
flavonoid in the human diet varies by region, and with cultural practices such as drinking 
tea or wine also having an influence. The average daily flavonoid intake in a western 
developed nation has been reported to be approximately 23 mg (Hiem, et al, 2002). Many 
years of research has been dedicated to the investigation of the antioxidant capacity of 
flavonoids, and their ability to protect cells from damage from oxidative stress. Recent 
studies have also been concerned with the potential ability of flavonoids to interact directly 
with cell signalling molecules that also play a role in the survival of cells after oxidative 
stress. 
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1.7 Flavonoid structure 
Flavonoids are all based on a standard central structure called the flavan nucleus (Fig 1.2). 
Subtypes of flavonoid are classified by the substitutions on this standard structure. Dietary 
flavonoids differ by the number and arrangement of hydroxyl, methyl and glycosidic groups 
on the central flavan nucleus. Tannins, a related chemical to flavonoids, are formed by the 
polymerisation of the underlying flavan nucleus.  
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Fig. 1.2 The flavan nucleus.  
The structure of flavonoids, being polyphenolic, gives the molecule great antioxidant 
capacity, as well as the potential to influence cell signalling. Research suggests that the 
number and arrangement  of hydroxyl group substitutions effects the antioxidant capacity 
of flavonoids in a positive way. Particular substitutions such as hydroxyl groups on position 
3 and 5 of the A ring and C2-C3 double bonding result in higher antioxidant activity (Chang 
et al, 2007). There are a number of subtypes of flavonoid, all based on the underlying flavan 
nucleus structure.  
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Class Example 
flavonoid 
Structure Dietary 
source 
Flavanol (+)-catechin 
O
OH
OH
OH
OH
HO
 
Tea 
Flavone Rutin 
O
OH
HO
O
OH
OH
O
O
OH
OH
HO
O
O
H3C
HO
OH
OH
 
Red wine, 
Buckwheat, 
tomato skin, 
Citrus 
Flavonol Quercetin 
O
OH
OH
OH
OH
HO
O  
Onion, 
lettuce, 
broccoli, 
Tomato, tea 
red wine, 
berries, olive 
oil, apple skin  
Flavanone Naringenin 
O
OH
OH
HO
O  
Citrus 
(Grapefruit) 
Isoflavone Genistin 
O
OH
OOH
O
O
OH
HO
HO
OH
 
Soybean 
Anthocyanidin Cyanidin 
O+
OH
OH
HO
OH
OH
 
Cherry, 
Raspberry, 
strawberry 
Table 1.3 Classes of flavonoid and their associated structure (Hiem, et al, 2002). 
Certain subtypes of flavonoid generally possess specific structural traits, for example 
flavanols all exhibit hydroxyl groups on the 3,5,7,3’ and 4’ locations on the flavan nucleus. 
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This particular subtype contains molecules such as (-)-epicatechin which is found in high 
quantities in tea (Heim, 2002).    
1.8 Quercetin 
Quercetin, a member of the flavonol subfamily, is one of the most frequently researched 
members of the flavonoid family. It has been shown to exhibit a structure that is both an 
effective antioxidant and a potent effector of cell signalling molecules.  The structure of 
quercetin is based on the flavan nucleus, with hydroxyl groups on the 3,5,7,3’ and 4’ 
carbons and a ketone group located on the at position 4 of the C ring of the flavan nucleus, 
as shown in Fig. 1.4. 
Quercetin has been demonstrated to be able to bind directly to the ATP binding pocket of 
some enzymes, this ability is directly linked to the hydroxyl group substitutions on the B 
ring of the flavonoid, as well as an unsaturated C2-C3 bond (Williams et al, 2004). Quercetin 
has been found to be one of the most abundant flavonoids in the human diet and is found 
in high levels in red wines, tomatoes, red berries, certain teas and onions. Naturally, it is 
responsible for the red pigmentation in a wide variety of plants, in its pure form it has a 
yellow coloration due to the ketone group on position 4 of the C ring of the flavan nucleus.  
O
OH
OH
OH
OH
HO
O  
Fig. 1.4 Structure of quercetin. Based on the flavan nucleus with hydroxyl groups on the 3,5,7,3’ and 4’ 
carbons, a ketone group located on the at position 4 of the C ring of the flavan nucleus. 
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1.9 Kaempferol 
Kaempferol is a flavonol, and is found in high levels in kale, broccoli, chives and other green 
plants (Choi, 2011). Studies have demonstrated that kaempferol can inhibit the 
phosphorylation of JNK and p38 MAPK in several cell lines, resulting in prevention of 
oxidative stress and apoptosis (Mansuri et al, 2014). Like quercetin, kaempferol has been 
shown to have antioxidant and cell signal modulating activities. Structurally, kaempferol 
has hydroxyl groups on the 4’, 3, 5 and 7  positions of the flavan nucleus with an 
unsaturated C2-C3 bond, and a ketone group located at position 4 of the C ring of the flavan 
nucleus, as shown in Fig. 1.5. This unsaturated bond, similar to quercetin, may allow 
kaempferol to bind directly to ATP binding pockets of some enzymes (Williams et al, 2004).   
 
O
OH
OH
OOH
HO
 
 
Fig 1.5 Structure of kaempferol.  
1.10 Myricetin 
Myricetin has been found to act as a direct antioxidant and also acts to induce antioxidant 
enzyme expression, specifically catalase (Wang et al, 2010). Myricetin has also been shown 
to directly interact with the PI3K/Akt and MAPK pathways (Kyoung et al, 2010). Myricetin 
can down-regulate the phosphorylation of p38 MAPK and JNK, suggesting anti-apoptotic 
effects (Mansuri et al, 2014). Structurally similar to quercetin and kaempferol, myricetin 
has hydroxyl groups on the 3’, 4’, 5’, 3, 5 and 7 positions of the flavan nucleus with an 
unsaturated C2-C3 bond, and a ketone group located at position 4 of the C ring of the flavan 
nucleus, as shown in Fig. 1.6.   
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Fig. 1.6 Structure of myricetin.  
1.11 Bioavailability of flavonoids 
Given the ubiquity of flavonoids in plants, flavonoids form a universal non-nutritious 
element of the human diet. They are particularly concentrated in luxury products such as 
red wine, chocolate and tea. The flavonoid content can be as high as 21.6 μM in chocolate 
and 14.3 μM in certain varieties of red wine (Pimentel et al, 2008). Consumption of 
flavonoids by humans varies for a number of geographical, cultural and economic reasons. 
The consumption of a wide variety of fruits and vegetables will be the leading contributor 
to dietary flavonoid intake. Using Japan as an example, daily consumption of quercetin 
specifically was estimated to be 16.2 mg/day based the consumption of common foods in 
the Japanese diet containing quercetin, such as onions, asparagus and lettuces (Nishimuro 
et al, 2015). Although based in Japan, these estimates could be applied to a balanced 
western diet, given that the majority of foods used to create the estimate are widely 
available. Furthermore, the estimate produced by Nishimuro et al (2015) does not take into 
account the consumption of wine. In the west the consumption of onions is the biggest 
contributor to flavonol (quercetin and kaempferol) intake, containing approximately 120-
160 mg/100 g (Peluso and Palmery, 2015). Average dietary consumption of kaempferol is 
slightly lower, and ranges from 2 – 11 mg/day (Calderón-Montaño et al, 2011). Dietary 
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intake of myricetin, principally from tea consumption, has been found to be 1.4 mg/day 
(Geybels et al, 2012).  
Despite the ubiquitous nature of flavonoid in the human diet, the bioavailability is further 
dependent on the absorption and metabolism of the flavonoids. Firstly the flavonoid is 
absorbed through the small intestine. Flavonoids from the diet usually possess a saccharide 
group, making them a glycoside. These must be first deglycosilated prior to absorption into 
the blood. This reaction is catalysed intracellularly by the enzyme β-glucosidase. The loss 
of the sugar moiety increases the hydrophobicity of the flavonoid, allowing them to pass 
through the epithelial cells. However, in some cases, glycosylated flavonoids are actively 
transported through the cell by glucose transporter proteins (Viskupičová et al, 2008). 
Flavonoids, specifically quercetin and its metabolites, are known to enter cells by both 
passive diffusion and active transport via organic anion transporters (Glaeser et al, 2014). 
Although because of the lack of specific transporters the majority of flavonoid enters cells 
passively, with hydrophobic flavonoids more able to cross cellular membranes (Barnes et 
al, 2011). A further regulator of flavonoid absorption is intestinal efflux, where various 
membrane transport proteins transport flavonoid back into the intestinal lumen. Quercetin 
specifically is thought to be transported out of the intestinal epithelium by multidrug-
resistance protein 2 (MRP 2), the mechanism of intestinal absorption and metabolism is 
shown in Fig. 1.7. Quercetin is transported very efficiently back into the intestinal lumen, 
and therefore intestinal efflux is a major factor in the bioavailability of quercetin for the 
rest of the organs in the body (Viskupičová et al, 2008).  
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Fig 1.7 Mechanism of Intestinal flavonoid absorbtion and metabolism. The transport of the flavonoid is 
facilitated by MRP1 & 2 (Multidrug resistance protein) and SGLT (Sodium-dependent glucose transporter). 
βG; β-Glucosidase, LPH; lactase phloridzin hydrolase (Adapted from Kanazawa, 2011).  
In a study using radiolabelled quercetin, after ingestion the absolute availability of 
quercetin in humans was estimated at 44.8 %, although this was likely enhanced by the 
experimental presence of ethanol (Guo and Bruno, 2015). In a separate study participants 
ingested 10 mg quercetin aglycone in a grape drink, and the average maximum plasma 
concentration was shown to be 0.16 µM, approximately 1.4 % of the ingested flavonoid. 
When sourced from onions (containing approximately 100 mg quercetin) the maximum 
plasma concentration of quercetin was approximately 6.4 % of the dose (Guo and Bruno, 
2015). In a similar study using onions as a dietary source, a peak concentration of quercetin 
and its metabolites was observed to be 7.6 µM after a meal of onions containing the 
equivalent of 100 mg quercetin (Labbé et al, 2009). After administration in a liquid medium 
a maximum plasma concentration of 2.01 µM quercetin aglycone was achieved. Similarly, 
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when in an alcoholic medium a maximum plasma concentration of 3.44 µM quercetin 
aglycone was achieved (Guo and Bruno, 2015). These observations demonstrate that  the 
form in which the quercetin is injected has a dramatic effect on the maximal plasma 
concentrations observed, and with the observation that ethanol increases the maximal 
plasma concentration, wine consumption could contribute to a higher flavonoid plasma 
concentration achieved (Guo and Bruno, 2015). Furthermore, the half-lives of quercetin 
metabolites, which range from 11 – 28 h, favours the theory that plasma concentrations of 
flavonoids could increase due to accumulation with repeated intakes, as would be the case 
with dietary intake (Labbé et al, 2009).   
Once absorbed into the blood the flavonoids are transported to the liver via the portal vein 
to undergo extensive metabolism before they enter the systemic blood stream.  In the liver 
the flavonoid can undergo a number of different metabolic changes, the most common of 
which are hydrolysis, oxidation, reduction or conjugation with one of several possible 
moieties; either sulphate, glucuronate or O-methyl groups.  Of these possibilities 
conjugation with glucuronic acid or sulphate groups are reported to be the most common. 
As well as taking place in the liver, glucoronidation of the flavonoids can also occur in the 
small intestine. This reaction is catalysed uridine-5’-diphosphate glucuronosyltransferases 
(UGTs) and is very efficient.   
 
A small proportion of the dietary flavonoids are not absorbed in the small intestine, and 
instead move on to the colon. In the colon flavonoids can be extensively metabolised by 
the native microflora (Serra et al, 2012).  
Once arrived at the target cells via the blood and diffused into the target cells flavonoids 
can then be subjected to further intracellular metabolism that converts the metabolite 
forms of the flavonoid back to the native aglycone. The enzyme β-Glucuronidase, located 
in the endoplasmic reticulum and lysosomes of cells, has been demonstrated to have a 
key role in the metabolism of flavonoids. Specifically it has been demonstrated to free the 
aglycone form of luteolin from its glucoronidated metabolite (Shimoi et al, 2001). 
Intracellular accumulation of quercetin and 3’-O-methylquercetin has been demonstrated 
previously in mitotic H9c2 cells. Peak intracellular quercetin levels were measured at ≈ 2 
nmol/mg protein, which was achieved in mitotic H9c2 cells after 1 h of exposure to 30 µM 
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quercetin (Angeloni et al, 2007). Interestingly, ≈ 1 nmol/mg protein of  3’-O-
methylquercetin was observed after 24 h exposure to 30 µM 3’-O-methylquercetin 
(Angeloni et al, 2007). These findings highlight the potential for cell in general, and H9c2 
cells in particular, to accumulate flavonoids and their metabolites during constant 
exposure. This accumulation may play an important role in the protective effect of 
flavonoids in vivo, as relatively high concentrations of flavonoid may be present 
intracellularly due to the constant exposure of cells to flavonoids from the diet.     
Once absorbed the flavonoids will eventually undergo excretion. Quercetin is mainly 
eliminated from the body via the bile in the form of its two major metabolites, 3’-O-
methylquercetin (3',4',5,7-tetrahydroxy-3-methoxyflavone)  and quercetin-3-glucoronide, 
the structures of which are shown below in Fig. 1.8 (Viskupičová et al, 2008). 
 
  
 
 
 
 
 
 
 
 
 
Fig 1.8 Major quercetin metabolite structures. A) quercetin-3-glucoronide B) 3’-O-methylquercetin. 
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1.12 Pro-oxidant intracellular metabolism of quercetin 
The structure of quercetin is an indicator of its antioxidant ability, which is believed to 
contribute to its cardioprotective effect in addition to modulation of cell signalling cascades. 
Conversely the intracellular metabolism of quercetin into the proxidants quinone and 
semiquinone could potentially increase intracellular ROS and lead to adverse effects 
(Metodiewa et al, 1999). The generation of intracellular ROS by oxidative degradation of 
quercetin and quinone reduction has been previously identified as concentration 
dependent.  
O
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Fig. 1.9 Intracelluar metabolism of quercetin leading to proxidant products. A summary of the intracellular 
ROS scavenging activity resulting in the formation of semiquinone and quinone from quercetin, 
stoichiometry not shown. (abbreviations: GSH; reduced Glutathione. LPO; Lactic peroxidase. DT-
diaphorase; NAD(P)H quinone oxidoreductase.) (Metodiewa et al, 1999). 
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As shown in Fig. 1.9, quercetin is converted to o-semiquinone in the presence of H2O2 and 
catalysed by LPO. o-semiquinone, containing oxygen radicals can then go on to cause 
potentially cytotoxic activities. Some o-semiquinone is converted back into the parent 
molecule quercetin, the remainder going on to be converted into o-quinone. In the 
presence of oxygen, o-semiquinone can also produce O2 •- superoxide and o-quinone. The 
O2 •- superoxide can then go on to produce more o-semiquinone from quercetin with an 
additional H2O2 production. Furthemore the O2 •- superoxide can react with o-semiquinone 
to form o-quinone and H2O2. o-semiquinone can also form o-quinone with the biological 
reducing agent GSH, form during the reduction reaction from GS•. This GSH can go on to 
form quercetin from o-semiquinone resulting in GS• in a reversible reaction. In addition, 
GSH can go on to form GS• and H2O2 in the presence of H+ ions (Metodiewa et al, 1999). 
These intracellular reactions illustrate that in the presence of oxygen, quercetin can give 
rise to the prooxidant products o-semiquinone and o-quinone. The major quercetin 
metabolite 3’-O-methyl quercetin can also undergo intracellular demethylation to form 
quercetin, which then goes on to participate in the scavenging of ROS. Eventually, GSH 
conjugates with o-quinone to form 2’-glutathionyl quercetin which, along with other 
unknown potentially prooxidant intermediates, is exported from the cell and excreted 
(Spencer et al, 2003). 
 
1.13 MAPK proteins 
 
The MAPK cell signalling pathway is involved in most aspects of cell biology, and is essential 
for proper cell function. It is a family that encompasses important proteins such as 
extracellular signal-regulated protein kinase 1 & 2 (ERK1/2), p38 MAPK and c-Jun N-
terminal kinase (JNK).  It is well associated with essential cell functions such as adhesion, 
differentiation, proliferation and cell survival. 
 
ERK1 and ERK2 are a pair of proteins that share 84 % protein sequence as well as most, if 
not all functions, thus it is common that they are referred to as ERK1/2. They are a 
ubiquitously expressed non-receptor protein, integral to the MAPK signalling cascade.  
ERK1/2 is activated by a signalling cascade that starts with H-Ras, K-Ras and N-Ras, which 
are produced in response to mitogenic stimuli. H-Ras, K-Ras and N-Ras then convert Ras-
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GDP to Ras-GTP. Ras-GTP then goes on to activate the Raf kinase family of proteins (A-, B- 
and C-Raf), which specifically catalyse the phosphorylation of MEK1 and MEK2. MEK1 and 
MEK2 phosphorylate the tyrosine and threonine in ERK1/2, which activates ERK1/2. The 
phosphorylated ERK1/2 can then act upon a number of its 175 cytoplasmic and nuclear 
substrates (Roskoski, 2012). Quercetin has been shown to be able to bind to the activation 
loop of MEK1 at pharmacologically relevant concentrations (1-2  µM).  
 
Studies on the cardioprotective mechanisms of flavonoids often monitor the 
phosphorylation of ERK1/2 as it is known to be a pro-survival cell signalling molecule. 
Previous studies using mitotic H9c2 cardiomyoblast cells have shown that the modulation 
of MAPK pathways and PI3K/Akt pathways by quercetin has a cardioprotective effect 
against oxidative stress (Angeloni et al, 2007).    
 
The MAPK, specifically the Raf-1/MEK/ERK1/2, pathway has been shown to be associated 
with proliferation of cardiac smooth muscle cells through mitogens such as 5-HT and 
platelet derived growth factor, and is also involved in cardiac injury. Hypoxia is known to 
cause phosphorylation of ERK1/2 in both rat and human cell lines (Morecroft et al, 2011). 
Furthermore, unopposed activation of ERK1/2 is a major contributing factor to hereditary 
pulmonary arterial hypertension. The activation of the Raf-1/MEK/ERK1/2 pathway is 
proposed to be linked with the activation of the PKCζ, particularly during hypoxia.  
The Raf-1/MEK/ERK1/2 pathway is highly regulated, particularly during hypoxia. The 
enzyme PEBP-1 (Phosphatidylethanolamine-binding protein 1) also known as RKIP (Raf 
kinase inhibitor protein) has been identified as one of the regulatory mechanisms of the 
Raf-1/MEK/ERK1/2 pathway during hypoxia (Morecroft et al, 2011). The unregulated 
phosphorylation of ERK1/2 during hypoxia, in PEBP-1 knockout mice, was shown to cause 
more drastic symptoms of pulmonary arterial hypertension, suggesting that inhibition of 
ERK1/2 is cardioprotective (Morecroft et al, 2011). Both Raf and MEK protein kinases are 
specific inhibition targets of quercetin, and has been shown to be a more efficient inhibitor 
of MEK than the specific inhibitor PD098059 (Russo et al, 2012). It is proposed that 
quercetin forms a hydrogen bond with ser212 in the MEK backbone, which causes an 
inactive form of the protein to stabilise. The inhibition of MEK would consequently lead to 
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decreased phosphorylation of ERK1/2, p38 MAPK and JNK, causing a cardioprotective 
effect (Russo et al, 2012). Pharmacologically relevant (2 µM) concentrations of quercetin 
are also known to be a potent inhibitor of 16 other kinase family enzymes involved in the 
cell cycle, and is able to cause arrest in the G2/M or G1 phase of the cell cycle (Russo et al, 
2012).   
JNK, also known as stress-activated protein kinase (SAPK), is a regulator of several cellular 
processes including apoptosis. Its pro-apoptotic action is thought to be mediated though 
the regulation of c-Jun and activated protein 1 (AP1). Similarly p38 MAPK is known to be 
involved in apoptosis. Activation of p38 MAPK occurs in response to a number of cellular 
stresses (Mansuri et al, 2014). A summary of the MAPK pathway, with particular regard to 
ERK1/2, JNK and p38 MAPK is shown below in Fig. 1.10.  
 
Fig. 1.10 ERK1/2, JNK and p38 MAPK cascades. MEK1/2 leads to the activation of JNK, ERK1/2 and p38 
MAPK, which catalyses the phosphorylation of proteins in the cytoplasm and nuclear transcription factors 
(adapted from Roskoski, 2012). 
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1.14 PI3K/Akt pathway 
The PI3K/Akt pathway is a strong intracellular pro-survival system, that is known to be 
modulated by flavonoids and their metabolites (Mansuri et al, 2014). The pathway 
regulates a variety of cell functions including survival, division, differentiation and 
transformation. Phosphoinositol 3-kinsases (PI3Ks) catalyse the reaction that transfers the 
γ-phosphate group from ATP to the hydroxyl group at the 3’ position of three substrates; 
phosphatidylinositol (PI), phosphatidylinositol-4-phosphate (PI4P) and 
phosphatidylinositol-4,5-bisphosphate (PIP2). PI3K signalling modulates many cellular 
processes, such as cell growth, differentiation, motility, gluconeogenesis and glycolysis.   
PI3Ks can be grouped into 3 classes. Class I PI3Ks catalyse PIP2 to PIP3 (Phosphatidylinositol 
(3,4,5)-trisphosphate), and can be further divided based on their activation pathway. The 
conversion of PIP2 to PIP3 is regulated by the lipid phosphatase PTEN (Phosphatase and 
tensin homolog) (Mendoza et al, 2011). Class 1A are activated through tyrosine kinases 
(RTKs) and class 1B through G protein-coupled receptors (GPRCs) Class II PI3ks regulate 
membrane trafficking through clathrin-coated vesicles, and Class III PI3Ks produce PI(3)P 
and have a role in autophagy.  
Structurally, class I PI3Ks consist of two subunits, regulatory and catalytic. The regulatory 
subunit binds to intracellular RTK phosphotyrosine residues or adaptor proteins, which 
leads to the relieving of intramolecular inhibition of the catalytic subunit and localises the 
catalytic subunit near the plasma membrane and its PIP2  substrate. PI3K can also be 
stimulated by Ras which binds directly to the catalytic subunit (Mendoza et al, 2011). The 
RTK signal is propagated by PI3K products binding to specific regions of downstream target 
proteins such as FYVE zinc-finger, pleckstrin homology and phox-homology domains 
(Courtney et al, 2010). A major target of PI3K is AKT, also known as PKB, the complete 
activation of which requires duel phosphorylation by PDK1 (3-phosphoinositide dependent 
protein kinase-1) and mTORC2 (mechanistic target of rapamycin complex 2) (Mendoza et 
al, 2011). 
It is a false to assume that cell signalling pathways work in isolation, and there is significant 
cross-talk between pathways and many share common core signalling molecules, which 
can lead to inhibition of multiple pathways by one target (Rozengurt et al, 2010).  
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Cross-talk between cell signalling pathways can be summarised by four types of 
interactions: 1) negative feedback loop, where a downstream molecule of a pathway 
inhibits the activation of an upstream molecule from the same signalling pathway; 2) cross-
inhibition, where a core molecule of a pathway inhibits a core member of a different 
pathway; 3) cross-activation, where a core member of a pathway upregulates an upstream 
molecule of another pathway; 4) pathway convergence, two or more signalling pathways 
directly act on the same protein (Mendoza et al, 2011). Furthermore, pathways can exhibit 
all four or any combination of these interactions. 
There is a great deal of cross-talk between the MAPK/ERK and PI3K/AKT pathways. Firstly, 
both pathways can be activated through RTK or GPCRs, therefore cross-talk begins at the 
receptor level. Cross-inhibition between the MAPK/ERK and PI3K/AKT pathways has been 
observed when MAPK/ERK is inhibited, furthermore AKT and Ras can cross-inhibit when 
AKT is stimulated by IGF-1 (Insulin-like growth factor 1) (Mendoza et al, 2011). MAPK/ERK 
can activate the PI3K pathway through several means. Ras-GTP can directly bind and 
activate PI3K, and active ERK can phosphorylate TSC2 (Tuberous Sclerosis Complex 2) and 
promote the activity of mTORC1 (Mendoza et al, 2011).   Several core kinase components 
of the MAPK/ERK and PI3K/AKT pathway affect the same downstream targets, including 
FOXO3A (Forkhead box O3), BAD (Bcl-2-associated death promoter), c-Myc and GSK3 
(Glycogen synthase kinase 3) (Mendoza et al, 2011). 
Interestingly several pro-apoptotic and anti-apoptotic transcription factors can be 
activated by Akt/PKB. Flavonoids are known modulators of the PI3K/Akt pathway. 
Kaempferol has been demonstrated to protect MC3T3-E1 cells from toxicity by modulation 
of the PI3K/Akt pathway (Choi, 2011). Similarly myricetin induces cell survival via the 
PI3K/Akt pathway, after H2O2 induced cell death with 30 µM myricetin treatment (Kyoung 
et al, 2010).  
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Fig. 1.11 The PI3K signalling cascade. The cascade has many effects on cell growth, differentiation, survival 
and metabolic activity, and can be activated by both RTKs and GPCRs. Arrows indicate activiation, squared 
arrow heads represent inhibition. Abbreviations: RTK, receptor tyrosine kinase; GCPR, G-protein coupled 
receptor; P, phosphate; G, G-protein; PTEN, phosphatase and tensin homolog; PDK1, Pyruvate 
dehydrogenase lipoamide kinase isozyme 1. (Adapated from Courtney et al, 2010). 
 
1.15 H9c2 cells 
H9c2 is a rat embryonic cardiomyoblast-derived cell line (Kimes and Brandt, 1976). H9c2 
cells have been used in a large number of studies as a model system for the characterisation 
of cardioprotective mechanisms of flavonoids (Gutiérrez-Venegas et al, 2010; Angeloni et 
al, 2012; Angeloni et al, 2007; Sun et al, 2012; Kim et al, 2010; Mojzisová et al, 2009). These 
studies have all used the H9c2 cell line in its mitotic form which, although 
electrophysiologically and biochemically similar to cardiomyocytes, are not fully 
differentiated (Hescheler et al, 1991). In their mitotic form H9c2 cells lack some properties 
of cardiomyocytes, they do not fuse to form multinucleated myotubes nor do they express 
gap junctions (Hescheler et al, 1991). The loss of myotube formation is attributed to 
dedifferentiation due to increased passage number and time spent in cell culture. It is 
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notable therefore that this present study is currently unique in the use of differentiated 
H9c2 cells to investigate the cardioprotective effects of flavonoids. 
 
1.16 H9c2 cell differentiation 
H9c2 cells can be made to differentiate into a more cardiomyocyte-like phenotype in 
culture, by supplementation with all-trans retinoic acid (RA) in a medium with decreased 
(1 %) serum content (Ménard et al, 1999). The final differentiated form of H9c2 consists of 
fusing and forming thin, elongated, multinucleated myotubes . The differentiated cells also 
form a more organised linear structure, with well organised actin filaments. This final 
differentiated form of H9c2 cells is obtained by chronic treatment of the cells with RA, 
meaning the cells are exposed to fresh RA every 48 hours (Ménard et al, 1999). The 
differentiation of H9c2 cardiomyoblasts into the more cardiomyocyte-like phenotype is 
regulated heavily by PI3K (Kim et al, 1999). It has been demonstrated that external signals 
such as insulin, insulin growth factor 1 (IGF-1), epidermal growth factor etc. activate PI3K 
signalling cascades via p85. This activation of PI3K leads to the downstream activation of 
PKB/Akt, which is activated by binding with the PI3K products phosphatidylinositol-3,4-
bisphophate (PtdIns(3,4)P2), or phosphatydylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3). 
This signal is then further propagated by phosphorylation of serine/ threonine residues of 
other proteins (Kim et al, 1999). pPKCδ has also been shown to be involved in the 
differentiation of H9c2 cells, mostly by its interaction with SC35 (Zara et al, 2010). 
Interestingly it has also been reported that ERK1/2 is not involved in the differentiation of 
H9c2 cells, despite it being a downstream signal of PI3K (Kim et al, 1999). It is a combination 
of these crucial events that result in the downstream transcription of genetic components 
that lead to the changes in morphology relating to the differentiation into the 
cardiomyocyte-like phenotype. The similitude of the cardiomyocyte-like differentiated 
H9c2 cell to in vivo cardiomyocytes will provide for a better model for the study of flavonoid 
dependent cardioprotection compared to previous studies using the mitotic form of the 
cell. 
Some of the characteristics of differentiated H9c2 cells compared to the mitotic form have 
been described in various studies, mostly focussing on differences in cytoskeletal 
contractile proteins and morphological changes, other studies have described the 
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metabolic differences between differentiated and mitotic H9c2 cells (Pereira et al, 2011; 
Dangel et al, 1996; Branco et al, 2013). Table 1.12 provides a summary of the main 
differences observed between a number of studies.  
 
Table 1.12 Summary of the observed differences between differentiated and mitotic H9c2 cells. 
Differentiated H9c2 cells express cardiac muscle-specific cytoskeletal features, as well has having different 
metabolic activity and differing expression of certain receptors (Pereira et al, 2011; Dangel et al, 1996; 
Branco et al, 2013). 
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1.17 Aims of this project 
 
The aims of the present study can be surmised as four main aims: 
• To differentiate H9c2 cardiomyoblasts into a more cardiomyocyte-like phenotype, 
and characterise this phenotype using immunocytochemistry, western blotting and 
MALDI-TOF MS/MS. 
• To investigate the cytoprotective mechanisms of quercetin, myricetin, kaempferol, 
quercetin-3-glucoronide and 3’-O-methylquercetin against oxidative stress caused 
by H2O2 exposure or hypoxic incubation. 
• To investigate the cytotoxic activity of quercetin, myricetin, kaempferol, quercetin-
3-glucoronide and 3’-O-methylquercetin on mitotic, differentiated and 
differentiating H9c2 cells. 
• Use MALDI-TOF MS/MS to investigate proteomically the mechanism of flavonoid-
mediated cytoprotection and flavonoid exposure to differentiated H9c2 
cardiomyocytes.    
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Chapter 2: 
Materials and 
Methods 
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2.0 Methods 
2.1 Cell Culture 
Rat embryonic cardiomyoblast-derived H9c2 cells were obtained from the European 
Collection of Animal Cell Cultures (Porton Down, Salisbury, UK). Mitotic cells were cultured 
in 25 cm2 cell culture flasks in Dulbecco’s modified Eagle’s Medium (DMEM) supplemented 
with 10 % (v/v) Foetal Bovine Serum (FBS),  2 mM L-glutamine, penicillin (100 U/ml) and 
Streptomycin (100 µg/ml). Cell cultures were maintained in a humidified incubator at 37°C 
with a controlled atmosphere of 95 % air/5 % CO2 until 70-80 % confluence was observed 
under light microscopy. Cells were sub-cultured first by detaching using trypsin (0.05 % 
w/v)/EDTA (0.02 % w/v) in sterile phosphate buffered saline (PBS). Once detached cells 
were sub-cultured using a 1:5 split ratio.     
i) H9c2 cell differentiation 
Differentiation of H9c2 cells was induced by culturing the cells for 7 days in the continued 
presence of 10 nM all-trans retinoic acid in DMEM growth medium supplemented with 1 % 
(v/v) FBS. The differentiation medium was replaced every 48 h. The cells were observed to 
confirm differentiation to a cardiomyocyte-like phenotype by the formation of 
multinucleated elongated myotubes. The differentiation was further confirmed with 
western blotting and immunocytochemistry monitoring the expression of cardiac specific 
troponin T.  
2.2 Immunocytochemistry 
The expression of cardiac specific troponin T was monitored using immunocytochemistry. 
H9c2 cells were seeded into an 8 well chamber slide (BD Falcon™ CultureSlide) at a density 
of 15,000 cells/well and cultured in fully supplemented DMEM growth medium for 24 h. 
The growth medium was aspirated and replaced with differentiation medium and cultured 
for 7 days as described above.  The differentiation medium as then aspirated and adherent 
differentiated H9c2 cells were washed three times with 37°C PBS for 5 min each wash. Cells 
were then fixed using 3.7 % (v/v) paraformaldehyde (Sigma-Aldrich, UK) in PBS for 15 min 
at room temperature without agitation, then washed in PBS three times for 5 min each 
time. The cellular location of the troponin T being inside the cell, it is then necessary to 
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permeabilise the fixed cells. Permeabilisation of the cells was performed by incubation with 
0.1% (v/v) Triton X-100 in PBS for 15 min at room temperature without agitation, followed 
by three washes with PBS for 5 min each wash. Fixed cells were then incubated in 3% (w/v) 
bovine serum albumin (BSA) in PBS for 2 h at room temperature to prevent non-specific 
binding of antibodies. After blocking, cells were then incubated overnight at 4°C in a 
humidified chamber with anti-cardiac specific troponin T primary antibody (1:1000) in 3 % 
(w/v) BSA in PBS. The primary antibody was then removed and the cells washed in three 
times in PBS for 5 min each wash. Cells were then incubated for 2 h at 37°C in a humidified 
chamber with the secondary anti-mouse antibody (1:1000; Abcam, UK) which possesses a 
FITC (Fluorescein isothiocyanate) fluorescent dye conjugate in 3 % (w/v) BSA in PBS. The 
culture slides were then washed three times in PBS for 5 min and air dried. Cell culture 
slides were then mounted using Vectashield® mounting medium (Vector laboratories Ltd, 
Peterborough, UK) containing DAPI (4',6-diamidino-2-phenylindole) nuclear counterstain to 
allow for nuclear visualisation. The slides were cover-slipped and sealed using clear, 
colourless nail varnish and visualised (FITC:  EX493/EM528; DAPI: EX360/EM460) using an 
Olympus DP71 fluorescent microscope system, equipped with an argon/krypton laser.     
2.3 Oxidative stress and Hypoxia-induced cell death 
To induce oxidative stress, fully differentiated or mitotic H9c2 cells were incubated in fully 
supplemented DMEM growth medium containing 600 µM hydrogen peroxide (H2O2) for 2 
h at 37°C. Alternatively, hypoxic cell death was induced by incubating fully differentiated 
H9c2 cells in un-supplemented DMEM growth medium (containing no FBS or L-Glutamine) 
in a hypoxic incubator set at the following conditions; O2 0.5 %, CO2 5.0 %, 37 °C, for 24 h. 
To assess the cytoprotective effects of the flavonoids or flavonoid metabolite, H9c2 cells 
were pre-treated with quercetin (100 µM, 30 µM, 10 µM, 3 µM or 1 µM) for 24 h prior to 
hypoxia or H2O2 treatment in fully supplemented DMEM growth medium, which was 
removed and replaced with the appropriate assay medium after pre-treatment.         
Where appropriate cell were also pre-treated for 30 min with one of the following protein 
kinase inhibitors; LY 294002 (30 µM; PI3K inhibitor), Wortmannin (100 nM; PI3K inhibitor), 
PD 98059 (50 µM; MEK1/2 inhibitor), SB 203580 (30 µM; p38 MAPK inhibitor) or SP 600125 
(10 µM; JNK1/2 inhibitor) prior to the quercetin pre-treatments, with the continued 
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presence of the inhibitors during the quercetin pre-treatment. Cells were also treated with 
the inhibitors for 24 h followed by H2O2 treatment and viability assessment.    
2.4 Cell viability assays 
i) MTT assay 
The viability of the H9c2 cells in culture was assessed using the MTT (thiazolyl blue 
tetrazolium bromide, Sigma-Aldrich) assay. Undifferentiated H9c2 cells were seeded at a 
density of 15,000 cells per well in 24-well cell culture plates (Sarstedt, Leicester, UK) and 
incubated overnight at 37°C in fully supplemented DMEM growth medium. Cell were then 
induced to differentiate for 7 days using the H9c2 cell differentiation method described 
above. The cells were then treated according to the protocol of the particular experiment 
being undertaken. Cells were incubated for 1 h in 0.5 μg/ml MTT solution in DMEM (fully 
supplemented) at 37°C.  The medium in each well was aspirated, taking care to leave the 
blue, insoluble formazan crystals at the bottom of the well intact. The formazan crystals 
were dissolved in 500 μl of DMSO (dimethyl sulphoxide) and the plate was agitated to 
ensure sufficient dissolution of the crystals. After which, 200 μl of the resulting solution 
was transferred into a 96-well plate (Sarstedt, Leicester, UK) and the absorbance of the 
solutions was read at 570 nm using a standard 96-well plate reader. The absorbance of the 
blank was subtracted from each assay absorbance reading, the viability of the cells is then 
directly proportional to the magnitude of the MTT reduction determined by the absorbance 
at 570 nm. 
ii) Lactate dehydrogenase assay 
 
Lactate dehydrogenase (LDH) leakage was assed using the CytoTox 96® non-radioactive 
cytotoxic assay kit (Promega, Southampton, UK). This kit allowed LDH release to be 
measured via a coupled chemical reaction that leads to the production of a coloured 
formazan product. Firstly, LDH released from the cells catalyses the formation of pyruvate 
and NADH from lactate and NAD+. The secondary reaction is catalysed by the 
dehydrogenase enzyme diaphorase (present in the substrate mix in the kit), and involves 
the formation of NAD+ and a red formazan product from NADH and a tatrazolium salt. LDH 
release is proportional to the red formazan product. H9c2 cells where seeded into 96-well 
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plates at a density of 5000 cells/well, and cultured for 24 h in fully supplemented DMEM 
growth medium. Cells were then differentiated for 7 days in differentiation medium as 
described above. Incubations were performed in 200 μl of the appropriate medium. 
Cellular debris was compacted to the bottom of wells by centrifugation (5 min, 300g) and 
fifty μl of supernatant was transferred to a non-sterile 96-well plate. 50 µl reconstituted 
assay buffer (10 ml assay buffer added to one bottle of substrate mix, in kit) was added to 
each well, the plates were then incubated in the dark for 30 min at room temperature with 
gentle agitation. The reaction was then terminated using 50 μl of assay stop solution (1 M 
acetic acid, in the kit). Change in absorbance was measured at 490 nm using a standard 
plate reader. LDH release was calculated as a percentage of basal LDH release acquired 
from an untreated control.  
 
iii) Coomassie blue staining 
 
Cells were stained for visualisation with light microscopy with Coomassie blue. To stain, 
growth medium was aspirated and the cells were washed with PBS three times. The cells 
were then fixed with -20 °C 90 % (v/v) methanol solution for 15 min. The fixing solution was 
aspirated and replaced with Coomassie blue staining solution (0.1% (w/v) Coomassie 
brilliant blue G, 50 % (v/v) methanol, 10 % acetic acid) and stained for 10 min. Staining 
solution was aspirated and stained cells were washed three times with deionised water and 
left to air dry. 
 
2.5 DCFDA assay for intracellular ROS 
To analyse intracellular ROS levels in differentiated H9c2 cells exposed to quercetin, the 
DCFDA (2’,7’-dichloroflurescein diacetate) ROS assay (Abcam, Cambridge, UK) was 
performed. H9c2 cells were cultured in 25 cm2 cell culture flasks and differentiated for 7 
days as per the H9c2 cell differentiation method. Differentiated cells were exposed to 100 
µM quercetin for 24, 48 or 72 h and  detached from the growth surface using trypsin (0.05 % 
w/v)/EDTA (0.02 % w/v)  and centrifuged for 5 min at 1000 RPM. The resulting pellet was 
re-suspended in 500 µl PBS containing 5 µM DCFDA dye and incubated for 30 min at 37°C 
in the dark. In the presence of ROS, DCFDA is oxidised to form the highly fluorescent 2’, 7’-
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dichlorodihydroflurescin, with the amount of fluorescence being directly proportional to 
the levels of intracellular ROS. After incubation, the cell suspension was transferred to FACS 
tubes (Fisher scientific, Loughborough, UK) and the DCFDA fluoresce was measured using 
a Gallios™ flow cytometer (Beckman Coulter), reading at a maximum excitation and 
emission spectra of 495 nm and 529 nm respectively. The flow cytometer was set to count 
10,000 cells in each treatment, and positive fluorescence was gated in relation to the 
untreated control. Results were reported as the percentage of cells showing positive 
fluorescence. Fluorescence data was further analysed using Kaluza Flow Cytometry Analysis 
(v1.2) software.   
2.6 Western Blot 
 
i) Cell lysis 
Western blotting was used to monitor the expression and/or activation of cell signalling 
molecules. Cells were cultured in 25 cm2 cell culture flasks, differentiated for 7 days as 
described above. Following experimentation cells were lysed using boiling 300 µl 0.5 % (w/v) 
sodium dodecyl sulphate (SDS) solution in Tris buffered saline (TBS;  20 mM Tris base, 150 
mM NaCl). Cells were removed from the growth surface of the flasks using a scraper to 
ensure complete lysis. The resulting lysates were transferred to 1.5 ml Eppendorf™ tubes 
and boiled for 10 min. Samples could then be stored at -20 °C if required.  
ii) Protein estimation 
The protein content of the lysates was calculated using the Bio-Rad DC Protein assay (Bio-
Rad laboratories, Hertfordshire, UK) method. Briefly, in a 96 well plate 5 μl samples of cell 
lysates were added to 25 µl of assay reagent A’ (prepared as per manufacturer’s 
instructions; 20 µl of reagent S and 1 ml of reagent A) and 200 µl assay reagent B. Samples 
were then incubated at room temperature in the dark under gentle agitation of 30 min. 
Absorbance was read at 620 nm using a standard 96 well plate reader. These absorbance 
reading were compared to a standard curve produced using BSA standards (Fig 2.1) to 
calculate the protein content of the samples.  
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Fig 2.1 protein standard curve produced with DC Lowry method and known BSA concentrations. 
iii) SDS-PAGE 
75 μl of each lysate sample was suspended in 25 μl of 4x Laemmli buffer (8 %  w/v SDS, 40 % 
(v/v) glycerol,  10 % (v/v) β-mercaptoethanol, 0.01 % (w/v) bromophenol blue, 250 mM 
Tris-HCl pH 6.8, in deionised water)  and boiled for 10 min. 0.75 mm thickness 15 % 
acrylamide gels (Resolving gel;  23 % (v/v) deionised water, 50 % (v/v) ProtoGel® acrylamide 
mix (30 % acrylamide solution 37.5:1 ratio, Geneflow Ltd, Staffordshire, UK), 25 % (v/v) 1.5 
M Tris-HCl pH 8.8, 1 % (v/v) SDS solution ( 10 % (w/v) Sodium dodecyl sulphate in deionised 
water) 1 % (v/v) APS solution ( 10 % (w/v) Ammonium persulfate in deionised water), 0.04 % 
(v/v) TEMED) were cast using a Bio-Rad Mini-Protean III system with a layer of stacking gel 
(Stacking gel; 68 % (v/v) deionised water, 17 % (v/v) ProtoGel® acrylamide mix, 12.5 % (v/v) 
1.0 M Tris-HCl pH 6.8, 1 % (v/v) SDS solution ( 10 % (w/v) Sodium dodecyl sulphate in 
deionised water) 1 % (v/v) APS solution ( 10 % (w/v) Ammonium persulfate in deionised 
water), 0.1 % (v/v) TEMED). The buffered lysate samples containing 30 µg of protein and 5 
μl of protein ladder (Precision Plus Protein™ dual standards, Bio-Rad laboratories, 
Hertfordshire, UK) were then loaded into the gel. Electrophoresis was then performed at 
200 V for 45 min, with the gels submerged in 1x electrophoresis buffer (2.5 mM Tris, 19.2 
mM glycine, 0.01 % (w/v) SDS, pH 8.3). The migration of the proteins was monitored visually 
by observation of the dye front movement, with additional running time added where 
appropriate to facilitate optimal separation.  Once protein separation was achieved the gels 
were removed from the electrophoresis tank and from the glass casting frames. Gels were 
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then placed in 4 °C western blot transfer buffer (25 mM Tris, 192 mM glycine and 20% (v/v) 
MeOH) for 5 min.  
iv) Western blot 
Proteins were transferred to a nitrocellulose membranes of appropriate size using Bio-Rad 
Trans-Blot system. Briefly, gels were layered in the system in the following order; Sponge, 
filter paper, gel, nitrocellulose membrane, filter paper, sponge. Layers were clamped into 
western blotting cassettes and placed into a tank containing transfer buffer and a cooling 
block. The western blot transfer was performed at 100 V for 1 h, or alternatively at 20 V for 
16 h at 4 °C. Nitrocellulose membranes were placed in Ponceau red stain (Sigma-Aldrich, 
UK) to visualise the protein bands and cut at the required molecular weight. Membranes 
were de-stained by washing in PBS for 5 min with agitation. Nitrocellulose membranes 
were blocked using blocking buffer (5 % (w/v) skimmed milk powder and 0.1% v/v Tween-
20 in TBS) for 1 h at room temperature with gentle agitation. Blocking solution was replaced 
with fresh blocking buffer and  one of the following primary antibody was added  (1:1000 
unless stated otherwise); phospho-specific ERK1/2, phospho-specific PKB (1:500), 
phospho-specific p38 MAPK, phospho-specific JNK or cleaved active caspase-3 (1: 500), and 
incubated overnight at 4°C under gentle agitation. The primary antibody was removed and 
the membranes washed vigorously for 5 min with TBS/tween 20 three times. Blocking 
solution and the appropriate secondary antibody coupled with horseradish peroxidase 
(HPR) was added (1:1000) and membranes incubated at room temperature for 2 h with 
gentle agitation. Following removal of secondary antibody, membranes were washed 
vigorously in TBS/Tween-20 three times for 5 min at room temperature. Blots were 
developed using the Ultra Chemiluminescence Detection System (Cheshire Sciences Ltd, 
Chester, UK) and quantified by densitometry using Advanced Image Data Analysis (AIDA) 
Software (Fuji; version 3.52). Replicates of each experiment were analysed on separate 
blots using primary antibodies specific to total unphosphorylated ERK1/2, PKB, JNK, p38 
MAPK or GAPDH (1:1000) to confirm uniform protein loading in the gels.   
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2.7 Proteomic analysis 
i) 2D gel electrophoresis 
2D gel electrophoresis was used to separate cellular proteins by two parameters, molecular 
weight and isoelectric point (pH), to allow the protein samples to be identified using MALDI-
TOF MS/MS. Cell cultures were grown in T75 cell culture flasks and treated according to 
the experimental protocol. The cell culture was then lysed totally using 300 µl urea lysis 
buffer (8 M urea,  50 mM DTT, 4 % (w/v) CHAPS,  0.2 % (v/v) Biolite® ampholytes (pH 3-10) 
(Bio-Rad laboratories, Hertfordshire, UK), in deionised water). The protein content of the 
cell lysate was then isolated using acetone precipitation, the cell lysate was added to -20 °C 
acetone in a proportion of 10 % (v/v) lysate to 90 % (v/v) acetone for 15 h and incubated 
at -20 °C. After the incubation the proteins form a visible precipitate, the lysate-acetone 
mixture was then centrifuged at 10,000 RCF for 10 minutes at 4 °C to pellet the proteins. 
The supernatant was decanted and the pellet left to dry out for 1 h in a fume cupboard, 
covered to prevent contamination. The dried protein was then suspended in 1X TBS buffer 
and further purified using a commercially available 2D clean-up kit from GE healthcare, 
following the manufacturer’s protocol. A 5 µl aliquot of the protein sample was used to 
perform a DC Lowry protein assay, to determine the protein content of the sample. With 
the protein concentration determined, 300 µg of protein was suspended in 120 µL 
rehydration buffer (8 M urea, 50 mM DTT, 4% (w/v)  CHAPS,  0.2% (v/v) ) Biolite® 
ampholytes (pH 3-10), 0.0002% (w/v) bromophenol blue, made in deionised water). The 
120 µl sample was transferred into an IEF focusing tray, ensuring an even spread on the 
bottom of the tray with the liquid making contact with both anode and cathode wires. A 7 
cm 3-10 pH IGP ReadyStrip™ (Bio-Rad laboratories, Hertfordshire, UK) was positioned on 
top of the protein sample, ensuring correct orientation and full contact with the protein 
sample without bubbles. The samples were allowed to undergo passive rehydration, where 
the sample is absorbed into the IPG gel, for 1 h at room temperature. The samples 
underwent active rehydration at 50 V for 16 h, with a layer of mineral oil (Bio-Rad 
laboratories, Hertfordshire, UK) placed on top of the IPG strip to prevent buffer evaporation. 
After rehydration IEF system electrode wicks (Bio-Rad laboratories, Hertfordshire, UK) 
were inserted in-between the IPG strip and the top of the electrodes in the focusing tray, 
these function to remove excess salts and ensure an effective focusing. The IPG strips were 
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focused with the following protocol, which separates the proteins in the first dimension; 
linear voltage slope up to 250 V was applied for 20 min. A second linear voltage slope 
increasing to 4000 V was applied for 2 h. A rapid voltage slope to 4000 V for 10,000 Volt-
hours was then applied. Finally a rapid voltage slope down to 500V was applied to the gel 
for 25 h. After focusing the IPG strips were equilibrated in preparation for the second 
dimension SDS gel electrophoresis. IPG strips were placed in an equilibration tray and 2500 
µl of equilibration buffer 1 (6 M urea, 2 % (w/v) SDS, 1.5 M Tris/HCl pH 8.8, 50 % (v/v) 
glycerol, 2 % (w/v) DTT, in deionised water) was added for 10 min at room temperature 
with gentle agitation. Buffer 1 was removed and replaced with 2.5 ml equilibration buffer 
2 (6 M urea, 2 % (w/v) SDS, 1.5 M Tris/HCl pH 8.8, 50 % (v/v) glycerol, 2.5 % (w/v) 
iodoacetamide, in deionised water) and incubated at room temperature for 10 min with 
gentle agitation.  
Once equilibrated the IPG strip were positioned on top of a 15 % (w/v) SDS acrylamide gel 
(incorporating a stacking gel). A 0.5 cm strip of filter paper was soaked in a mixture of 10 % 
(v/v) protein ladder (Precision Plus Protein™ dual standards, Bio-Rad laboratories, 
Hertfordshire, UK) and 90 % (v/v) 4x laemmli buffer (8 %  w/v SDS, 40 % (v/v) glycerol,  10 % 
(v/v) β-mercaptoethanol, 0.01 % (w/v) bromophenol blue, 250 mM TRIS-HCL pH 6.8, in 
deionised water) and placed at the side of the IPG strip to allow for molecular weight 
comparison. The IPG strip and ladder were then sealed to the gel with molten ReadyPrep™ 
overlay agarose (Bio-Rad laboratories, Hertfordshire, UK), which was allowed to solidify. 
The second dimension separation was then carried out by electrophoresing the gel at 200 
V for 45 min, in a electrophoresis tank (Bio-Rad laboratories, Hertfordshire, UK) containing 
1 x electrophoresis buffer. The bromophenol blue present in the IPG strips allowed for 
visible tracking of the dye front to ensure optimal separation of protein.  After 
electrophoresis the gels were removed from the glass backing plates and washed for 5 min 
three times in deionised water. The gels were stained for 16 h using ProtoBlue™safe 
colloidal coomassie G-250 stain (Bio-Rad laboratories, Hertfordshire, UK).  After staining 
the gels were washed for 1 h in deionised water to remove any background staining. The 
stained gels were then photographed using a Syngene G-box with Genesnap software. The 
gels were then stored in a 0.001 % w/v sodium azide solution in deionised water at 4 °C. 
The gels were kept flat by placing them in-between two layers of acetate plastic.    
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ii) SameSpot Analysis 
Photographed gels were analysed using Progenesis SameSpot (V 3.1.3030.23662, Non-
linear Dyramics, UK) software. Gel images were aligned to a gel selected to be a control, 
either untreated differentiated or untreated mitotic H9c2 cells. Densitometric analysis of 
the gel spots was then performed by the software, which identifies gel spots that are more 
densely stained in the gels. This allows the software to locate proteins that have increased 
or decreased in expression. The significance of the change in density of the gel spots is then 
reported with p < 0.05 being reported as a significant change. The significantly changed 
spots were assigned a number, and spot picking map of the gel were produced, highlighting 
the significantly changed protein spots and labelling them with their respective number. 
iii) De-staining 
Proteins identified as being significantly changed were picked out of the gels using a pipette 
tip cut to an appropriate size and the gel spot was placed in a 1 ml Eppendorf™ tube 
containing a mixture of equal volumes 50 mM ammonium bicarbonate, deionised water 
and acetonitrile. The spots were incubated in this mixture for 5 min at 37 °C under gentle 
agitation. The supernatant was carefully removed and replaced with a mixture containing 
equal volumes of 50 mM ammonium bicarbonate, deionised water and acetonitrile and 
incubated at room temperature for 15 min with gentle agitation. The gel spots were then 
dehydrated by adding an equal volume of 100 % acetonitrile to the mixture and incubated 
for 5 min at room temperature with gentle agitation. The supernatant was then removed 
and replaced with 50 mM ammonium bicarbonate solution and incubated for 5 min at 
room temperature with gentle agitation. An equal volume of 100 % acetonitrile was added 
to the 50 mM ammonium bicarbonate solution and incubated for 15 min at room 
temperature under gentle agitation. This supernatant was then removed and replaced with 
100 % acetonitrile for 1 min at room temperature, which was then removed and replaced 
with deionised water for 5 min to ensure the gel spots were fully rehydrated.  The 
supernatant was then removed and replaced with the trypsin digestion mixture (1 µl Mass 
spectrometry grade Promega gold trypsin, 7.6 µl deionised water and 16.6 µl 100 mM 
ammonium bicarbonate) and incubated for 16 h at 37 °C. The digestion reaction was then 
terminated by adding 1 µl 1 % (v/v) Trifluoroacetic acid (TFA).  
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iv) ZipTip reverse phase chromatography 
After tryptic digestion the protein digests were prepared for MALDI-TOF MS by using C18 
ZipTips (200 Å pore size) (Millipore, Hertfordshire, UK) to purify and concentrate the 
peptide sample. A Milllipore C18 ZipTip was prepared first by cleaning in 80 % v/v 
acetonitrile by cycling 10 µl through the pipette tip three times, followed by cycling 10 µl 
0.1 % v/v TFA three times. The peptide digest was then bound to the C18 ZipTip 
chromatography medium by cycling 10 µl of the peptide digest sample 25 times. The C18 
ZipTip was then washed by cycling 10 µl 0.1 % TFA three times. The bound peptides were 
then eluted from the chromatography medium by the uptake of 5 µl of 80 % acetonitrile 
and cycling through the C18 ZipTip 25 times into a sterile 0.5 ml Eppendorf™ tube. 1.5 µl of 
the peptide digest was then spotted onto a MTP 384 ground steel Mass Spectrometry 
target plate (Bruker, UK) and 1.5 µl of CHCA matrix mixture (5.0 mg/ml α-Cyano-4-
hydroxycinnamic acid (Bruker, UK), 50 % v/v acetonitrile, 0.1 % v/v TFA) was added to the 
peptide digest spot and allowed to air dry for 15 min, covered to prevent contamination. 1 
µl peptide calibrant mixture (Bruker peptide calibration standard II; see appendix I) along 
with 1 µl CHCA matrix mixture was spotted onto the target plate adjacent to the protein 
samples.  
v) MALDI-TOF MS/MS 
The target plate was inserted into a Bruker Ulraflextreme MALDI-TOF TOF Mass 
Spectrometer, which was operated by Bruker-Daltonics FlexControl (v 3.3, build 108) 
software. Peptides were analysed in reflectron positive ion mode, with the mass range of 
800-3500 Da. The mass spectrometer was calibrated using the calibrant mixture. Once 
calibrated samples were analysed with laser power and shots (≈ 1000-3000 shots) 
optimised for each individual sample to give the best signal-to-noise ratio (SNR). The 
peptide mix mass spectrum was then exported to Bruker-Daltonics FlexAnalysis (v3.3, build 
80) software to produce a peak list of m/z and intensity, using the SNAP algorithm. Known 
trypsin self-digestion product m/z peaks were removed from the spectrum. Protein 
identification was determined using Bruker-Daltonics Biotools (v 3.2, build 2.3) software 
linked to mascot (v 2.1) server. Database search parameters were set to the following: 
Search: peptide mass fingerprint (PMF); Database: SwissProt (May 2012a); Variable 
modifications:  Carbamidomethylation (C), Methone oxidation (M); Mass Tolerance: 150 
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ppm; Mass values: Monoisotopic; Max missed cleaveages: 2; Charge state: 1+; Enzyme: 
Trypsin; Taxonomy: Rattus. Protein identity was reported as significant (p < 0.05) according 
to protein score. 
 
Protein identification was further investigated using MALDI-TOF MS/MS. m/z peaks of 
identified sample protein peptide fragments were selected for further investigation 
according to intensity and SNR. Selected peptide fragments were fragmented using LIFT 
(MS/MS) mode and the resulting fragment spectra were analysed using Bruker-Daltonics 
Biotools (v 3.2, build 2.3) software linked to mascot (v 2.1) server, using the same 
parameters as the previous PMF database searches except the type of search was changed 
to MS/MS ion search and Fragment Mass Tolerance was set to ± 0.8 Da. 
 
2.8 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6. One-way ANOVA (analysis of 
variance of means) was used to compare three or more sets of data, with T-test being used 
to compare two sets of data. Tukey’s multiple comparison post hoc analysis was used to 
further demonstrate significant differences between multiple data sets. Significance was 
deemed to be represented as p < 0.05 and highlighted with an asterix (*), all data is 
presented as the mean ± S.E.M.    
2.9 Materials  
Quercetin, quercetin 3-glucuronide, and all-trans retinoic acid were purchased from Sigma-
Aldrich l Co. Ltd. (Poole, Dorset, UK). 3’-O-methyl quercetin was purchased from 
Extrasynthese (France). LY 294002, PD 98059, SB 203580, SP 600 125 and wortmannin were 
inhibiters were obtained from Tocris Bioscience (Bristol, UK). Dulbecco’s modified Eagle’s 
Medium (DMEM), foetal bovine serum (FBS), trypsin (10 ×), L-glutamine (200 mM), 
penicillin (10,000 U/ml)/streptomycin (10,000 µg/ml) were purchased from Lonza Group 
Ltd. Antibodies were obtained from the following suppliers: monoclonal anti-phospho-
specific ERK1/2 (Thr202/Tyr204) from Sigma-Aldrich; polyclonal anti-phospho-specific PKB 
(Ser473), polyclonal anti-total unphosphorylated PKB, monoclonal anti-total 
unphosphorylated ERK1/2, polyclonal anti-total unphosphorylated JNK, polyclonal anti-
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total unphosphorylated p38 MAPK, monoclonal anti-phospho-specific p38 MAPK, 
monoclonal anti-total tropomyosin-1, monoclonal anti-α-tubulin and polyclonal anti-
cleaved active caspase 3 were from New England Biolabs (UK) Ltd;  monoclonal anti-
phospho-specific JNK was from Santa Cruz Biotechnology Inc; monoclonal anti-cardiac 
specific troponin T, monoclonal anti-CBR1 and monoclonal anti-GAPDH from Abcam 
(Cambridge, UK). All other chemicals were of analytical grade. Stock concentrations of 
quercetin (100 mM) were dissolved in DMSO, which was present in all treatments including 
the control at a final concentration of 0.1 % (v/v). 
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3.0 Differentiation of H9c2 cells 
The use of differentiated H9c2 cells in the context of this present study is essential, given 
the numerous differences between mitotic and differentiated H9c2 and what they 
represent when oxidative stress is considered. Mitotic H9c2 cells have been observed to 
exhibit metabolism similar to the “Warburg effect” (Pereira et al, 2011). This effect is 
primarily observed in cancer cells and describes the propensity for cells to produce energy 
at a higher rate due to accelerated glycolysis and lactic acid fermentation, as opposed to 
the more usual oxidation of pyruvate. This effect in mitotic H9c2 cells would allow them to 
continue production of high amounts of energy even during ischaemic attack, decreasing 
their sensitivity to oxidative stress, indeed the “Warburg effect” is thought to be an 
adaption to low-oxygen environments (Pereira et al, 2011). This is further supported by 
observations that differentiated H9c2 cells have a reduced oxidative capacity when 
compared to mitotic H9c2 cells (Comelli et al, 2011). Although several studies into the 
cytoprotective effects of flavonoids have used mitotic H9c2 cells (Gutiérrez-Venegas et al, 
2010; Angeloni et al, 2012; Angeloni et al, 2007; Sun et al, 2012; Kim et al, 2010; Mojzisová 
et al, 2009), given the innate resistance and tolerance to oxidative stress of mitotic H9c2 
cells, differentiated H9c2 represent a better model for the study of those effects. Therefore, 
this current chapter will establish a repeatable model for H9c2 cell differentiation, confirm 
this differentiation and investigate proteins expressed in H9c2 cells after differentiation.  
H9c2 cells can be made to differentiate into a more cardiomyocyte-like phenotype in 
culture by supplementation with all-trans retinoic acid (RA) in a medium with decreased 
(1%) serum content (Ménard et al, 1999). Phenotypically differentiated H9c2 cells form thin, 
elongated, multinucleated myotubes, and are expected to express cardiac specific markers.  
To develop a better model for in vivo cardiomyocytes, the differentiation of H9c2 cells will 
be assessed using several criteria. As shown in Table 1.12 it is known that differentiated 
H9c2 cells express cardiac specific markers, therefore to assess the differentiation of H9c2 
cells the expression of cardiac specific troponin T Will be determined (Pereira et al, 2011). 
This will be coupled with the observation of morphological features including myotubule 
development and multiple nuclei, as these are also known markers of H9c2 differentiation 
(Branco et al, 2013).  
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There are currently no studies that have used proteomics to investigate the difference in 
proteins expressed  between mitotic and differentiated H9c2 cells. Therefore, this present 
study will use two-dimensional electrophoresis and MALDI-TOF MS/MS to elucidate the 
proteomic differences between mitotic and differentiated H9c2 cells.  
 
This chapter aims to monitor the differentiation of H9c2 cells in the following ways: 
• Using Coomassie staining and light microscopy to characterise the phenotypical 
change in differentiated H9c2 cells. 
• Using fluorescent immunocytochemistry to monitor the expression of the cardiac 
specific marker troponin T and phenotypical change in differentiating H9c2 cells. 
• Using western blotting to quantify the expression on troponin-T in differentiating 
H9c2 cells. 
• Using proteomic methods to identify novel protein(s) that significantly change in 
expression after differentiation. 
• Using western blotting to confirm the findings of proteomic analysis. 
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3.1 Morphological change during differentiation  
Mitotic H9c2 cardiomyoblasts have been used extensively in the study of the 
cardioprotective effects of flavonoids. H9c2 cells were differentiated for 7 days and then 
fixed and stained using Coomassie blue to assess visually the morphological changes. After 
7 days the cells change markedly in appearance, becoming more cardiomyocyte-like. The 
morphological changes after differentiation can be observed in Fig. 3.1.  
 
 
 
 
 
 
Fig. 3.1 Light micrograph of H9c2 cells. Mitotic H9c2 cells in fully supplemented DMEM medium (A) have a 
fibroblast like structure, with densely staining nuclei and cytoskeleton (blue arrowhead). After 7 days 
differentiation in differentiation medium (B) the cells phenotype has changed to thin, elongated, 
multinucleated myotubes (red arrowhead). 
3.2 Expression of cardiac specific troponin 
To create a model more similar to in vivo cardiomyocyte-like phenotype, in terms of 
morphology, electrophysiology and biochemistry, H9c2 cells were differentiated by 
culturing in differentiation medium for 1, 3, 7 and 9 days. Differentiated H9c2 cells were 
expected to express the cardiac specific marker cardiac troponin T, along with other 
cytoskeletal markers (Ménard et al, 1999). In vivo, troponin proteins are an essential part 
of the contractions mechanism of muscles, through their interaction with tropomyosin, 
actin and myosin (Zara et al, 2010). Immunocytochemical staining of cardiac troponin T was 
performed on H9c2 cells at different stages of differentiation, namely 1, 7 and 9 days, along 
with an undifferentiated control, shown in Fig. 3.2.  
 
 
50 µm 
 
A) B) 
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Fig. 3.2 Cardiac specific troponin expression during the differentiation of H9c2 cells. Immunocytochemistry 
using florescent microscopy was used to visualise the expression of cardiac troponin T, using anti-cardiac 
specific antibody and a FITC tagged secondary antibody (green) and DAPI nuclear counterstain (blue). 
Images are representative of 3 separate experiments. 
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Fig. 3.3 Cardiac specific troponin expression after 7 days differentiation of H9c2 cells. The multinucleated, 
spindle phenotype of differentiated H9c2 cells is further demonstrated through the use of 
immunocytochemistry to stain cardiac troponin T, using anti-cardiac specific antibody and a FITC tagged 
secondary antibody (green) and DAPI nuclear counterstain (blue). Images are representative of 3 separate 
experiments. 
The immunocytochemistry demonstrates the development of the multinucleated spindle-
like myotubule morphology typical of cardiomyocytes after 7 days differentiation. 
Furthermore the expression of cardiac specific troponin T is visible with the increase in 
green florescence (Fig 3.1). To further demonstrate the increase in expression of cardiac 
specific troponin, western blotting was performed on cells at various stages of 
differentiation.   
 
 
 
 
 
 
 
 
 
   20 µm 
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Fig. 3.4 Cardiac troponin 1 expression was assayed for after 1, 3, 7 and 9 days of exposure to differentiation 
medium. Cardiac specific troponin expression assayed by western blot, data expressed as percentage of 
undifferentiated control cells, after 7 and 9 days cardiac troponin is expressed at a significantly increased 
level (*p < 0.05 vs. control).  Data are expressed as a percentage of control cells (0 days = 100%) and 
represent the mean ±S.E.M of three independent experiments.      
 
As shown in Figure 3.4 the expression of cardiac specific troponin was significantly (p < 0.05) 
increased after 7 days exposure to differentiation medium, confirming the differentiation 
of the H9c2 cells into a more cardiomyocyte-like phenotype. 
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3.3 Proteomic analysis 
To identify novel proteins associated H9c2 cell differentiation, cell lysates were prepared 
from differentiated H9c2 cells and mitotic H9c2 cells. The lysates were prepared using 
specific 2D gel electrophoresis lysis buffer, two-dimensional gel electrophoresis was then 
performed, the gels stained and imaged according to the section 2.7 Proteomic analysis. A 
representative gel from undifferentiated cell lysate is shown in Fig 3.5 and differentiated 
cell lysate is shown in Fig. 3.6, all proteomic gels can be seen in Appendix 2. 
 
 
 
 
 
 
 
 
 
Fig 3.5 Expression pattern of proteins undifferentiated H9c2 cells. Proteins are separated first according to 
isoelectric point along a pH gradient, and then according to mass with polyacrylamide gel. Mass (kDa) has 
been highlighted using protein standards. Image is a representative gel of three separate experiments 
performed separately.  
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Fig 3.6 Expression pattern of proteins from differentiated H9c2 cells. Visual analysis shows potential density 
differences in some of the protein spots when compared to the undifferentiated cell gel image in fig 3.4. 
The image shown is a representative gel of three separate experiments performed separately.  
 
Images of three separate 2D gels of differentiated H9c2 cells and mitotic H9c2 cells were 
analysed using Progenesis SameSpot software as described in section 2.7 part ii. Images 
were aligned to a selected control image, in this case a representative 2D gel of mitotic 
H9c2 cells. Protein spots were identified by the software and assigned an identity number. 
The relative density of the protein spots was then calculated and the change in density of 
the protein spots between the two sets of gels was analysed using the using the software. 
The significance of the difference in dentistry was calculated using ANOVA and the protein 
spots ranked according to their significance, shown in Fig. 3.7, and highlighted on a spot 
picking map of a reference gel image, Fig. 3.8. Spot ID numbers 1, 20, 57 and 36 were found 
to be significantly changed in density in differentiated H9c2 cells when compared to mitotic 
H9c2 cells.   
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Fig. 3.7 Progenesis Samespot analysis of protein spot densities. The difference in density between the two 
sets of gels, differentiated H9c2 cells and mitotic H9c2. Protein spots A) spot ID 1, B) spot ID 20, C) spot ID 
36 and D) spot ID 57. A, B and C was shown to be of a higher density consistently in the gels of differentiated 
H9c2. The difference in density of protein spot was found to be significant for each spot using ANOVA 
analysis. A) ***: p < 0.005 B) **: p < 0.02 C) *: p < 0.032 D)*: p < 0.043. Data are expressed as the mean log 
normalised volume of protein spot ±S.E.M of three independent experiments in each group. 
 
 
 
A) 
B) 
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Fig. 3.8 Spot picking map of significantly changed protein spots in differentiated H9c2 cells. Spot ID 36 and 
Spot ID 57 are shown to be approximately 50 kDa, spot ID 1 is shown to be approximately 37 kDa and spot 
ID 20 between 37 and 25 kDa.  
 
These significantly changed protein spots were then picked from the three gels of the 
lysates from the differentiated H9c2, according to the spot picking map (Fig 3.8).  The spots 
were tryptically digested, and purified in preparation for MALDI-TOF MS/MS according to 
section 2.7 part iii and iv. The identity of the proteins within the spot was determined using 
MALDI-TOF MS/MS according to section 2.7 part V. Mass spectra of the protein fragments 
from MS/MS analysis are shown in Appendix 2. 
The analysis of spot ID 20 identified it as possibly being tropomyosin α4-chain or 
tropomyosin α1-chain, as both tropomyosin α1-chain and tropomyosin α4-chain are the 
same weight it is likely that they are both present within the same protein spot when 
resolved with 2D gel electrophoresis. The findings of the MALDI-TOF MS/MS are 
summarised below in table 3.9.  
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Table 3.9 Proteins significantly up-regulated in differentiated H9c2 cells identified using MALDI-TOF MS/MS. 
The identity of the four spots tested were found to be tropomyosin β-chain , tropomyosin α-1 chain, 
tropomyosin α-4 chain, cytoplasmic actin and vimentin. *PMF score > 51 considered significant (p > 0.05). 
#MS/MS score > 21 considered significant (p >0.05). PMF sequence coverage, PMF score, RMS error and 
MS/MS score are expressed as the mean of scores from 3 separate protein spots from different gels. 
 
 
 
 
 
 
 
Progenesis 
spot number 
mass  RMS 
error 
(ppm) 
Identification  PMF 
Score* 
PMF 
Sequence 
Coverage (%) 
Progenesis 
score  
MS/MS 
Score#  
MS/MS Peptides     
1 32817     106 Tropomyosin beta 
chain 
77.6 9 p < 0.005 73 K.LVILEGELER.S 
R.KLVILEGELER.S   
20 28492     118 Tropomyosin 
alpha-1 chain  
88 39 p < 0.02 76.2 R.KLVIIESDLER.A 
R.IQLVEEELDR.A 
R.RIQLVEEELDR.A 
20 28492     26 Tropomyosin 
alpha-4 chain  
63.6 45 p < 0.02 92.5 R.KIQALQQQADDAE 
57 41710     97 Actin 
(Cytoplasmic)  
67.3 53 p < 0.043 79.5 K.IWHHTFYNELR.V  
36 53700         55 Vimentin  103.8 56 p < 0.032 79.7 R.ISLPLPNFSSLNLR.E  
R.SLYSSSPGGAYVTR.S  
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MALDI-TOF MS/MS identified five proteins that are expressed in a significantly different 
concentration in differentiated H9c2 cells. All five are cytoskeletal proteins, three of which 
were identified to be part of the tropomyosin family. The up-regulation of various 
tropomyosin subtypes further demonstrates the differentiation of the H9c2 cells into a 
more cardiomyocyte-like phenotype.   
To further demonstrate the up-regulation of tropomyosin in differentiated H9c2 cells 
western blot for tropomyosin-1 was performed. As shown in Fig. 3.10 tropomyosin was 
significantly up-regulated in the differentiated cells when compared to the undifferentiated 
control. This finding confirms those of the MALDI-TOF MS/MS.  
 
 
 
 
 
 
 
 
 
Fig. 3.10 Cardiac specific Tropomyosin-1 expression in 7 day differentiated of H9c2 cells. Expression of 
Tropomyosin-1 is significantly (*: p < 0.05) increase after 7 days of differentiation. Data are expressed as a 
percentage of control cells (0 days = 100%) and represent the mean ±S.E.M of three independent 
experiments.      
 
From these observations it can be said that the H9c2 cells become differentiated after 7 
days exposure to differentiation medium. This is demonstrated by the expression of cardiac 
specific troponin T and tropomyosin, as well as the development of a more cardiomyocyte-
like phenotype, with multinucleated, spindle shaped myotubules. Therefore, for the rest of 
the present study, cells differentiated for 7 days in differentiation medium were used as a 
standard model for differentiated H9c2 cardiomyocytes.  
Tropomyosin 1 
11      12     13 
undifferentiated differentiated 
passage 11      12     13 
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3.4 Summary of findings 
It was demonstrated that the method for differentiating H9c2 cells in culture described in 
2.1 cell culture was effective in causing differentiation. This was assessed by quantitative 
measurement of cardiac specific troponin-1 over the differentiation period, and visually 
confirmed using immunocytochemical staining of troponin-1 in differentiated H9c2 cells. 
Proteomic analysis using two-dimensional gel electrophoresis and MALDI-TOF MS/MS 
identified several more cytoskeletal proteins associated with H9c2 cell differentiation, 
namely tropomyosin β-chain , tropomyosin α-1 chain, tropomyosin α-4 chain, cytoplasmic 
actin and vimentin. The increased expression of tropomyosin was further demonstrated 
using western blotting. 
3.5 Discussion of Differentiation. 
Previous studies into the protective mechanisms of flavonoids have used mitotic H9c2 cells 
as a model system (Gutiérrez-Venegas et al, 2010; Angeloni et al, 2012; Angeloni et al, 2007; 
Sun et al, 2012; Kim et al, 2010; Mojzisová et al, 2009). Mitotic H9c2 cells are generally 
accepted as a reliable model for cardiomyocytes, since they are electrophysiologically and 
biochemically similar to cardiomyocytes, but mitotic H9c2 cells lack certain features that 
would make them ideal of modelling in vivo cardiomyocytes (Hescheler et al,  1991). In 
mitotic form H9c2 cells do not form the classic myotubule structures associated with 
cardiomyocytes, and features such as gap junctions are not present. A novel element of 
this present study is the use of the differentiated H9c2 cells as a more cardiomyocyte-like 
model for the investigation of the effects of dietary flavonoids.  
 
i) Characterisation of differentiated H9c2 cells  
 
H9c2 cells have the potential to differentiate into either cardiac or skeletal myoctyes, this 
differentiation is dependent on the conditions of the differentiation medium (Comelli et al, 
2011). The differentiation method used in the present study, namely the incubation of the 
mitotic cells for 7 days with 1 % FBS supplemented DMEM and 10 nM all-trans retinoic acid, 
is in line with several previous studies using differentiated H9c2 cells (Ménard et al, 1999, 
Kageyama et al, 2002 and Comelli et al, 2011). To confirm the differentiation of the H9c2 
68 
 
cells in the present study into the cardiac myocyte phenotype it was necessary to measure 
the expression of cardiac markers in the cells during the differentiation and after the 
differentiation period. The cardiac specific marker troponin-1 has been used in previous 
studies to monitor the differentiation of H9c2 cells (Comelli et al, 2011). Using 
immunocytochemistry cardiac specific troponin-T was shown to be expressed after 7 days 
exposure to the differentiation conditions (Fig. 3.2 & Fig. 3.3). Western blotting was used 
to further demonstrate the increased expression of troponin-T during differentiation. As 
shown in Fig. 3.4 troponin-T expression increased to significantly high levels after 7 days 
incubation with differentiation media. After 9 days differentiation the expression of 
troponin-T appears to decrease, this may due to death of the differentiated cells, as the 
differentiated H9c2 cells no longer mitotically divide (Comelli et al, 2011). Based on cardiac 
troponin-T expression and observable phenotypical change, the method of differentiation 
used in this present study was effective in differentiation of H9c2 cardiomyoblast in a more 
cardiomyocyte-like phenotype.  
 
ii) Proteomic investigation into the differentiated H9c2 cell phenotype 
 
The expression of novel proteins after H9c2 cardiomyocyte differentiation was analysed 
proteomically with a MALDI-TOF MS/MS approach. To the author’s knowledge, no studies 
have used a proteomic approach to investigate the difference of expression of proteins 
between H9c2 cells in cardiomyoblast phenotype and the differentiated cardiomyocyte-
like phenotype. Protein spots from two-dimensional gel electrophoresis gels of both 
cardiomyoblast and cardiomyocyte-like phenotypes were selected for MALDI-TOF MS/MS 
from their significance score after progenesis SameSpot analysis and their visual 
distinctiveness. The proteins highlighted in section 3.3 proteomic analysis represent those 
that were observed and significantly identified on three separate occasions from three 
independent experiments. Proteins that were not identified in three independent 
experiments were omitted. Furthermore, difficult to distinguish protein spots were not 
selected for MALDI-TOF MS/MS. These omissions explain the relatively small number of 
verifiable protein identities despite the apparent abundance of proteins spots identified by 
progenesis SameSpot analysis. This also explains why troponin-T was not identified by 
MALDI-TOF MS/MS despite being a well-known marker of the cardiomyocyte-like 
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phenotype of H9c2 cells (Comelli et al, 2011). All the proteins identified and highlighted in 
section 3.3 proteomic analysis (Table 3.9) were consistently identified with a combination 
of MALDI-TOF MS and MALDI-TOF MS/MS and had distinctive protein spots on the two-
dimensional gel electrophoresis gels. MS/MS MALDI-TOF was performed on the proteins 
identified using MALDI-TOF to provide further evidence of their identity, and all proteins 
detailed on Table 3.9 were shown to have a very strong MS/MS score, representing a 
confident identification. All the proteins what were reliably identified were cytoskeletal in 
nature. It is known that the differentiation of H9c2 cells into the cardiomyocyte-like 
phenotype confers cytoskeletal changes to the cell, principally in the formation of 
cardiomyocyte-like ultrastructural features such as myofilament bundles (Comelli et al, 
2011). Myofilament formation is a precursor to the development of sarcomere like 
structural development in the differentiated H9c2 cell. Several sub-types of tropomyosin 
and actin were identified as being significantly increased in expression in differentiated 
H9c2 cells when compared to the cells in their mitotic form. It is likely that the cardiac 
cytoskeletal elements such as tropomyosin and actin identified from the MALDI-TOF 
MS/MS are directly associated with the formation of the myofilaments known to occur in 
differentiated H9c2 cells (Comelli et al, 2011). The filamentary structure of the cytoskeleton, 
the more organised, linear arrangement can also be visualised using immunocytochemistry 
(Fig. 3.2 & 3.3) and chemical staining techniques (Fig. 3.1). From the MALDI-TOF MS/MS 
analysis vimentin was also identified as being increased in expression in differentiated H9c2 
cells. Vimentin has been previously identified as a marker for H9c2 cardiomyocyte 
differentiation, therefore the finding that vimentin was increased in expression in the 
present study further demonstrates the efficacy of the differentiation method and 
supports the conclusion that the cells have differentiated into a more cardiomyocyte-like 
phenotype (Selmin et al, 2005). Vimentin has also been investigated for potential links with 
flavonoid mediated cytoprotection, using the flavonoid epigallocatechin-3-gallate (Hsieh et 
al, 2013). Epigallocatechin-3-gallate was shown to form complexes with vimentin that 
could lead to cytoprotective effects due to the potent anti-oxidant activity of 
epigallocatechin-3-gallate (Hsieh et al, 2013). Given the structural similarity between 
epigallocatechin-3-gallate and other flavonoids such as quercetin, the potential for other 
flavonoids to form conjugations with vimentin and other cytoskeletal proteins such as β-
actin and myosin may augment the protective effect of the flavonoids and increase the 
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protective effect observed in differentiated H9c2 cells when compared to their mitotic form, 
since the expression of these cytoskeletal structures is comparatively lower in the H9c2 
cells cardiomyoblast form (Hsieh et al, 2013).  
 
iii) Confirmation of tropomyosin expression 
 
The increased expression of tropomyosin-1 after differentiation was further demonstrated 
using western blotting (Fig 3.10). Studies have identified that differentiation of H9c2 cells 
causes mitochondrial developments specifically demonstrating that the mitochondria 
increase in size and undergo ultrastructural changes (Comelli et al, 2011). Differentiated 
H9c2 cells are also shown to have reduced oxidative capacity when compared to the 
undifferentiated cardiomyoblast form. This reduced oxidative capacity will allow for a more 
effective characterisation of the protective effects of dietary flavonoids, as any observed 
protective effect will be most likely due to the inducement of the effect from the flavonoid 
rather than the innate oxidative capacity of the H9c2 cells themselves. The identification of 
vimentin up regulation in the present study further suggests mitochondrial development 
in differentiated H9c2 cells, since vimentin is known to be associated with the development 
of organelles, such as mitochondria and the sarcoplasmic reticulum, in muscle cells (Comelli 
et al, 2011).  
 
iv) Conclusion 
 
In conclusion, from the results shown in chapter 3, the method of differentiation used in 
this present study was shown to be effective in the differentiation of H9c2 cells. This 
differentiation was demonstrated through the expression of cardiac specific troponin, and 
the subsequent novel identification of the increased expression of vimentin, tropomyosin 
and actin, known cardiac muscle and general muscle markers in the differentiated H9c2 
cells, through the use of MALDI-TOF MS/MS (Selmin et al, 2005). The myofilament 
development, as evidenced by the presence of tropomyosin, vimentin and actin, shows 
that the differentiated H9c2 cell is similar to primary cardiomyocyte cell cultures, further 
demonstrating that the differentiated H9c2 cells is of a cardiomyocyte-like phenotype. The 
differentiated H9c2 cells will provide a novel model, which are phenotypically and 
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electrophysiologically similar to in vivo cardiac cells, for the purpose of investigating the 
cytoprotective and cytotoxic effects of dietary flavonoids (Hescheler et al, 1991). The 
proteins identified by MALDI-TOF MS/MS provide new information about the 
cardiomyocyte-like phenotype of H9c2 cells acquired after differentiation through the use 
of all-trans retinoic acid and serum depleted DMEM growth medium.  
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Chapter 4: 
Cytoprotective 
potential of 
flavonoids 
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4.0 Cytoprotective potential of flavonoids  
This chapter aims to demonstrate the cytoprotective effect of flavonoids and their 
metabolites on differentiated H9c2 cells against oxidative stress induced by hypoxia and 
H2O2 exposure. Although the protective effect of flavonoids is known to occur in mitotic 
H9c2 cells, differentiated H9c2 cells provide a more cardiomyocyte-like phenotype model 
to study the cytoprotective effects of flavonoids. As demonstrated in Chapter 3, the 
differentiation of H9c2 cells leads to the expression of cardiac specific markers and a 
change in morphology. As described previously mitotic H9c2 cells exhibit certain metabolic 
characteristics that increase its survivability in conditions of oxidative stress (Pereira et al, 
2011). Firstly the difference in survivability of mitotic and differentiated H9c2 cells will be 
investigated by assaying the viability of both mitotic and differentiated H9c2 cells after 
exposure to hypoxia and H2O2.  
Once differentiated cells are shown to be more susceptible to oxidative stress-induced cell 
death the cytoprotective effects of flavonoids and their metabolites will be investigated. 
This will be achieved by assaying the viability of differentiated H9c2 cells after pre-
treatment with three flavonoids (kaempferol, myricetin and quercetin) and exposure to 
hypoxia and H2O2. There is considerable variation in the exposure time and concentration 
of flavonoids used previously to investigate the cytoprotective effect of flavonoids in 
mitotic H9c2 cells (Gutiérrez-Venegas et al, 2010; Angeloni et al, 2012; Angeloni et al, 2007; 
Sun et al, 2012; Kim et al, 2010; Mojzisová et al, 2009). When obtained via diet the peak 
plasma concentration of quercetin and its metabolites was shown to be 7.6 µM (Labbé et 
al, 2009). Plasma half-lives of quercetin metabolites have been shown to be between 11-
28 h, therefore after repeated intake of flavonoid rich food such as onions, these 
metabolites may accumulate in the plasma (Labbé et al, 2009). Furthermore, flavonoids 
and their metabolites have also been observed to accumulate intracellularly and undergo 
metabolism, with aglycone forms of the flavonoid being formed from their metabolites by 
β-Glucosidase enzymes (Kanazawa, 2011). Reportedly peak intracellular concentrations of 
quercetin were 2 nmol/mg protein after 1 h exposure to 30 µM quercetin (Angeloni et al, 
2007). Considering the bioavailability of the flavonoids, previous investigations, and the 
possibility of intracellular flavonoid accumulation, a range of 1-100 µM concentrations of 
flavonoid will be used when exposing the differentiated H9c2 cells. Although the dietary 
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intake of kaempferol and myricetin is considerably lower than quercetin, the same 
exposure concentrations will be used, as to reflect the intracellular and plasma 
accumulation. Previous studies investigating flavonoid induced cytoprotection have used a 
range of exposure times, most commonly 1-24 h (Gutiérrez-Venegas et al, 2010; Angeloni 
et al, 2012; Angeloni et al, 2007; Sun et al, 2012; Kim et al, 2010; Mojzisová et al, 2009). 
The use of a 1 h exposure time reflects the in vivo exposure of the cells shortly after a meal, 
and has been shown to be adequate time to allow for intracellular flavonoid accumulation 
(Angeloni et al, 2007). As the half-life of quercetin metabolites surpass 24 h, an exposure 
time of 24 h reflects the exposure of in vivo cells after one or several meals (Labbé et al, 
2009). A 24 h exposure time may also lead to greater intracellular flavonoid accumulation 
and a greater cytoprotective effect. Considering this, 1 h and 24 h exposure times to the 
flavonoid will be used to investigate the cytoprotective effect.   
The effect of flavonoid pre-treatment on protein kinases associated with cytoprotection, 
namely PKB, ERK1/2, JNK and p38 MAPK will be investigated using western blotting. Both 
these signalling cascades (PI3K and MAPK) are associated with cell survival and have been 
investigated previously in mitotic H9c2 cells with respect to flavonoid induced 
cytoprotection (Angeloni et al, 2007). There is considerable cross-talk between these two 
cascades, therefore if flavonoids are able to modulate the phosphorylation of one or 
several key molecules in one cascade it is likely to have an effect on the other (Mendoza et 
al, 2011). Quercetin has been shown to form a hydrogen bond with ser212 in the MEK 
backbone, inactivating the protein. Inhibition of MEK would consequently lead to 
decreased phosphorylation of ERK1/2, p38 MAPK and JNK (Russo et al, 2012). PI3K 
inhibition has also been observed when ERK1/2 is inhibited (Mendoza et al, 2011). 
Quercetin was also predicted to be able to form 14 hydrogen bonds inside a computer 
modelled ATP binding motif at the Tyr1044, Thr1046, Arg1047, Gly1073, Gly1075, Lys1076, Ser1077, 
Tyr1087, and Glu1201 amino acids (Qian et al, 2004). This predicted binding may be a major 
contributing factor to the observed inhibition of MEK.  
As the inhibitory effect of flavonoids on cell signalling cascades is a suspected mechanism 
of flavonoid-induced cytoprotection the effects of specific inhibitors of PKB, ERK1/2, JNK 
and p38 MAPK will be investigated using western blot, specifically PD98059 (50 µM, 
MEK1/2 inhibitor) and LY294002 (30 µM, PI3K inhibitor), Wortmannin (100 nM, PI3K 
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inhibitor), SB203580 (30 µM, p38 MAPK inhibitor) and SP600125 (10 µM, JNK inhibitor). 
The exposure time and concentrations of inhibitors used followed the manufacturer’s 
recommendations.  Firstly the specific inhibitors will be used to compare to the effects of 
flavonoids. The effect of the specific inhibitors on cell viability using the same exposure 
times to those used to investigate the effect of flavonoids will be investigated. Furthermore, 
the cytoprotective effect of the inhibitors will be investigated, to determine if the inhibition 
of a specific signal is responsible for the cytoprotective effect of flavonoids.  
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4.1 Determining optimal H2O2 treatment conditions  
Treatment with H2O2 was used in the present study as a chemical inducer of oxidative stress, 
to simulate ischaemic attack in vitro. To ascertain the appropriate time and concentration 
of hydrogen peroxide exposure MTT reduction and LDH release cell viability assays were 
used. Firstly to determine optimal concentration differentiated H9c2 cells were treated 
with a range of concentrations of H2O2 (200-100 µM) for 2 h. The results of the cell viability 
assays are shown in Fig. 4.1. Differentiated H9c2 cells were also exposed to 600 µM H2O2 
for various time points to determine the optimal time for H2O2 treatment with regard to 
cell death. This was assayed using MTT reduction and LDH release cell viability assays. 
Results of these cell viability assays is shown in Fig. 4.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.1 The effects of concentration of H2O2 on differentiated H9c2 cell viably after 2 h exposure as 
measured by A) MTT reduction and B) LDH release assays. Both assays show that a minimum of 600 µM 
H2O2 is required to illicit significant (*: p < 0.05; **: p < 0.01; ***: p < 0.005; ****: p < 0.001) cell death. Data 
are expressed as the percentage of control cells (C =100%) and represent the mean ± SEM of three 
independent experiments. 
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Fig 4.2 The effects of exposure time of 600 µM H2O2 on differentiated H9c2 cell viably. Measured by A) MTT 
reduction and B) LDH release assays. Both assays show that time points 6, 4 and 2 h 600 µM H2O2 exposure 
caused  significant (*: p < 0.05; **: p < 0.01; ***: p < 0.005; ****: p < 0.001) cell death. Data are expressed 
as the percentage of control cells (C =100%) and represent the mean ± SEM of five independent 
experiments. 
From the data shown in figs. 4.1 and 4.2 it is clear that a minimum of 2 h exposure to 600 
µM H2O2 on differentiated H9c2 cells causes significant decrease in viability as measured 
by MTT reduction and LDH release assays. Undifferentiated H9c2 cardiomyoblast cells 
showed less sensitivity to H2O2 induced cell death as measured by MTT reduction and LDH 
release, as shown in Fig. 4.3 and Fig. 4.4. This may be a reflection of the more immature 
phenotype of the undifferentiated H9c2 cardiomyoblast cells. 
A) 
B) 
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Fig. 4.3 The effects of concentration of H2O2 on undifferentiated H9c2 cell viably after 2 h exposure.  
Measured by A) MTT reduction and B) LDH release assays. Both assays show that a minimum of 800 µM 
H2O2 is required to illicit significant (*: p < 0.05; **: p < 0.01; ****: p < 0.001) cell death. Data are expressed 
as the percentage of control cells (C =100%) and represent the mean ± SEM of three independent 
experiments. 
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Fig 4.4. The effects of exposure time of 800 µM H2O2 on undifferentiated H9c2 cell viably. Measured by A) 
MTT reduction and B) LDH release assays. Both assays show that a minimum of 2 h treatment with 800 µM 
H2O2 causes significant (*: p < 0.05; ***: p < 0.005; ****: p < 0.001) cell death. Data are expressed as the 
percentage of control cells (C =100 %) and represent the mean ± SEM of four independent experiments. 
Fig 4.3 and 4.4 demonstrate that undifferentiated H9c2 cells are less sensitive to H2O2 
induced cell death, as shown by the necessity of a minimum 800 µM treatment to elicit a 
significant loss in viability as measured by LDH release and MTT reduction, as compared to 
the minimum 600 µM required for differentiated cells. This is also reflected in the increased 
exposure time required to induce a loss in viability in undifferentiated H9c2 
cardiomyoblasts, as shown in Figs 4.2 and 4.4.     
 
 
A) 
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4.2 Hypoxia model design  
To determine the optimal duration of hypoxia differentiated H9c2 cells were exposed to 6 
or 24 h of hypoxia (0.5 % O2) and viability was assayed using MTT reduction. The viability 
of the cells was then compared to a normoxia control. From this assay (Fig. 4.5) it was 
demonstrated that 24 h hypoxia causes a significant loss in cell viability as measured by 
MTT reduction. Therefore for the duration of the present study, 24 h was used as the 
standard incubation time to induced significant cell death from hypoxia.  
 
 
Fig. 4.5 The effects of duration of Hypoxia on differentiated H9c2 cell viably as measured by MTT reduction. 
Significant (****: p < 0.001) cell death occurred during both treatment times when compared to normoxic 
control, although 24 hours in hypoxia caused a more significant (p < 0.0001) cytotoxic effect than 6 hours 
(p = 0.0003). Data are expressed as the percentage of control normoxia cells (Normoxia  = 100 %) and 
represent the mean ± SEM of nine independent experiments. 
 
4.3 Cytoprotective effects of flavonoid pre-treatment against Hydrogen peroxide induced 
cell death 
With the optimal conditions for simulating oxidative stress with H2O2 determined, as 
described in section 4.1, differentiated H9c2 cardiomyocytes were pre-treated with various 
concentrations of three different flavonoids; myricetin, kaempferol and quercetin. Initially, 
the experimental design also included the flavonoid naringenin, but due to time constraints 
investigations were not continued. The preliminary investigations into the protective 
effects of naringenin showed no significant effects (data not presented). Firstly, 
differentiated H9c2 cells were pre-treated with 30 µM or 100 µM of flavonoid for 1 h and 
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the exposed to 600 µM H2O2 for 2 hours, viability was then measured using LDH release 
and MTT reduction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.6 Effect of 1 h quercetin pre-treatment on cell viability during 600 µM H2O2 induced oxidative stress. 
Measured by A) MTT reduction assay and B) LDH release assay. Hydrogen peroxide caused significant cell 
death compared to control cells (a denotes significance vs untreated control cells). The MTT reduction assay 
showed that 100 μM concentration of quercetin, induced significant protection from cell death compared 
to hydrogen peroxide treatment. The LDH release assays showed that 100 μM and 30 μM pretreatment 
caused significant protection compared to hydrogen peroxide treatment. (*: p < 0.05; **: p < 0.01; ***: p < 
0.005; ****: p < 0.001; b denotes significance vs H2O2 treatment). Data are expressed as the percentage of 
control cells (C = 100 %) and represent the mean ± SEM of seven independent experiments 
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Fig 4.7 Effect of 1 h myricetin pre-treatment on cell viability during 600 µM H2O2 induced oxidative stress. 
Measured by A) MTT reduction assay and B) LDH release assay. Hydrogen peroxide caused significant cell 
death compared to control cells. The MTT reduction assay and LDH release assays showed no 
concentrations of myricetin were able to illicit a significant protective effect after 1 h pretreatment (**: p 
< 0.01; ***: p < 0.005). Data are expressed as the percentage of control cells (C = 100 %) and represent the 
mean ± SEM of three independent experiments. 
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Fig 4.8. Effect of 1 h kaempferol pre-treatment on cell viability during 600 µM H2O2 induced oxidative stress. 
Measured by  A) MTT reduction assay and B) LDH release assay. Hydrogen peroxide caused significant (a 
denotes significance vs untreated control cells) cell death compared to control cells. The MTT reduction 
assay and LDH release assays show 1 h pretreatment with 100 µM kaempferol was able to illicit a significant 
protective effect. (**: p < 0.01; ***: p < 0.005; ****: p < 0.001; b denotes significance vs H2O2 treatment). 
Data are expressed as the percentage of control cells (C = 100 %) and represent the mean ± SEM of three 
independent experiments. 
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As demonstrated by Figs. 4.6, 4.7 and 4.8, quercetin was shown to be the most potent 
flavonoid in terms of inducing a protective effect against H2O2 induced cell death after 1 h 
pre-treatment. Therefore, flavonoid pre-treatment time was increased to 24 h to further 
investigate the protective effect of the three flavonoids. Differentiated cells were pre-
treated with a range of concentrations of one flavonoid for 24 h and then exposed to 600 
µM H2O2 for 2 h. Firstly, a range of concentrations of quercetin were used to pre-treat 
differentiated cells for 24 h, the cells were exposed to 600 µM H2O2 for 2 h and the viability 
was assayed using MTT reduction and LDH release assays.  The protective effect of 24 h 
pretreatment with the other two flavonoids, kaempferol and myricetin, against 2 h 
exposure to 600 µM H2O2 was assayed using MTT reduction.     
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Fig. 4.9 Effect of 24 h quercetin pre-treatment on cell viability during H2O2 induced oxidative stress. 
Measured by A) MTT reduction assay and B) LDH release assay. Hydrogen peroxide caused significant (****: 
p < 0.001; a denotes significance vs untreated control cells) cell death compared to control cells. The MTT 
reduction assay showed that several concentrations of quercetin induced significant protection; 100 μM 
(****: p < 0.001) and 30 μM (*: p < 0.05) from cell death compared to hydrogen peroxide alone (b  denotes 
significance vs H2O2 treatment). LDH assays showed that 100 μM (***: p > 0.005) and 30 μM (**: p > 0.01) 
caused significant protection compared to hydrogen peroxide treatment. ). Data are expressed as the 
percentage of control cells (C = 100 %) and represent the mean ± SEM of six independent experiments. 
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Fig. 4.10 Protective effect of 24 h flavonoid pretreatment on differentiated H9c2 cell viability after H2O2 
treatment. H2O2 treatment caused a significant decrease in MTT reduction in both experiments (A, *: p > 
0.05; B, **: p > 0.05; a denotes significance vs untreated control cells). 24 h kaempferol pretreatment 
caused no significant protective effect with any concentration tested, whereas 100 µM myricetin caused a 
significant (**:  p > 0.01; b  denotes significance vs H2O2 treatment) protective effect as measured by MTT 
reduction. Data are expressed as the percentage of control cells (C = 100 %) and represent the mean ± SEM 
of three independent experiments. 
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As demonstrated by Figs. 4.9 and 4.10, quercetin was again shown to be the most potent 
flavonoid in terms of inducing a protective effect against H2O2 induced cell death after 24 
h pre-treatment. The protective effect of 24 h pretreatment with myricetin was only 
induced with 100 µM concentration, and Kaempferol showed no significant protective 
effect. This protective effect can be further demonstrated by observing the cellular 
morphology, as shown in Fig. 4.11. The cellular damage induced by H2O2 treatment is visible 
in the form of damaged cells in cells treated with H2O2 and those pre-treated with 100 µM 
kaempferol, whereas cells pre-treated with 100 µM quercetin and myricetin show little 
damage, further illustrating the cytoprotective effect.    
 
 
 
 
 
 
 
 
Fig. 4.11 The effect of flavonoid pre-treatment on visible cellular damage from H2O2 exposure. A) Untreated 
differentiated H9c2 cells. B) differentiated H9c2 cells exposed to 600 µM H2O2 for 2 h. C) Differentiated 
H9c2 cells pretreated for 24 h with 100 µM kaempferol and exposed to 600 µM H2O2 for 2 h. D) 
Differentiated H9c2 cells pretreated for 24 h with 100 µM myricetin and exposed to 600 µM H2O2 for 2 h. 
E) Differentiated H9c2 cells pretreated for 24 h with 100 µM quercetin and exposed to 600 µM H2O2 for 2 
h. Visible cellular damage (red arrowheads) is present in images B and C. Stained with Coomassie blue.  
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4.4 Cytoprotective effects of flavonoid pre-treatment hypoxia induced cell death 
Differentiated H9c2 cardiomyocytes were pre-treated with various concentrations of three 
different flavonoids; myricetin, kaempferol and quercetin. Firstly, differentiated H9c2 cells 
were pre-treated with 30 µM or 100 µM of flavonoid for 1 h and the exposed to 24 h 
hypoxia (0.5 % O2), viability was then measured using MTT reduction 
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Fig 4.12 Effect of 1 h flavonoid pretreatment on differentiated H9c2 cell viability after 24 h hypoxia. In each 
experiment 24 h hypoxia caused a significant (****: p < 0.001) loss in cell viability as measured by MTT 
reduction assay. With all flavonoids tested (A: Quercetin, B: Kaempferol, C: Myricetin) 1 h pretreatment 
with 100 µM or 30 µM was not sufficient to cause any significant protective effect. Data are expressed as 
the percentage of control normoxia cells (normoxia C = 100 %) and represent the mean ± SEM of three 
independent experiments. 
A
 
B
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As evidenced by Fig. 4.12, 1 h pretreatment with flavonoids proved to be insufficient to 
stimulate a protective effect with the concentrations tested. Therefore the effect of 24 h 
pretreatment with flavonoids was assayed with regard to the ability to induce a protective 
effect against 24 h hypoxia exposure using MTT reduction assay. 
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Fig. 4.13 Effect of 24 h flavonoid pretreatment on H9c2 cell viability after 24 h hypoxia. In both incidences 
24 h hypoxia caused a significant decrease in MTT reduction compared to normoxia controls. Kaempferol 
(A) and myricetin (B) at all concentrations tested failed to induce a significant protective effect in 
differentiated H9c2 cells after 24 h pretreatment. 24 h pretreatment with 30 µM and 100 µM myricetin 
caused a significant decrease in MTT reduction after 24 h pretreatment in normoxic conditions (**: p < 0.01; 
****: p < 0.001). Data are expressed as the percentage of control normoxia cells (normoxia C = 100 %) and 
represent the mean ± SEM of three independent experiments. 
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Fig. 4.14 Effect of 24 h quercetin pre-treatment on cell viability during 24 h hypoxia induced oxidative stress. 
Measured by A) MTT reduction assay and B) LDH release assay. 24 h hypoxia caused significant (****: p < 
0.001; a denotes significance vs untreated control cells) cell death. Both MTT reduction and LDH release 
assays showed 24 h pre-treatment with 100 μM quercetin induced significant (*: p < 0.05; b  denotes 
significance vs H2O2 treatment ) protection from cell death compared to hypoxia cells alone. Data are 
expressed as the percentage of control normoxia cells (normoxia C = 100 %) and represent the mean ± SEM 
of nine independent experiments. 
As demonstrated in figures 4.13 and 4.14 24 h pre-treatment with 100 µM quercetin was 
able to significantly protect differentiated H9c2 cells from oxidative stress caused by both 
hypoxia and H2O2 treatment. Furthermore, 30 µM quercetin pretreatment was shown to 
be protective against H2O2 treatment with both assay methods. Therefore, 100 and 30 µM 
quercetin pretreatment was selected to be used for investigations into the cell signaling 
pathways involved in quercetin mediate cytoprotection.    
A) 
B) 
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4.5 Protective effects of quercetin metabolites  
The protective effect of the two major metabolites of quercetin, 3’-O-methyl quercetin 
(Q3M) and quercetin-3-glucoroninde (Q3G), against 2 h 600 µM H2O2 exposure was tested 
using  MTT reduction and LDH release assays. Fig. 4.15 shows that 100 µM Q3M pre-
treatment for 24 h was sufficient to illicit a significant protective, whereas Q3G showed no 
such effect, this may be a consequence of the less lipophilic nature of Q3G. 
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Fig. 4.15 Protective effect of 24 h quercetin metabolite pretreatment on differentiated H9c2 cell viability 
after H2O2 treatment. H2O2 treatment caused a significant decrease in MTT reduction and increase LDH 
release in all experiments (A and C, ****: p > 0.001; B, ***: p > 0.005; D, **: p < 0.01; a denotes significance 
vs untreated control cells). 24 h Q3G pre-treatment caused no significant protective effect with any 
concentration tested (A and B), whereas 100 µM Q3M caused a significant (*:  p > 0.05; b  denotes 
significance vs H2O2 treatment) protective effect as measured by MTT reduction and LDH release. Data are 
expressed as the percentage of control cells (C = 100 %) and represent the mean ± SEM of five independent 
experiments. 
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4.6 Protein kinase phosphorylation during flavonoid mediated cardioprotection against 
hydrogen peroxide 
As previously observed 30 µM and 100 µM concentrations of quercetin was able to induce 
a significant cardioprotective effect after 24 h pre-treatment in differentiated H9c2 
cardiomyocytes against oxidative stress caused by exposure to 600 µM H2O2. To investigate 
the mechanism of this cardioprotective effect western blotting was used to monitor the 
phosphorylation of four protein kinases involved in cell survival and cell death; ERK1/2, PKB, 
p38 MAPK and JNK. Differentiated H9c2 cells were pre-treated for 24 h with 30 µM or 100 
µM quercetin, the flavonoid was removed and the cells then exposed to 600 µM H2O2 for 
2 h, after which the cells were lysed and western blotting performed.  
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Fig. 4.16 Effect of 30 µM quercetin on H2O2-induced protein kinase activation. Differentiated H9c2 cells (7 
days) were treated with 30 µM quercetin 24 h prior to 2 h insult with 600 µM H2O2, cells were then lysed 
and western blotting performed using specific antibodies for phosphorylated and total  A) ERK1/2, B) p38 
MAPK, C) PKB and D) JNK. In all incidences exposure with 600 µM H2O2 caused a significant increase in 
phosphorylation of the protein kinases ( A & B, ***: p < 0.005; C, **: p < 0.01; D, *: p < 0.05;  a denotes 
significant vs control cells). A significant reduction in phosphorylation of ERK1/2, PKB and p38 MAPK was 
observed in cells pre-treated for 24 h with 30 µM quercetin and then exposed to 600 µM H2O2 (A & B, ***: 
p < 0.005; C, *: p < 0.05; b denotes significance vs H2O2 treated cells). No significant variation was observed 
in total specific blots of each protein kinase.  Data are expressed as a percentage of control cells (control = 
100%) and represent the mean ±S.E.M of three independent experiments.   
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Fig. 4.17 Effect of 100 µM quercetin on H2O2-induced protein kinase activation. Differentiated H9c2 cells (7 
days) were treated with 100 µM quercetin 24 h prior to 2 h insult with 600 µM H2O2, cells were then lysed 
and western blotting performed using specific antibodies for phosphorylated and total  A) ERK1/2, B) p38 
MAPK, C) PKB and D) JNK. In all incidences exposure to 600 µM H2O2 caused a significant increase in 
phosphorylation of the protein kinases (A & C, ****: p < 0.001; B, ***: p < 0.005; D, **: p < 0.01; a denotes 
significant vs control cells). A significant reduction in phosphorylation of ERK1/2, PKB, p38 MAPK and JNK 
was observed in cells pre-treated for 24 h with 100 µM quercetin and then exposed to 600 µM H2O2 (C, 
****: p < 0.001; A & D, ***: p < 0.005; B, **: p < 0.01;  b denotes significance vs H2O2 treated cells). No 
significant variation was observed in total specific blots of each protein kinase.  Data are expressed as a 
percentage of control cells (control = 100 %) and represent the mean ±S.E.M of three independent 
experiments.      
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As can be observed in Figs. 4.16 and 4.16, exposure to 600 µM H2O2 for 2 h consistently 
induces a significant increase in phosphorylation of ERK1/2, PKB, p38 MAPK and JNK in 
differentiated H9c2 cardiomyocytes. Generally it can be seen that in after pre-treatment 
with quercetin the protein kinases expression is inhibited when compared to the activation 
that occurs during the treatment with H2O2. 
4.7 Protein kinase phosphorylation during flavonoid mediated cardioprotection against 
hypoxia 
As previously observed 100 µM concentration of quercetin was able to induce a significant 
cardioprotective effect after 24 h pre-treatment in differentiated H9c2 cardiomyocytes 
against ischaemic damage caused incubation in hypoxic conditions for 24 h. Four cell 
signalling molecules; ERK1/2, PKB, p38 MAPK and JNK were once again used to investigate 
the mechanism of the flavonoid mediated cardioprotective effect. Differentiated H9c2 cells 
were pre-treated for 24 h with 30 µM or 100 µM quercetin, the flavonoid was removed and 
the cells then incubated in hypoxic condition (0.5 % O2) for 24 h, after which the cells were 
lysed and western blotting performed. 
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Fig. 4.18 Effect of 30 µM quercetin on hypoxia-induced protein kinase activation. Differentiated H9c2 cells 
(7 days) were treated with 30 µM quercetin 24 h prior to 24 h incubation in hypoxic conditions, cells were 
then lysed and western blotting performed using specific antibodies for phosphorylated and total  A) 
ERK1/2, B) p38 MAPK, C) PKB and D) JNK. In all incidences hypoxic incubation caused a significant increase 
in phosphorylation of the protein kinases (D, ****: p < 0.001; A & C, ***: p < 0.005;  B, **: p < 0.01; a 
denotes significant vs control normoxia cells). A significant reduction in phosphorylation of ERK1/2, PKB, 
p38 MAPK and JNK was observed in cells pre-treated for 24 h with 30 µM quercetin prior to hypoxic 
incubation for 24 h (D, ****: p < 0.001; A & B, ***: p < 0.005; C, **: p < 0.01;  b denotes significance vs 
hypoxia incubated cells). Data are expressed as a percentage of control cells in normoxic conditions (control 
= 100%) and represent the mean ±S.E.M of three independent experiments. 
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Fig. 4.19 Effect of 100 µM quercetin on hypoxia-induced protein kinase activation. Differentiated H9c2 cells 
(7 days) were treated with 100 µM quercetin 24 h prior to 24 h incubation in hypoxic conditions, cells were 
then lysed and western blotting performed using specific antibodies for phosphorylated and total  A) 
ERK1/2, B) p38 MAPK, C) PKB and D) JNK. Only ERK1/2 and JNK saw a significant increase in 
phosphorylation after hypoxic incubation (A, **: p < 0.01; D, ****: p < 0.001; a denotes significant vs control 
normoxia cells). A significant reduction in phosphorylation of ERK1/2, PKB and JNK was observed in cells 
pre-treated for 24 h with 100 µM quercetin prior to hypoxic incubation for 24 h (D, ****: p < 0.001; A, **: 
p < 0.01; B, *: p < 0.05;  b denotes significance vs hypoxia incubated cells.  Data are expressed as a 
percentage of control cells in normoxic conditions (control = 100%) and represent the mean ±S.E.M of three 
independent experiments.    
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As shown in figs. 4.18 and 4.19 24 h pre-treatment with 30 µM and 100 µM quercetin has 
a significant effect on the phosphorylation of protein kinases during hypoxic incubation. 
Mainly the protein kinases are present in their phosphorylated form at higher levels during 
hypoxia, and 24 h pre- treatment with quercetin causes this to decrease. This reduction in 
phosphorylation of protein kinases may be involved in the cardioprotective mechanism of 
flavonoids.  
4.8 protein kinase inhibitors and flavonoids mediated cardioprotection 
Inhibition of protein kinases by quercetin may be part of the mechanism of flavonoid 
mediated cardioprotection. Specific protein kinase inhibitors were used to investigate the 
effect of inhibition of these protein kinases, and to potentially mimic the inhibitory 
characteristics and cardioprotective effect of quercetin in particular and flavonoids in 
general.  
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Fig. 4.20 Effect of quercetin on ERK1/2 and PKB phosphorylation. Differentiated H9c2 cells (7 days) were 
treated with 100 µM, 30 µM quercetin for 24 h or PD98059 (50 µM, MEK1/2 inhibitor) and LY294002 (30 
µM, PI3K inhibitor) for 30 min. Cells were then lysed and analysed using western blotting for A) Phospho-
ERK1/2 or B) Phospho-PKB using phosphor-specific antibodies. Separate samples were analysed using 
antibodies that recognise total ERK1/2 and PKB. Treatment with 100 µM quercetin (Q 100 µM) was shown 
to cause a significant inhibitory effect (A, *: p < 0.05; B, ****: p > 0.001) on both ERK1/2 and PKB that is 
comparable with the effect of the specific inhibitors PD98059 and LY294002 (A, *: p < 0.05; B, ***: p > 
0.005).  Data are expressed as a percentage of control cells in conditions (control = 100%) and represent 
the mean ± S.E.M of three independent experiments.     
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The effects of the specific inhibitors PD98059 and LY294002 were shown to be comparable 
to 100 µM quercetin after 24 h exposure. The protective effect of protein kinase inhibition 
against 600 µM H2O2 exposure and the potential ameliorative effect of these specific 
inhibitors on quercetin mediated cardioprotection was then investigated by MTT reduction 
assay. In addition to PD98059 (50 µM, MEK1/2 inhibitor) and LY294002 (30 µM, PI3K 
inhibitor), Wortmannin (100 nM, PI3K inhibitor), SB203580 (30 µM, p38 MAPK inhibitor) 
and SP600125 (10 µM, JNK inhibitor) were used to investigate the effect of protein kinase 
inhibition of cardioprotection. 
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Fig. 4.21 Effect of protein kinase inhibitors on quercetin-induced cardioprotection. A) differentiated H9c2 
cells were exposed to protein kinase inhibitor for 24 h. 24 h exposure to LY294002 caused a significant (*: 
p < 0.05) decrease in MTT reduction. B) Differentiated H9c2  cells were treated with  kinase inhibitor for 30 
min prior to 24 h exposure to 30 µM quercetin, after which the cells were exposed to 600 µM H2O2 for 2 h. 
Exposure to 600 µM H2O2 for 2 h caused a significant ( **: p < 0.01; a denotes significance vs untreated 
control) decrease in MTT reduction. Without inhibitor pre-treatment, 30 µM quercetin pre-treatment for 
24 h induced a significant (*: p < 0.05; b denotes significance vs H2O2 treated control) protective effect. No 
significant difference was observed vs the untreated control or and H2O2 treated control in those cells pre-
treated with inhibitor prior to 24 h exposure to 30 µM quercetin. C) Differentiated H9c2 cells were exposed 
to protein kinase inhibitor for 24 h and then exposed to 600 µM H2O2 for 2 h.  Exposure to 600 µM H2O2 for 
2 h caused a significant (**: p < 0.01) decrease in MTT reduction vs untreated control. 24 h exposure to 
inhibitors induced no significant protective effect as each was shown to have a significant decrease in MTT 
reduction compared to the untreated control (PD98059, **: p < 0.01; Wortmannin, ***: p < 0.005; LY294002, 
****: p < 0.001; SB203580 & SP600125, *: p < 0.05). Data are expressed as a percentage of control cells in 
conditions (control = 100%) and represent the mean ± S.E.M of six independent experiments.     
A) 
B) 
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From Fig. 4.21 it can be seen that acting singularly protein kinase inhibitors do not confer 
a protective effect that is comparable to that of quercetin, nor was the protective effect of 
quercetin perturbed by the presence of inhibitors.   
4.9 Results summary 
Quercetin was shown to have a cytoprotective effect on differentiated H9c2 cells, as it was 
able to protect differentiated H9c2 cells from damage from H2O2 treatment with a pre-
treatment time of 1 h as well as 24 h. The results further demonstrated that this protective 
effect can be elicited by a concentration of 30 µM quercetin, which may be achievable 
pharmacologically in vivo, considering intracellular and plasma accumulation after 
repeated doses. Quercetin was able to protect differentiated H9c2 cells from death caused 
by hypoxia at 100 µM with a pre-treatment time of 24 h. Of the two quercetin metabolites 
tested 3’-O-methyl quercetin was found to exhibit a similar protective effect to quercetin 
against cell death caused by H2O2 exposure, whereas quercetin-3-glucorinde showed no 
protective effect. The protective effect of quercetin pre-treatment is likely associated with 
the inhibitory effect on protein kinases demonstrated in 4.6. The inhibitory effect of 30 µM 
and 100 µM quercetin pre-treatment on the phosphorylation of ERK1/2, PKB, JNK and p38 
MAPK during H2O2 treatment and hypoxia further suggests that this is a potential 
mechanism of the protective effect of quercetin.  
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4.10 Discussion of flavonoid mediated cytoprotective effect 
This chapter investigated the potential cytoprotective effects of quercetin, kaempferol, 
myricetin and two of the major quercetin metabolites, 3’-O-methyl quercetin and quercetin-
3-glucorinde. Specifically with regard to their ability to protect differentiated H9c2 cells 
from oxidative induction of cell death from H2O2 exposure or incubation in hypoxic 
conditions. 
i) Mitotic and differentiated cell comparison  
Firstly the optimal concentration and exposure time for H2O2 treatment on differentiated 
and mitotic H9c2 cells was determined in order to compare the susceptibility to oxidative 
cell death. As illustrated in Figs. 4.3 and 4.4 mitotic H9c2 cells require exposure to a higher 
concentration of H2O2 compared to differentiated H9c2 cells (Figs 4.1 and 4.2). The 
observed increased susceptibly of the differentiated H9c2 cells to cell death from H2O2 
exposure is in agreement with the observation made in previous studies, which have shown 
that differentiated H9c2 cell have a reduced oxidative capacity (Comelli et al, 2011). This 
finding further demonstrates the value of using differentiated H9c2 cells as a model cell 
line for the present study. The reduced oxidative capacity of the cardiomyocyte-like 
phenotype of the differentiated H9c2 cell is more similar to in vivo cardiomyocytes than 
that of the embryonic cardiomyoblast undifferentiated H9c2 cell. The cytoprotective effect 
of the studied flavonoids will thus be better reflective of the actions of flavonoids on 
cardiomyocytes in vivo. The susceptibility of the differentiated H9c2 cells to cell death from 
incubation in hypoxic conditions for various times was investigated. Incubation for 24 h was 
shown to have the most significant effect on cell viability, measured by MTT reduction (Fig 
4.5).  
ii) Flavonoid-mediated cytoprotection from H2O2 exposure 
With the establishment of the optimal conditions of inducing cell death through H2O2 
exposure and incubation in hypoxic conditions the cytoprotective effect of the flavonoids 
and the major quercetin metabolites could then be assayed. Firstly, 1 h pre-treatment with 
myricetin was shown to be ineffective in inducing cytoprotection against H2O2 exposure. 
Quercetin was able to induce a consistent protective effect after 1 h pre-treatment, 
observed with both LDH release and MTT reduction assays. The protective effect of 
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kaempferol was observed only with the LDH release assay. The observation that 
kaempferol did not show a protective effect after 1 h pre-treatment measured by the MTT 
reduction assay makes it difficult to confirm if a protective effect was induced, as the LDH 
release assay has been previously shown to be less reliable in terms of detecting cytotoxic 
insults compared to MTT reduction (Fotakis et al, 2006). It is preferable therefore to 
observe a protective effect with both MTT reduction and LDH release. After 24 h pre-
treatment quercetin was able to induce a significant cytoprotective effect with 30 µM and 
100 µM concentrations. This finding is in agreement with other studies using mitotic H9c2 
cells as a model system, it is of note that this present study is the first to identify this 
cytoprotective effect of quercetin in differentiated H9c2 cells (Angeloni et al, 2007). No 
observable cytoprotective effect was induced by 24 h pre-treatment with myricetin at the 
concentrations tested. This contrasts with studies that have previously shown myricetin to 
be able to protect cells from oxidative stress induced apoptosis, although these studies 
were not using cardiomyocyte cells as a model system (Kyoung et al, 2010). Cardiac effects 
induced by myricetin have been observed using a Langendorff perfused heart, where 
myricetin induced an increased concentration of intracellular cAMP, which may be related 
to cytoprotective effects (Angelone et al, 2011). Kaempferol was observed to have a 
potential cytoprotective effect against H2O2 exposure with 24 h pre-treatment with 100 µM 
concentrations. This finding is the first concerning kaempferols cytoprotective effect on 
differentiated H9c2 cells against H2O2 exposure. Kaempferol has been previously shown to 
have a protective effect on mitotic H9c2 cells against simulated ischaemia/reperfusion 
injury, which may be partly mimicked by H2O2 exposure (Kim et al. 2008). The protective 
effect observed by Kim et al. (2008) was elicited from 10 µM kaempferol, although this was 
using mitotic H9c2 cells as a model which have an inherently greater oxidative capacity 
(Comelli et al, 2011). The protective effect induced by the flavonoids myricetin and 
quercetin can be observed with morphological analysis (Fig. 4.11).  
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iii) Flavonoid-mediated cytoprotection from hypoxia 
Pre-treatment (1 h) with myricetin, kaempferol and quercetin was not able to induce a 
significant cytoprotective effect from cell death caused by 24 h incubation in hypoxic 
conditions. The non-induction of a cytoprotective effect was also observed with myricetin 
and kaempferol when differentiated H9c2 cells were pre-treated for 24 h with the flavonoid. 
This contrasts with the protective observation of a cytoprotective effect being observed 
with 24 h pre-treatment with myricetin against H2O2 exposure. As stated previously, 
kaempferol has been shown to have a protective effect against ischaemia/reperfusion 
injury. Several differences in methodology between the present study and that of Kim et al. 
(2008) may explain why no protective effect was observed in the present study with 
kaempferol pre-treatment. A protective effect using kaempferol was observed, ischaemia 
was induced for 12 h without the use of a hypoxic incubator and mitotic H9c2 cells were 
used as a model system. Furthermore cells were in the constant presence of kaempferol, 
in comparison to the present study were flavonoid was removed from the cell growth 
medium after pre-treatment and prior to hypoxic incubation (Kim et al. 2008). The present 
study is the first to use myricetin with differentiated H9c2 cells and a hypoxic model of 
oxidative stress induced cell death. Pre-treatment for 24 h with 100 µM quercetin was 
shown to have a cytoprotective effect against hypoxia induced cell death. This observation 
shows that when compared to the other two flavonoids tested, quercetin was the most 
effective in inducing a cytoprotective effect, as it was observed to protect cells from both 
hypoxic and H2O2 exposure induced oxidative stress cell death, generally at 100 µM 
concentrations.  
iv) Cytoprotective effect of quercetin metabolites 
The protective effects of 24 h pre-treatment with the two major quercetin metabolites, 3’-
O-methylquercetin and quercetin-3-glucoronide, against H2O2 exposure was investigated 
(Fig. 4.15). It was demonstrated that 24 h pre-treatment with 100 µM 3’-O-methyl quercetin 
was able to induce a significant protective effect on the differentiated H9c2 cells. In contrast, 
quercetin-3-glucoronide was not able to produce any significant protective effect. The 
partition coefficient (LogP) of both metabolites and quercetin was calculated as follows; 
quercetin 3-glucuronide (-0.49), quercetin (1.68) and 3’-O-methyl quercetin (1.96). These 
LogP values show that quercetin and 3’-O-methylquercetin are similarly lipophilic, whereas 
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the negative LogP of quercetin 3-glucuronide suggests a greater lipophobicity. The 
lipophobic nature of quercetin-3-glucorinde may partially explain why no protective effect 
was elicited from 24 h pre-treatment. Migration through the cellular membrane and 
binding of quercetin-3-glucorinde to membrane bound proteins would be ameliorated by 
its lipophobic structure, which would prevent intracellular ROS scavenging (Chang et al, 
2007). The hydroxyl group substitutions on the B ring of quercetin, as well as an 
unsaturated C2-C3 bond, allow it to bind with ATP binding sites in some enzymes (Williams 
et al, 2004). The hydroxyl group substitutions on the B ring of quercetin-3-glucorinde are 
changed from those of quercetin (Figs 1.4 & 1.7) (Williams et al, 2004). The structural 
differences between quercetin, kaempferol and myricetin may also partially explain why 
myricetin is able to induce a protective effect in differentiated H9c2 cells when insulted 
with H2O2 exposure. The partition coefficient of myricetin, 1.392, is quite similar to that of 
quercetin, were the partition coefficient of kaempferol was calculated as 2.172. These 
calculations suggests that all three flavonoids are lipophilic, and thus able to migrate 
through the cell membrane and potentially associate with membrane bound proteins. 
Structurally, both myricetin and kaempferol have the unsaturated C2-C3 present in 
quercetin, and myricetin has similar hydroxyl group substitutions on the B ring of the flavan 
nucleus structure. The structural similarity and LogP of myricetin to quercetin may explain 
partly why myricetin is able to induce a protective effect in differentiated H9c2 cells, as it 
would allow myricetin to potentially bind to similar or the same proteins as quercetin.      
v) Involvement of protein kinases in flavonoid-mediated cytoprotection  
To understand the mechanism of flavonoid mediated cardioprotection, the effects of 
quercetin on H2O2- and hypoxia induced protein kinase (ERK1/2, PKB, JNK and p38 MAPK) 
activation in differentiated H9c2 cells was investigated using western blotting. Quercetin 
was selected as a model flavonoid for this investigation as previous findings in the present 
study identify quercetin as the most potent flavonoid in inducing a cytoprotective effect in 
differentiated H9c2 cells.  Previous studies have shown that several protein kinases, 
including the ones investigated in the present study, are activated in response to reactive 
oxygen species (Kamata and Hirata, 1999). This increased activation of protein kinase 
activity by ROS has been demonstrated in cardiomyocytes (Clerk et al, 1998; Pham et al, 
2000; Takeishi et al, 1999).  As demonstrated in section 4.6 Figs 4.16 and 4.17, 2 h exposure 
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to 600 µM H2O2 caused a significant increase in phosphorylation of ERK1/2, PKB, JNK and 
p38 MAPK in differentiated H9c2 cells, in agreement with previous reports. Pre-treatment 
for 24 h with both 30 µM and 100 µM quercetin significantly reduced the phosphorylation 
of ERK1/2, PKB, JNK and p38 MAPK when compared to H2O2 treated cells. Quercetin pre-
treatment (30 µM) failed to significantly reduce the phosphorylation of JNK (Fig.  4.16), 
although not significant the phosphorylation is noticeably reduced, and lack of significance 
is most likely due to the large variance observed in H2O2 induced phosphorylation of JNK. 
Similarly, 24 h incubation in hypoxic conditions lead to an increased activation of protein 
kinases (Fig. 4.18). Unusually this was not observed clearly in Fig. 4.19 with PKB and p38 
MAPK. Pre-treatment for 24 h with 100 µM and 30 µM quercetin was shown to significantly 
reduce the phosphorylation induced by hypoxia incubation, except for p38 MAPK with 100 
µM. Basal expression of ERK1/2 and PKB was shown to be unaffected by quercetin after 24 
h pre-treatment in terms of significant inhibition (Figs. 4.16 - 4.19), despite the fact that 
quercetin is known to be a competitive inhibitor of MEK1 and PI3Kγ, upstream regulators 
of ERK1/2 and PKB respectively.  Significant inhibition of basal ERK and PKB expression by 
24 h pre-treatment with 100 µM quercetin was observed in Fig. 4.20, though not by 24 h 
pre-treatment with 30 µM quercetin. This basal level inhibition was compared to the 
inhibition induced from PD98059 (50 µM) and LY 294002 (30 µM), specific inhibitors for MEK1 
and PI3K respectively.  The observed inhibition of ERK1/2 and PKB during oxidative stress is 
likely therefore to be induced through a pathway independent of MEK1 and PI3K inhibition. 
As shown in Fig. 4.21 24 h incubation with specific inhibitors for protein kinases caused no 
significant loss in cell viability, save for LY294002. Furthermore, the specific inhibitors had 
no effect on quercetin induced cardioprotection, and the inhibitors alone caused no 
significant protective effect. Inhibition of a single kinase by a selective inhibitor caused no 
protective effect, whereas the protective effect of quercetin was associated with the 
inhibition of several kinases. As quercetin is a non-selective inhibitor, the inhibition of 
multiple kinases at the same time may be conducive to a cytoprotective effect. Therefore, 
using several specific inhibitors in conjunction to induce a cytoprotective effect should be 
considered in future investigations. Contrary to the observations made in the present study, 
it has been suggested that the principal mechanism of quercetin induced cytoprotection in 
mitotic H9c2 cells is the activation of ERK1/2 and PI3K (Angeloni et al, 2007). This discrepancy 
may be a result of using differentiated H9c2 cells as a model system, which have been shown 
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to be more physiologically similar to in vivo cardiomyocytes, rather than mitotic H9c2 cells. 
The mechanism of quercetin induced cytoprotection from hypoxia and H2O2 exposure most 
likely involves the modulation of oxidative stress induced protein kinase activation that are 
involved in apoptosis and cell survival. Cell death from oxidative stress has been linked with 
the mitochondria-dependent or intrinsic apoptotic pathways, which have been shown to be 
inhibited by the flavonoid isorhamnetin in mitotic H9c2 cells through the inactivation of 
ERK1/2 (Sun et al, 2012). Isorhammetin is almost structurally identical to quercetin, and 
therefore it is plausible that quercetin acts in a similar manner. A major mechanism of 
quercetin induced cytoprotection is therefore inactivation of ERK1/2, inhibiting 
downstream pro-apoptotic signalling. Quercetin has been shown to also inhibit ERK1/2, 
PKB, JNK and p38 MAPK activation in mitotic H9c2 cells in response to other stimuli 
(Gutiérrez-Venegas et al, 2010). Furthermore, myricetin and kaempferol have also been 
shown to inhibit the activation of JNK and p38 MAPK in a number of difference cell lines, 
resulting in prevention of oxidative stress induced apoptosis (Mansuri et al, 2014). The 
observations made in the present study agree that quercetin is a potent inhibitor of several 
protein kinases, which will contribute majorly to the observed cytoprotective effect.  It is 
notable that specific inhibitors alone did not induce a significant protective effect against 
oxidative stress induced cell death, despite the inhibition of these protein kinases being a 
major mechanism of quercetin mediated cytoprotection. Previous studies on quercetin 
mediated cardioprotection in H9c2 cells have also identified several other mechanisms that 
contribute to the cytoprotective effect (Dong  et al, 2014). Quercetin was shown to induce 
upregulation of the mitochondrial regulatory protein Bmi-1, decrease ROS production by 
inhibiting Nox1 and inhibiting Ca2+- dependant ATP hydrolysis, ATP-dependant Ca2+ uptake 
and Ca2+ release (Dong et al, 2014).  This suggests that quercetin specifically, and flavonoids 
in general, induce a protective effect as a result of synergistic inhibition of multiple protein 
kinases, rather than inhibition of single protein kinases, combined with decreasing ROS 
generation and ROS scavenging activity (Dong et al, 2014).  
After ingestion quercetin is glycosylated, therefore native quercetin levels in the plasma 
are often undetectable (Russo et al, 2012). After metabolism in the liver to the 
glucuronidated, sulphated or methylated metabolites, the quercetin metabolites can be 
absorbed by cells and de-conjugated to form native quercetin, which has been shown to 
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be more potent in terms of cytoprotectivity (Kawai et al, 2008). Metabolites of quercetin 
have been shown to be less potent in inducing a cytoprotective effect when compare to 
quercetin, the present study agrees with this observation, as 3’-O-methyl quercetin was only 
effective at 100 µM concentrations (Williamson et al, 2005). The findings of this present study 
also suggest the inability of differentiated H9c2 cells to de-conjugate quercetin 3-glucuronide 
as no significant cytoprotective effect was observed using this metabolite.   
vi) Implications of flavonoid induced cytoprotection 
Quercetin was shown to induce a cytoprotective effect with concentrations ≥ 30 µM after 24 
h exposure and subsequent exposure to H2O2. Similarly, 3’-O-methyl quercetin induced a 
protective effect at 100 µM concentration after exposure to H2O2. To protect against hypoxia 
induced cell death a concentration of 100 µM quercetin was required. The bioavailability of 
flavonoids and the maximum achievable plasma concentrations (7.6 µM quercetin and 
quercetin metabolites) without supplementation are a great deal lower than these 
concentrations (Labbé et al, 2009). Therefore, based on these observations, the 
cytoprotective effects observed in this chapter are unlikely to be achievable in vivo from 
dietary flavonoids. Further investigations into the intracellular accumulation of quercetin 
and other flavonoids, resulting from exposure to the aglycone or metabolites followed by 
their intracellular deconjugation, are required to determine more accurately the 
concentrations required to induce a cytoprotective effect in vivo. In addition, the results of 
this chapter highlight that quercetin has a potent and significant effect on cell signalling 
molecules under laboratory conditions, which may form the basis of a cytoprotective effect.     
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Chapter 5: 
Cytotoxicity of 
flavonoids 
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5.0 Cytotoxicity of flavonoids 
In the presence of oxygen the intracellular metabolism of quercetin, its metabolites, and 
other flavonoids has been shown to lead to the creation of reactive oxygen species (ROS) 
and other pro-oxidant effects (Metodiewa et al, 1999). Although short term exposure to 
quercetin was shown to reduce intracellular ROS (Dong et al, 2014). Extended periods of 
exposure to ROS leads to apoptosis, although the mechanism by which ROS induce 
apoptosis is still unclear. It is proposed that ROS leads to the oxidation of mitochondrial 
pores, leading to the release of cytochrome-c and the activation of pro-apoptotic cell 
signals and enzymes such as Caspase-3 (Simon  et al, 2000). Therefore, prolonged exposure 
to flavonoids may induce apoptosis due to their intracellular accumulation and metabolism.  
Therefore, this chapter aims to investigate the cytotoxic effects of prolonged exposure to 
dietary flavonoids and major quercetin metabolites on H9c2 cells for the first time.  
The effect of prolonged (≥24 h) exposure to concentrations of quercetin, kaempferol, 
myricetin and the quercetin metabolites quercetin-3-glucoronide and 3’-O-
methylquercetin on cell viability will be investigated using MTT reduction and LDH release 
assays. As with the investigation into the cytoprotective effects of flavonoids (Chapter 4) 
the range of concentrations (1-100 µM) used reflect the bioavailability of flavonoids in vivo, 
as well as the potential for intracellular and plasma accumulation of flavonoid following 
repeated dietary intake (Labbé et al, 2009).  
 
The differences in the metabolic activity of mitotic (proliferating) and differentiating H9c2 
may impact on the potential cytotoxic effect of prolonged flavonoid exposure, as mitotic 
H9c2 cells are known to be less sensitive to oxidative stress, which in this case would be 
caused by intracellular ROS generation (Pereira et al, 2011). Furthermore, as differentiated 
H9c2 cells are known to have an increased mitochondrial mass, this may contribute to an 
increased sensitivity to cytotoxicity induced by flavonoid dependant ROS generation 
(Branco et al, 2013). Considering this, the effect of prolonged (≥24 h) exposure to 
flavonoids and flavonoid metabolites will be investigated in mitotic (proliferating), 
differentiating and fully differentiated H9c2 cells using cell viability assays. 
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The direct modulation of cell signalling molecules represents another mechanism by which 
flavonoids may induce cytotoxicity. Quercetin is known to inhibit MEK, and consequently 
the PI3K pathway; furthermore Apoptosis is also heavily regulated by the MAPK and PI3K 
cell signalling pathways (Russo et al, 2012; Mendoza et al, 2011; Simon et al, 2000). To 
investigate how prolonged flavonoid exposure affects these cell signals will be determined 
using western blotting to monitor the phosphorylation of ERK1/2, PKB, p38 MAPK and JNK. 
Caspase-3 activation will also be monitored using western blotting, as the activation of 
Caspase-3 is a significant marker of apoptosis and may be induced by the mitochondrial 
damage caused by intracellular ROS generation as well as the cell signalling activity 
modulated by flavonoids (Simon et al, 2000).       
  
It is proposed that flavonoids will undergo pro-oxidant intracellular metabolism to produce 
ROS in H9c2 cells after prolonged exposure (Metodiewa et al, 1999). To quantify 
intracellular ROS generation arising from flavonoid exposure the DCFDA ROS assay will be 
used in conjunction with flow cytometry, where intracellular ROS levels will be measured 
after 24, 48 and 72 h exposure to flavonoid. Combined with cell viability observations and 
the monitoring of cell signal phosphorylation and Caspase-3 activation, a clearer picture of 
flavonoid induced cytotoxicity can be produced.   
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5.1 Cytotoxicity of flavonoids on proliferating cardiomyoblasts 
To measure the effects of exposure to flavonoids on proliferating cardiomyoblasts, 
undifferentiated H9c2 cells were exposed to a range of concentrations (100, 30, 10, 3 and 
1  µM) of a particular flavonoid, either quercetin, myricetin or kaempferol. Cell were 
exposed for 24, 48 or 72 h, after which the viability of the cells was assayed using LDH 
release and MTT reduction assays. 
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Fig 5.1 Effect of Kaempferol exposure on proliferating H9c2 cell viability. MTT reduction (A, B, C) and LDH 
release (D, E, F) assays showed that kaempferol at all concentrations tested produced no significant 
changes in viability at time points tested; 24 h (A,D), 48 h (B,E) and 72 h (C ,F). Data are expressed as the 
percentage of control cells (24 h C =100%) and represent the mean ± SEM of three independent 
experiments. 
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Fig 5.2 Effect of Myricetin on proliferating H9c2 cell viability. MTT reduction (A,B, C) and LDH release (D, E, 
F) assays. 100 µM myricetin after 48 h exposure (B) caused a significant (*: p < 0.05) decrease in MTT 
reduction. After 72 h as measured by MTT reduction (C) 30 µM (*: p < 0.05) and 100 µM (**: p < 0.01) both 
caused a significant decrease in MTT reduction.  Data are expressed as the percentage of control cells (24 
h C =100%) and represent the mean ± SEM of three independent experiments. 
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Fig 5.3 Effect of quercetin on proliferating H9c2 cell viability. MTT reduction (A,B, C) and LDH release (D, E, 
F) assays. 1 µM and 10 µM quercetin after 48 h exposure (B) caused a significant (1 µM & 10 µM, *: p < 
0.05) decrease in MTT reduction.  After 72 h as measured by MTT reduction (C) all concentrations of 
quercetin caused a significant decrease in MTT reduction ( 3 µM, **: p < 0.01; 1 µM & 10 µM, ***: p < 0.005; 
30 µM & 100 µM, ****: p < 0.001). Data are expressed as the percentage of control cells (24 h C =100%) 
and represent the mean ± SEM of three independent experiments. 
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From these assays shown on Fig. 5.1, 5.2 and 5.3 it is demonstrated that quercetin and 
myricetin have a significant effect on proliferating H9c2 cell viability, mainly at 30 µM and 
100 µM concentrations, and after at least 48 h exposure time.   
 
5.2 Cytotoxicity of flavonoids on differentiating cardiomyoblasts 
To determine the effects of flavonoids on the viability of H9c2 cells during differentiation, 
cells were incubated with a flavonoid and well as differentiation medium. The viability of 
the cells was assayed using MTT reduction and LDH release at three time points, 24 h, 72 h 
and 7 days. Every 48 h the differentiation medium as replaced along with the relevant 
concentration of flavonoid.  
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Fig 5.4 Effect of kaempferol on differentiating H9c2 cell viability. MTT reduction (A,B, C) and LDH release 
(D, E, F) assays. As measured with LDH release 72 h treatment with 30 µM kaempferol (E) caused a 
significant ( *: p < 0.05) increase in LDH release compared to the control. After 7 days exposure to 
kaempferol (F) 10, 30 and 100 µM concentrations elicited a significant increase in LDH release (10 µM & 
100 µM, **: p < 0.01; 30 µM, ***: p < 0.005). Data are expressed as the percentage of control cells (24 h C 
=100%) and represent the mean ± SEM of three independent experiments. 
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Fig 5.5 Effect of myricetin on differentiating H9c2 cell viability. MTT reduction (A,B, C) and LDH release (D, 
E, F) assays. As measured with MTT reduction 24 h treatment with 10, 30 and 100 µM myricetin (A) caused 
a significant ( 10 µM & 30 µM, **: p < 0.05; 100 µM, ***: p < 0.005) decrease in MTT reduction  compared 
to the control. After 72 h exposure to myricetin (B) 100 µM concentration caused a significant decrease in 
MTT reduction (**: p < 0.01). 7 days exposure to myricetin (C) at 30 µM and 100 µM caused significant 
decreases in MTT reduction,  (30 µM **: p < 0.01; 100 µM, ****: p < 0.001). Data are expressed as the 
percentage of control cells (24 h C =100%) and represent the mean ± SEM of three independent 
experiments. 
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Fig 5.6 Effect of quercetin on differentiating H9c2 cell viability. MTT reduction (A,B, C) and LDH release (D, 
E, F) assays. After 72 h exposure to quercetin, 10, 30 and 100 µM caused a significant change in both MTT 
reduction (B) and LDH release (E). The MTT reduction assay (B) showed that 10, 30 and 100 µM caused 
significant (***: p < 0.005) decrease in MTT reduction. The LDH release assay (E) showed 10 µM caused a 
significant (**: P < 0.01) increase in LDH release, whereas 30 µM and 100 µM exposure caused a more 
significant (***: p < 0.005) increase. Data are expressed as the percentage of control cells (24 h C =100%) 
and represent the mean ± SEM of three independent experiments. 
 Figs 5.4, 5.5 and 5.6 show that quercetin and myricetin have a significant effect on the 
viability of differentiating H9c2 cells measured by MTT reduction.  
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5.3 Cytotoxicity of flavonoids on differentiated cardiomyocytes 
To measure the effects of exposure to flavonoids on differentiated H9c2 cardiomyocytes, 
7 day differentiated H9c2 cells were exposed to a range of concentrations (100, 30, 10, 3 
and 1 µM) of flavonoid (quercetin, myricetin or kaempferol). Cell were exposed for 24 h, 
48 h or 72 h, after which the viability of the cells was assayed using LDH release and MTT 
reduction assays. 
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Fig 5.7 Effect of kaempferol on differentiated H9c2 cell viability. MTT reduction (A,B, C) and LDH release (D, 
E, F) assays. At all concentrations and time points tested (24 h: A & D, 48 h: B & E, 72 h C & F) kaempferol 
caused no significant changes in LDH release or MTT reduction. Data are expressed as the percentage of 
control cells (24 h C =100%) and represent the mean ± SEM of three independent experiments. 
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Fig 5.8 Effect of myricetin on differentiated H9c2 cell viability. MTT reduction (A,B, C) and LDH release (D, 
E, F) assays. After 48 h exposure to 100 µM myricetin (B) there was a significant (*: p < 0.05) decrease in 
MTT reduction. After 72 h (C), exposure to 30 µM and 100 µM myricetin caused significant decreases (30 
µM, *: p < 0.05; 100 µ, **: p < 0.01) in MTT reduction. Data are expressed as the percentage of control cells 
(24 h C =100%) and represent the mean ± SEM of three independent experiments. 
 
 
 
 
A) 
B) 
C) 
D) 
E) 
F) 
128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.9 Effect of quercetin on differentiated H9c2 cell viability. MTT reduction (A,B, C) and LDH release (D, 
E, F) assays. 100 µM quercetin treatment for 24 h (D) caused a significant (*: P < 0.05) increase in LDH 
release. After 48 h exposure to 100 µM quercetin both MTT reduction and LDH release assays (B & E) show 
a significant change (B, *: p < 0.05; E, **: p < 0.01). The LDH release assay also showed 30 µM quercetin to 
have a significant effect (*: p < 0.05) after 48 h (E). After 72 h exposure to 100 µM quercetin MTT reduction 
and LDH release assays (C & F) show a significant effect (C, *: p < 0.05; F, ***: p < 0.005). The LDH release 
assay also showed 30 µM quercetin had a significant effect (**: p < 0.01) after 72 (F). Data are expressed 
as the percentage of control cells (24 h C =100%) and represent the mean ± SEM of three independent 
experiments. 
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From figs. 5.7, 5.8 and 5.9 it is shown that 30 µM and 100 µM quercetin and myricetin have 
a significant effect on differentiated H9c2 cell viability after at least 48 h exposure. Both 
MTT reduction and LDH release showed that 100 µM causes a significant toxic effect after 
48 h, this can be seen to be the most reliable method of inducing flavonoid mediated 
cytotoxicity. The cytotoxicity of 30 µM and 100 µM quercetin exposure is further 
demonstrated visually in Fig. 5.10.  
 
Fig. 5.10 Visible cytotoxic Effect of quercetin exposure on differentiated H9c2 cells. Differentiated H9c2 
cells were incubated without quercetin for A) 24 h, B) 48 h C) 72 h, with 30 µM quercetin for D) 24 h, E) 48 
h, F) 72 h, or 100 µM quercetin for G) 24 h, H) 48 h, I) 72 h. Visible cell death (red arrowheads) occurs after 
48 h  exposure to both 30 µM and 100 µM quercetin. Stained with Coomassie blue.  
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5.4 Cytotoxicity of quercetin metabolites on differentiated cardiomyocytes  
To measure the effects of exposure to quercetin metabolites on differentiated H9c2 
cardiomyocytes, 7 day differentiated  H9c2 cells were exposed to a range of concentrations 
(100, 30, 10, 3 and 1  µM) of either 3’-O-methyl quercetin (Q3M) or quercetin-3-glucorinde 
(Q3G) . Cell were exposed for 24 h, 48 h or 72 h, after which the viability of the cells was 
assayed using LDH release and MTT reduction assays. 
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Fig 5.11 Effect of 3’-O-methyl quercetin on differentiated H9c2 cell viability. MTT reduction (A,B, C) and LDH 
release (D, E, F) assays. After 24 h exposure the LDH release assay (D) shows 100 µM 3’-O-methyl quercetin 
(Q3M) caused a significant change (*: p < 0.05) compared to control. After 48 h exposure (B) showed that 
3 µM, 10 µM, 30 µM and 100 µM Q3M caused a significant decrease in MTT reduction (10 µM & 100 µM, 
**: p > 0.01; 3 µM & 30 µM, ***: p < 0.005). LDH release (E) also showed 100 µM Q3M caused a significant 
increase in LHD release (*: p > 0.05). After 72 h exposure MTT reduction (C) showed that 3 µM, 10 µM, 30 
µM and 100 µM Q3M caused a significant decrease in MTT reduction (3 µM, *: p > 0.01; 10 µM, **: p > 0.01; 
30 µM & 100 µM, ***: p < 0.005). Data are expressed as the percentage of control cells (C =100%) and 
represent the mean ± SEM of six independent experiments. 
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Fig 5.12 Effect of quercetin-3-glucorinde on differentiated H9c2 cell viability. MTT reduction (A,B, C) and 
LDH release (D, E, F) assays. quercetin-3-glucorinde (Q3G) at all concentrations tested produced no 
significant changes in viability at points tested; 24 h (A,D), 48 h (B,E) and 72 h (C,F). Data are expressed as 
the percentage of control cells (C =100 %) and represent the mean ± SEM of six independent experiments. 
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5.5 Protein kinase expression associated with flavonoid induced cytotoxicity   
As 100 µM quercetin exposure to differentiated H9c2 cells was shown to produce the most 
consistent cytotoxicity these parameters were used to test for the effect of flavonoid 
exposure on protein kinase phosphorylation. Differentiated cells were exposed to 100 µM 
quercetin for 24 h, 48 h and 72 h and the phosphorylation of ERK1/2, PKB, p38 MAPK and 
JNK were monitored using western blotting.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
134 
 
 
 
 
Fig. 5.13 Effect of prolonged quercetin exposure on protein kinase activation. Following exposure to 100 
µM quercetin for 24 h, 48 h or 72 h cell lysates were harvested and activation of protein kinases was 
analysed using western blotting for A) ERK 1/2 B) PKB C)p38 MAPK D) JNK using phosphor-specific 
antibodies along. Samples were then analysed on separate blots for total versions of the protein kinases 
using total specific antibodies. It is shown that 72 h exposure to 100 µM quercetin causes a significant (*: 
p < 0.05) increase in phosphorylated levels of  A) ERK 1/2 B) PKB C)p38 MAPK and D) JNK. It is also observed 
that 24 h and 48 h exposure to 100 µM quercetin causes a significant (*: p < 0.05) change in B) PKB 
phosphorylated expression. No significant change was seen in levels of total protein kinase expression for 
all kinases analysed.        
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Fig. 5.14 Effect of prolonged exposure to quercetin on caspase-3 activation. Following exposure to 100 µM 
quercetin for 24 h, 48 h or 72 h cell lysates were harvested and activation of Caspase-3 was monitored with 
western blotting using anti-cleaved caspase-3 specific antibody. It is shown that 48 h and 72 h exposure to 
100 µM quercetin causes as significant (*: p < 0.05) increase in caspase-3 activation.  
As shown in fig. 5.13, it can be observed that 72 h exposure to 100 µM quercetin causes 
levels of phosphorylated ERK1/2, PKB, p38 MAPK and JNK to increase. This increase in 
protein kinase phosphorylation at this time point suggests a relationship between the 
previously observed incidences of quercetin mediated cell death measured by MTT 
reduction and LDH release assays. The increased activation of caspase-3 at 48 h and 72 h 
as shown in fig. 5.14 also coincide with the observation of loss of cell viability at these time 
points using MTT reduction and LDH release. This suggests a role for apoptosis in flavonoid 
associated cytotoxicity.  
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5.6 Intracellular ROS associated with prolonged flavonoid exposure 
The potential relationship between flavonoid induced cytotoxicity and intracellular ROS 
was investigated using the DCFDA assay. Differentiated (7 days) H9c2 cardiomyocytes were 
exposed to 100 µM quercetin for 24 h, 48 h or 72 h, and then the presence of intracellular 
ROS was assayed using the DCFDA fluorescent probe and flow cytometry.   
 
Fig 5.15 Effect of quercetin on reactive oxygen species (ROS) production. Differentiated H9c2 cells were 
treated with 100 µM quercetin for 24, 48 and 72 h. ROS production was measured using flow cytometry 
and the fluorescent probe DCFDA. Both 48 h and 72 h exposure to 100 µM quercetin caused a significant 
(*: p < 0.05; **: p < 0.01) increase in fluorescing cells counted. Data are expressed as the percentage of 
positive fluorescing cells (10,000 sampled) in each condition, and represent toe mean ± S.E.M of three 
independent experiments.     
As shown on fig. 5.15 both 48 h and 72 h exposure to 100 µM quercetin caused a significant 
increase in intracellular ROS. These time points and the concentrations of quercetin match 
exactly those shown in Fig. 5.10 to cause significant reduction in cell viability, this highlights 
the possibility that a major mechanism of flavonoid cytotoxicity is causing an increase in 
intracellular ROS. This pattern of cell death associated events can also be seen with the 
activation of caspase-3 after 48 h and 72 h exposure to quercetin, further demonstrating 
the link between flavonoid exposure, ROS production and apoptosis.   
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5.7 Summary of findings 
This chapter identified that flavonoids, as well as having a cytoprotective effect, can have 
a cytotoxic effect when cells are exposed to concentrations of flavonoid for prolonged 
periods (> 24 h). Quercetin and myricetin were shown to have a cytotoxic effect on mitotic, 
differentiating, and differentiated H9c2 cardiomyocytes. Kaempferols cytotoxic effects 
were observed only in H9c2 cells undergoing differentiation. Quercetin was shown to have 
the most consistently measureable cytotoxic effect, as the cytotoxicity of 100 µM exposure 
was confirmed with both cell viability assays at both 48 h and 72 h exposure times. Of the 
two metabolites tested 3’-O-methylquercetin was shown to have a cytotoxic effect on 
differentiated H9c2 cells after 48 h at a 3-100 µM concentration range. The phosphorylation 
of ERK1/2, PKB, JNK, p38 MAPK and activation of caspase-3 during prolonged exposure to 100 
µM quercetin was investigated using western blotting. The levels of phosphorylated cell 
signals was significantly raised after 72 h exposure to 100 µM quercetin, and caspase-3 
activation was significantly increased after 48 h and 72 h exposure to 100 µM quercetin. The 
significantly increased phosphorylation occurs when cytotoxicity was observed, and the 
activation of caspase-3 suggests apoptosis is a consequence of prolonged exposure to 
quercetin. The potential pro-oxidant effect of prolonged quercetin exposure was investigated 
using the DCFDA assay to measure intracellular reactive oxygen species. Intracellular ROS was 
found to be significantly raised after 48 h and 72 h exposure, which links with the previous 
time point observations with regard to cytotoxic effect, phosphorylation of protein kinases 
and activation of caspase-3.    
5.8 Discussion of flavonoid-mediated cytotoxicity. 
i) Cytotoxicity of Flavonoids 
In the present study quercetin was shown to have no cytotoxic effect after 24 h exposure 
on mitotic, differentiating or differentiated H9c2 cells. This finding is in agreement with 
previous studies that have used only mitotic H9c2 cells, showing that no significant toxicity 
is associated with quercetin exposure for 24 h with concentrations up to 100 µM (Angeloni 
et al, 2007). In differentiated cells cytotoxic effects as a result of quercetin exposure were 
observed after 48 h with 30 µM and 100 µM concentrations, with significant reduction in 
MTT reduction and increases in LDH release. After 72 h exposure significant cytotoxicity 
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was also observed.  Myricetin was also shown to have cytotoxic effects on differentiated 
H9c2 cells after 48 h exposure. The observation of flavonoid induced cytotoxicity after 
prolonged ( ≥ 48 h) exposure has not previously been reported. In mitotic H9c2 cells a 
similar effect was observed with myricetin and quercetin, as cytotoxicity after 72 h 
exposure was significant with myricetin concentrations of 30 µM and 100 µM, and all 
concentrations of quercetin tested. The significant cytotoxic effect was only observable 
using the MTT reduction assay, although it is known that this is more accurate in detecting 
cytotoxic events (Fotakis et al, 2006). In H9c2 cells undergoing differentiation myricetin, 
quercetin and kaempferol induced significant cytotoxic effects. Quercetin produced a 
cytotoxic effect after 72 h exposure with concentrations ≥ 10 µM measured by MTT 
reduction and LDH release. A concentration of 10 µM would be achievable in vivo with 
supplementation or flavonoid rich foods (Russo et al, 2012). Previous studies have 
identified that quercetin has cytotoxic effects in combination with other drugs in a number 
of different cell lines (Russo et al, 2010; Spencer et al, 2003; Repetto et al, 2008). The 
mechanism by which quercetin and other flavonoids induce the observed cytotoxic effect 
is most likely due to intracellular metabolism into pro-oxidant intermediates, as shown in 
chapter 1 Fig 1.8 (Metodiewa et al, 1998). Intracellular ROS generation associated with 
quercetin exposure was measured by the DCFDA assay, as shown in Fig. 5.15. Intracellular 
ROS increased with 100 µM quercetin exposure after 48 h, which coincides with the 
induction of significant levels of cytotoxicity in differentiated H9c2 cells.  
 
ii) Cytotoxicity of quercetin metabolites  
The cytotoxicity of the two major quercetin metabolites 3’-O-methyl quercetin and 
quercetin 3-glucuronide on differentiated H9c2 cells was also investigated, which showed 
that quercetin 3-glucuronide has no significant cytotoxic effect. As previously shown in the 
present study, the lipophobicity of quercetin 3-glucuronide was a probable cause for the 
lack of protective effect observed. Therefore, this lipophobicity may also be a contributing 
factor to its lack of cytotoxic effect. Previous studies agree with the observation as a similar 
metabolite, quercetin 7-glucuronide, was shown to have no significant cytotoxic effect on 
neuronal cell lines (Spencer et al, 2006). Conversely 3’-O-methyl quercetin was shown to 
induce cytotoxicity after 48 h and 72 h exposure with doses as low as 3 µM. Previous studies 
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have shown that after 24 h concentrations ranging between 1-30 µM do not induce 
cytotoxicity in mitotic H9c2 cells, in agreement with this present study (Angeloni et al, 2007). 
Although, cytotoxicity has been induced by 3’-O-methyl quercetin in neuronal cells after 6 h 
exposure, indicating the toxic potential of the metabolite (Spencer et al, 2006). Although a 
significant decrease in MTT reduction was observed in differentiated cells exposed for 72 
h to 3-100 µM 3’-O-methyl quercetin no significant LDH released was observed, suggesting 
that 3’-O-methyl quercetin may have an effect on mitochondrial function while not inducing 
a disruption of the cell membrane leading to LDH leakage. Like the parent molecule quercetin, 
a contributing factor to the cytotoxicity of  3’-O-methyl quercetin is most likely due to 
intracellular metabolism promoting the production of intracellular ROS, or the deconjugation 
of the metabolite intracellularly followed by intracellular ROS generation by the metabolism 
of the aglycone (Viskupičová et al, 2008).     
iii) Role of cell signalling in flavonoid-mediated cytotoxicity  
To investigate more fully the mechanism by which quercetin induces a cytotoxic effect, 
western blotting was used to monitor the phosphorylation of the pro-survival cell signalling 
molecules ERK1/2 and PKB, and the pro-apoptosis signalling molecules JNK and p38 MAPK 
in addition to the activation of the apoptosis marker capase-3. Quercetin has been shown 
to induce significant activation of caspase-3 in neuronal cells, which coincides with its 
cytotoxic effects (Spencer et al, 2006). Using western blotting quercetin (100 µM) was able 
to induce caspase-3 activation after 48 h and 72 h exposure in differentiated H9c2 cells. 
This suggest that quercetin induces apoptotic cell death after 48 h exposure, which would 
also suggest that the cytotoxic effect of myricetin and 3’-O-methyl quercetin induce a similar 
response. As quercetin is known to be a potent inhibitor of MEK1 and P1-3Kγ, upstream 
regulators of ERK1/2 and PKB, it is expected that the mechanism of cytotoxicity of quercetin 
involves the attenuation of ERK1/2 and PKB activation and the activation of the pro-apoptotic 
signals JNK and p38 MAPK (Hers et al, 2007; Lu and Xu, 2006). Quercetin demonstrates a more 
potent inhibition of MEK1 than the commercially available and widely used MEK1 inhibitor 
PD98059 (Lee et al, 2008). In the present study, as shown in Fig. 5.13 24 h exposure to 100 
µM quercetin significantly attenuated the phosphorylation of PKB and reduced the 
phosphorylation of ERK1/2. Interestingly after 48 and 72 h exposure the levels of 
phosphorylated PKB significantly increase, suggesting a bi-phasic pattern of quercetin 
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interactions with PKB. The actions of quercetin on PKB and ERK1/2 are varied and conflicting, 
as Angeloni et al (2007) reported that quercetin at 30 µM activates ERK1/2 and PKB in mitotic 
H9c2 cells. Quercetin mediated activation of ERK1/2 has also been reported in macrophages 
(Chow et al, 2005) pancreatic β cells (Youl et al, 2010) and HepG2 cells, where it also induces 
an increase in JNK, p38 MAPK and PKB phosphorylation (Weng et al, 2011).  However 
quercetin has been shown to inhibit the phosphorylation of ERK1/2 and PKB in neuronal 
cell lines (Spencer et al, 2003), and PKB inhibition plays a crucial role in the reported anti-
proliferative effects of quercetin on cancer cells (Gulati et al, 2006). As shown in Fig. 4.20 
24 h exposure to 30 µM quercetin did not cause a significant effect on the phosphorylated 
levels of ERK1/2 or PKB,  whereas 24 h exposure to 100 µM quercetin significantly 
attenuated ERK1/2 and PKB phosphorylation (Fig 4.20 and 5.13). The effect of 24 h 
exposure to 100 µM quercetin is analogous to the effect of the two selective inhibitors for 
MEK1 and PI3K, PD98059 and LY294002 respectively. In the present study exposure to 100 
µM quercetin for 72 h caused a significant increase in the phosphorylated levels of ERK1/2, 
p38 MAPK, JNK and PKB in the differentiated H9c2 cells. Quercetin induced cytotoxicity can 
therefore be linked to apoptosis, as both JNK and p38 MAPK are pro-apoptotic cell signals 
(Mansuri et al, 2014). Other mechanisms of quercetin induced cytotoxicity have been 
shown to be JNK independent (Kim and Lee, 2007). The mechanism by which quercetin 
induces JNK and p38 MAPK phosphorylation remains unclear, quercetin has been shown to 
stimulate the upstream kinases TAK1 and MKK3/6 which are associated with p38 MAPK 
(Chang et al, 2012). Clearly, flavonoid induced cytotoxicity involves the modulation of 
several protein kinases, both associated with survival and apoptosis.       
iv) Implications of flavonoid induced cytotoxicity 
The findings detailed in this current chapter and chapter 4 present somewhat of a paradox. 
Quercetin was shown to induce a cytoprotective effect with concentrations ≥ 30 µM after 24 
h exposure, whereas after 48 h exposure these same concentrations were shown to cause 
significant cell death in differentiated H9c2 cells. This present study is the first time these 
effects have been demonstrated at the same time. Considering the bioavailability of quercetin, 
with the reported maximal plasma concentration achievable being < 10 µM, it is unlikely that 
cardiac cells in vivo will be exposed to the concentrations that were observed to cause 
cytotoxicity in a single dose from dietary sources (Labbé et al, 2009). Similarly, as shown in 
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chapter 4, the doses required to elicit a cytoprotective effect are higher than the currently 
achievable plasma concentration from dietary sources. Of the metabolites investigated 3’-O-
methyl quercetin was shown to cause significant cytotoxicity with doses ≥ 3 µM. Quercetin 
and its metabolites in the plasma have been shown to surpass this concentration, furthermore 
the lipophilicity of quercetin and  3’-O-methyl quercetin suggest it could be accumulated in 
cells (Labbé et al, 2009). Although, when considering the half-life of the quercetin 
metabolites exposure to the required does to induce cytotoxicity in vivo is unlikely. The 
results of this chapter therefore represent a phenomenon that is only be created artificially. 
Despite this, these results highlight that quercetin in particular and flavonoids in general 
can have major effects on cells under certain conditions, currently achievable in a 
laboratory.        
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Chapter 6: Proteomic 
identification of 
flavonoid mediated 
cardioprotective 
associated proteins 
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6.0 Proteomic identification of flavonoid mediated cardioprotective associated proteins. 
Exposure to quercetin has been observed to cause inhibition of the MAPK and PI3K 
pathways in mitotic H9c2 cells in previous studies and differentiated cells as shown in 
Chapter 4 (Gutiérrez-Venegas et al, 2010; Angeloni et al, 2012; Angeloni et al, 2007; Sun et 
al, 2012; Kim et al, 2010; Mojzisová et al, 2009). As these cell signal cascades can lead to 
the activation of protein expression, it is proposed that flavonoid exposure may lead to the 
increased expression of proteins associated with these pathways (Courtney et al, 2010; 
Roskoski, 2012). For the first time proteomic methods will be used to investigate the effects 
of quercetin exposure on protein expression in differentiated H9c2 cells treated with 
quercetin and differentiated H9c2 cells treated with quercetin and subsequently exposed 
to oxidative stress.  
Quercetin has been previously shown using proteomic methods to induce increased 
expression of several proteins in mitotic H9c2 cells treated with 1 mM quercetin and 5 mM 
H2O2 (Chen et al, 2013). Using the information obtained regarding the concentrations and 
exposure time of quercetin that induces a cytoprotective effect from this present study, 
the proteins expressed in differentiated H9c2 cells treated with 30 µM and 100 µM for 24 
h will be investigated. Furthermore, protein expression in differentiated H9c2 cells treated 
for 24 h with 30 µM and 100 µM quercetin prior to oxidative insult from 600 µM H2O2 
exposure for 2 h will also be investigated. Following identification of proteins by MALDI-
TOF MS, western blotting will be used to further measure the expression of the identified 
proteins.  
The nature of the cell signalling cascades and their interaction with flavonoids are complex 
and remain mostly unknown. It is hoped that using proteomic methods to investigate 
proteins expressed resulting from quercetin exposure will provide novel insight into the 
mechanism of flavonoid mediated cytoprotection.  
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6.1 Two-dimensional gel electrophoresis 
To identify novel proteins associated with flavonoid mediated cardioprotection cell lysates 
from specific treatments were prepared and subjected to two-dimensional gel 
electrophoresis. Two-dimensional gels were prepared from differentiated H9c2 cells 
exposed to 600 µM H2O2 for 2 h (Fig 6.3), differentiated H9c2 cells pre-treated for 24 h with 
100 µM quercetin and then exposed to 600 µM H2O2 for 2 h (Fig 6.1) and differentiated 
H9c2 cells pre-treated for 24 h with 30 µM quercetin and then exposed to 600 µM H2O2 for 
2 h (Fig. 6.2). Furthermore, Two-dimensional gels were prepared from lysates from cells 
treated with 100 µM (Fig. 6.4) and 30 µM (Fig. 6.5) without the additional 600 µM H2O2 
treatment, to determine if the expression of some novel proteins is associated with 
flavonoid treatment alone. The lysates were prepared using specific 2D gel electrophoresis 
lysis buffer, as described in section 2.7. Two-dimensional gel electrophoresis was then 
performed, the gels stained and imaged according to the section 2.7. An example gel from 
each set of three for each of the treatment conditions are shown below, full sets of the 
three gels for each treatment can be seen in Appendix 2.    
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Fig 6.1 Expression pattern of proteins in 100 µM quercetin pre-treated differentiated H9c2 cells after 
exposure to H2O2. Proteins are separated first according to isoelectric point along a pH gradient, and then 
according to mass with polyacrylamide gel. Mass (kDa) has been highlighted using protein standards. Image 
is a representative gel of three separate experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
pH 3-10 
250 kDa 
150 kDa 
100 kDa 
75 kDa 
50 kDa 
37 kDa 
25 kDa 
20 kDa 
M
as
s  
146 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.2 Expression pattern of proteins in 30 µM quercetin pre-treated differentiated H9c2 cells after 
exposure to H2O2. Mass (kDa) has been highlighted using protein standards. Image is a representative gel 
of three separate experiments.  
 
 
 
 
 
 
 
 
 
Fig 6.3 Expression pattern of proteins in differentiated H9c2 cells after exposure to H2O2. Mass (kDa) has 
been highlighted using protein standards. Image is a representative gel of three separate experiments. 
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Fig 6.4 Expression pattern of proteins in differentiated H9c2 cells after 24 h treatment with 100 µM. Mass 
(kDa) has been highlighted using protein standards. Image is a representative gel of three separate 
experiments performed separately.  
 
 
 
 
 
 
 
 
 
 
Fig 6.5 Expression pattern of proteins in differentiated H9c2 cells after 24 h treatment with 30 µM. Mass 
(kDa) has been highlighted using protein standards. Image is a representative gel of three separate 
experiments performed separately.  
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6.2 Progensis SameSpot analysis 
Images of three separate 2D gels of differentiated H9c2 cells exposed to 600 µM H2O2 for 
2 h and differentiated H9c2 cells pre-treated for 24 h with 100 µM quercetin and then 
exposed to 600 µM H2O2 for 2 h were analysed using Progensis SameSpot software as 
described in section 2.7 part ii. Images were aligned to a selected control image, a 
representative 2D gel of differentiated H9c2 cells exposed to 600 µM H2O2 for 2 h was used 
when determining the effects of 30 µM or 100 µM quercetin pre-treatment . Protein spots 
were identified by the software, which were confirmed to be viable spots by visual 
confirmation. Protein spots were then assigned an identity number. The relative density of 
the protein spots was then calculated and the change in density of the protein spots 
between the two sets of gels was analysed using the software. The significance of the 
difference in dentistry was calculated using ANOVA and the protein spots ranked according 
to their significance, and highlighted on a spot picking map of a reference gel image. Firstly, 
the difference between differentiated H9c2 cells exposed to 600 µM H2O2 for 2 h and 
differentiated H9c2 cells pre-treated for 24 h with 100 µM quercetin was investigated (Fig 
6.6), followed by the difference between differentiated H9c2 cells exposed to 600 µM H2O2 
for 2 h and differentiated H9c2 cells pre-treated for 24 h with 30 µM quercetin (Fig. 6.8). 
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Fig. 6.6 Progensis samespot analysis of protein spot densities in 100 µM quercetin pre-treated cells and 600 
µM H2O2 treated cells. The difference in density between the two sets of gels, differentiated H9c2 cells 
exposed to 600 µM H2O2 for 2 h (H2O2) and differentiated H9c2 cells pre-treated for 24 h with 100 µM 
quercetin and then exposed to 600 µM H2O2 for 2 h (Q100), of three protein spots A) spot ID 8, B) spot ID 
28 and C) spot ID 48. Each spot was shown to be of a higher density consistently in the gels of differentiated 
H9c2 cells pre-treated for 24 h with 100 µM quercetin and then exposed to 600 µM H2O2 for 2 h when 
compared to differentiated H9c2 cells exposed to 600 µM H2O2 for 2 h alone. The increase in density of 
protein spot was found to be significant for each spot using ANOVA analysis . A) *: p < 0.011 B) *: p < 0.023 
and C) *: p < 0.04. Data are expressed as the mean log normalised volume of protein spot ±S.E.M of three 
independent experiments in each group. 
From the analysis shown in Fig. 6.6 spot ID numbers 8, 28 and 48 were found to be 
significantly more dense in differentiated H9c2 cells pre-treated with 100 µM quercetin for 
24 h and then exposed to 600 µM H2O2 for 2 h when compared to differentiated H9c2 cells 
exposed to 600 µM H2O2 for 2 h. These spots were then picked from the three gels of the 
lysates from the differentiated H9c2 cells pre-treated with 100 µM quercetin for 24 h and 
then exposed to 600 µM H2O2 for 2 h, according to the spot picking map (Fig. 6.7). 
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Fig 6.7 Spot picking map of significantly changed protein spots. Spot ID 8 is shown to be approximately 37 
kDa, Spot ID 46 between 37 and 25 kDa and spot ID 28 less than 20 kDa.  
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Fig. 6.8 Progensis samespot analysis of protein spot densities in 30 µM quercetin pre-treated cells and 600 
µM H2O2 treated cells. The difference in density between the two sets of gels, differentiated H9c2 cells 
exposed to 600 µM H2O2 for 2 h (H2O2) and differentiated H9c2 cells pre-treated for 24 h with 30 µM 
quercetin and then exposed to 600 µM H2O2 for 2 h (Q30). One spot (ID 14) was found to be significantly 
(*: p < 0.028)  upregulated.   
 
 
 
 
 
 
 
 
 
 
Fig 6.9 Spot picking map of significantly changed protein spots. Spot ID 14 is shown to be 
approximately 37 kDa.  
 
 
 
 
 
 
pH 3-10 
250 kDa 
150 kDa 
100 kDa 
75 kDa 
50 kDa 
37 kDa 
25 kDa 
M
as
s  
20 kDa 
14 
152 
 
Spot ID numbers 8, 28 and 48 were found to be significantly more dense in differentiated 
H9c2 cells pre-treated with 30 µM quercetin for 24 h and then exposed to 600 µM H2O2 for 
2 h when compared to differentiated H9c2 cells exposed to 600 µM H2O2 for 2 h in addition 
to the previously identified upregulation with 100 µM quercetin pre-treatment. Spot ID 14 
was found to be uniquely upregulated with 30 µM quercetin pre-treatment (Fig. 6.8), and 
was therefore selected for identification. In addition to the 4 proteins highlighted in Figs. 
6.7 and 6.9 the cytoskeletal proteins identified in chapter 3.0 (Fig. 3.8 spot picking map) 
were also shown to be at a higher density after pre-treatment with both 30 µM and 100 
µM quercetin compared to cells exposed to 600 µM H2O2 for 2 h.   
Novel proteins that are induced to be expressed by flavonoid treatment alone was 
determined by using Progenesis SameSpot analysis to compare 2D gels produced from cells 
treated for 24 h with 30 µM ( Fig. 6.5) or 100 µM (Fig. 6.4) quercetin to each other.  Three 
protein spots (Spots ID 18, 42 and 46) were identified as significant (Fig. 6.10) and visually 
distinct to enable picking. The density of spots 18 and 46 were significantly increased in 
cells lysates from cell treated for 24 h with 30 µM quercetin (Fig. 6.11), whereas spot 42 
was significantly denser in cells lysates from cells treated with 100 µM quercetin (Fig. 6.12).  
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Fig. 6.10 Progensis samespot analysis of protein spot densities in 100 µM quercetin treated cells and 30 µM 
quercetin treated cells. The difference in density between the two sets of gels, differentiated H9c2 cells 
exposed to 100 µM quercetin for 24 h (Q100) and differentiated H9c2 cells exposed to 30 µM quercetin for 
24 h (Q30), of three protein spots A) spot ID 18, B) spot ID 42 and C) spot ID 46. The increase in density of 
protein spot was found to be significant for each spot using ANOVA analysis. A) *: p < 0.026 B) **: p < 0.006 
and C) ***: p < 0.001. Data are expressed as the mean log normalised volume of protein spot ±S.E.M of 
three independent experiments in each group.  
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Fig 6.11 Spot picking map of significantly changed protein spots after 30 µM flavonoid treatment. Spot ID 
18 is shown to be approximately 75 kDa and spot ID 46 between 37 and 50 kDa. This spot picking map uses 
a representative gel of cells treated with 100 µM as a reference image. 
 
 
 
 
 
 
 
 
 
 
Fig 6.12 Spot picking map of significantly changed protein spots after flavonoid 100 µM treatment. Spot ID 
42 is shown to be between 50 and 75 kDa. This spot picking map uses a representative gel of cells treated 
with 30 µM as a reference image. 
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6.3 MALDI-TOF MS identification of proteins 
 The identified spots were tryptically digested, and purified in preparation for MALDI-TOF 
MS according to section 2.7 part iii and iv. The identity of the proteins found to have an 
increased expression resulting from flavonoid pre-treatment and subsequent H2O2 
exposure are summarised in Table 6.13. MALDI-TOF MS/MS data of the proteins found to 
be expressed in an increased density  after 24h exposure to 100 µM or 30 µM quercetin is 
summarised in table 6.14. 
 
Table 6.13 Summary of MALDI-TOF MS data of proteins associated with flavonoid induced cytoprotection.  
The identity of the four spots tested were found to be Carbonyl reductase (NADPH) 1 (CBR1) , Galectin-1,  
Phosphatidylethanolamine-binding protein 1 (PEBP-1) and PRKC apoptosis WT1 regulator protein (PAWR). 
*PMF score > 51 considered significant (p > 0.05). †PRKC apoptosis WT1 regulator protein was identified in 
one of the three spot ID 14 analysed with a statistically significant PMF score. PMF sequence coverage and 
PMF score and RMS error are expressed as the mean of scores from 3 separate protein spots from different 
gels.         
Progenesis 
spot 
number 
mass RMS 
error 
(ppm) 
Identification  PMF 
Score* 
PMF 
Sequence 
Coverage 
(%) 
Progenesis 
score 
8 30559 44 Carbonyl  
Reductase (NADPH) 1 
53.5 56 p < 0.011 
28 14847     43 Galectin-1 54.5 60 p < 0.023 
48 20788     21 Phosphatidylethanolamine-
binding protein 1 
69.5 74 p < 0.04 
14 35844 35 PRKC apoptosis WT1 
regulator protein† 
54  p < 0.028 
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Table 6.14 Summary of MALDI-TOF MS/MS  data of protein expression associated with flavonoid exposure. 
Spot ID 18 and Spot ID 46 proteins, Glutamate receptor (ionotropic kainite 4) and Calumenin, were shown 
to be expressed at a greater density in differentiated H9c2 cells exposed to 30 µM quercetin for 24 h. Spot 
ID 42 protein, identified as Annexin-III, was shown to be expressed at a greater density in differentiated 
H9c2 cells exposed to 100 µM quercetin for 24 h.  #MS/MS score > 21 considered significant (p >0.05). RMS 
error and MS/MS score are expressed as the mean of scores from 3 separate protein spots from different 
gels.  
 
From the MALDI-TOF MS data  and the Progenesis SameSpot analysis (Table 6.13) it can be 
seen that CBR-1, galectin-1 and PEBP-1 expression is significantly increased in cell lysates 
from differentiated H9c2 cells pre-treated for 24 h with 100 µM quercetin and then 
exposed to 600 µM H2O2 for 2 h when compared to differentiated H9c2 cells exposed to 
600 µM H2O2 for 2 h. This suggests that these proteins are involved in flavonoid mediated 
cardioprotection. The MALDI-TOF MS/MS data (Table 6.14) for proteins associated with 
flavonoid treatment shows that different concentrations of quercetin induce the 
expression of different proteins.     
 
Progenesis 
spot 
number 
mass RMS 
error  
 
(ppm) 
Identification  Progenesis 
score 
MS/MS 
Score#  
MS/MS Peptides     
18 107154 92 Glutamate 
receptor, 
ionotropic 
kainate 4 
p < 0.026 26 K.GQRSNYALKILQFTR.N 
42 36300 40 Annexin-III p < 0.006 107 K.GELSGHFEDLLLAVVR.L 
46  36973  30 Calumenin p < 0.001 175 K.EEIVDKYDLFVGSQATDFGEALVR.H 
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6.4 Western blot confirmation of CBR-1 expression 
MALDI-TOF analysis identified CBR-1 expression was increased in of differentiated H9c2 
cells pre-treated for 24 h with 100 µM quercetin and then exposed to 600 µM H2O2 for 2 h 
(Table 6.13). Further confirmation of this increase in expression was investigated using 
western blotting (Fig. 6.15). CBR-1 specific antibodies were used to monitor CBR-1 
expression in differentiated H9c2 cells pre-treated for 24 h with 100 µM quercetin and then 
exposed to 600 µM H2O2 for 2 h and differentiated H9c2 cells exposed to 600 µM H2O2 for 
2 h, α-tubulin was used as a housekeeping protein to ensure even loading.  
 
 
 
 
 
 
 
 
 
 
Fig. 6.15 Effect of quercetin pre-treatment on CBR-1 expression during oxidative stress. Cells pre-treated 
with for 24 h with 100 µM quercetin and then exposed to 600 µM H2O2 for 2 h (Treated) showed a 
significantly (*: p < 0.05) increased expression of CBR-1 when compared to the control differentiated H9c2 
cells exposed to 600 µM H2O2 for 2 h. White bars represent the expression of CBR-1, black bars represent 
the expression of α-tubulin. Data are expressed as a percentage of control cells (control = 100%) and 
represent the mean ±S.E.M of three independent experiments.     
 
 
 
 
CBR1 
α-Tubulin 
 100 μM quercetin     -        -       -         +        +        + 
                 600 µM H2O2 
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From the western blot analysis and mass spectrometry data it can be seen that quercetin 
pre-treatment followed by oxidative stress causes a significant increase in CBR-1, compared 
to cells not treated with quercetin. This suggests that CBR-1 has a role in flavonoid 
mediated cardioprotection.    
6.5 Proteomics Discussion 
This present study represents the first of its kind in using proteomic methods (MALDI-TOF 
MS) to investigate the effects of quercetin pre-treatment on differentiated H9c2 cells. 
Furthermore this present study is, to the author’s knowledge, the first to report protein 
expression resulting from exposure to different quercetin concentrations alone. One 
previous study investigated the effects of quercetin pre-treatment and subsequent 
exposure to H2O2 on protein expression in mitotic H9c2 cells, however this study used 1 
mM quercetin pre-treatment for 1 h and exposure to 5 mM H2O2 for 20 min (Chen et al, 
2013). The concentration of quercetin used in the study by Chen et al (2013) is 
pharmacologically unrealistic (1 mM), as it is far greater than the known concentrations 
achievable in vivo (Labbé et al, 2009).  Furthermore, when compared to the 600 μM H2O2 
used in this present study, the 5 mM H2O2 used by Chen et al (2013) is a less realistic model 
for oxidative stress caused by ischaemic attack. The proteomic findings of this present study 
were gained using a more appropriate and accurate model of in vivo cardiomyocytes, 
pharmacologically relevant concentrations of quercetin and an appropriate concentration 
of H2O2 to simulate ischaemia. Proteomic analysis of protein expression during 100 µM and 
30 µM pre-treatment and subsequent exposure to 600 µM H2O2 identified several novel 
proteins associated with the quercetin mediated cytoprotective effects. CBR-1, Gelectin-1, 
PEBP-1 and PRKC apoptosis WT1 regulator protein (PAWR) were identified as being 
associated with flavonoid mediated cytoprotection, as their expression was up regulated 
after quercetin pre-treatment and subsequent  600 µM H2O2 exposure.  Furthermore, 
Annexin-III, calumenin and Glutamate receptor (ionotropic kainate 4) were shown to be 
associated with flavonoid treatment alone. Western blotting was used to confirm the 
increased expression of CBR1 in response to flavonoid pre-treatment and 600 µM H2O2 
exposure, and CBR1 was shown to have increased expression in cells pre-treated with 100 
µM quercetin.   
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i) CBR1 
The enzyme Carbonyl reductase 1 (CBR1) has been previously associated with protection 
against oxidative stress, although its exact function and role in ischaemia is still not fully 
understood (Kim et al, 2014). CBR1 is an NADPH-dependant cytosolic enzyme belonging to 
the short-chain dehydrogenase/reductase superfamily found in most tissue including liver, 
kidney and neuronal tissues. CBR1 metabolises endogenous substrates such as 
prostaglandin E2 and S-nitroso-glutathione, and is also able to metabolise some xenobiotic 
substrates (Ito et al, 2013). During oxidative stress, specifically exposure to hydrogen 
peroxide, CBR1 has been shown to have an inhibitory action of the phosphorylation status 
of MAPKs (p38 MAPK, ERK1/2 and JNK) and PKB  cell signalling pathways in HT-22 neuronal 
cell lines (Kim et al, 2014). The specifics of this inhibitory action remains unknown.  It is 
proposed therefore that CRB1 protects ischaemic cell death by inhibition of pro-apoptosis 
cell signalling pathways. The interactions between flavonoids, including rutin, quercetin 
and kaempferol, and CBR1 have been previously studied, although not in the context of 
cardioprotection (Carlquist et al, 2008). Most notably CBR1 has been identified as a 
resveratrol binding protein, with the 3, 5 dihydroxyl group on the ‘A’ ring of resveratrol 
identified as contributing to the binding of the CBR1 protein. The importance of the 3, 5 
dihydroxyl group is further demonstrated by the binding of CBR1 to the flavonoid  7-
monohydroxyethylrutoside, which possesses the same 3, 5 dihydroxyl group as resveratrol 
(Gonzalez-Covarrubias et al, 2008). This 3, 5 dihydroxyl group on the ‘A’ ring of the flavan 
nucleus (Fig 1.2) is also present on quercetin and its two major metabolites, thus it may 
have the potential to interact with the CBR1 enzyme in a similar manner to resveratrol and 
7-monohydroxyethylrutoside. The apparent “promiscuity” of the active site of CBR1 may 
also play in important role in the binding of flavonoid compounds, given that the enzyme 
already has a large number of substrates (Carlquist et al, 2008). The binding of several 
different flavonoids, including rutin and quercetin, to the active site of CBR1 was reported 
to cause inhibition of the reducing activity of the enzyme with regard to the interaction 
with the xenobiotic compound doxorubicin (Carlquist et al, 2008). This inhibitory action of 
flavonoids may have an effect on the potential cytoprotective activity of CBR1. CBR1 was 
shown to be up regulated in response to 24 h quercetin (100 μM) pre-treatment during 600 
μM H2O2 exposure, with MALDI-TOF MS and western blot. CBR1 has been shown to have 
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an inhibitory effect on the activation of MAPK and PKB proteins, the same effect was 
observed in differentiated H9c2 cells with flavonoid pre-treatment and H2O2 exposure (Kim 
et al, 2014). This suggests that part of the inhibitory effect of the flavonoids on ERK1/2,  JNK 
and p38 MAPK, PKB may be related to the up-regulation of CBR1. The mechanism of this 
interaction is unclear, but may involve direct binding of the flavonoid to CBR1, although 
this has been reported to decrease the reducing activity of the enzyme.    
ii) Gelectin-1 
Gelectin proteins are members of the β-galactoside-binding protein family, and are thought 
to be involved in cellular mechanisms concerned with cell-to-cell interactions, growth 
regulation and differentiation. Galectin content in cells is known to change in association 
with differentiation (Gillenwater et al, 1998). Galectin-1 was found to be up-regulated in 
response to quercetin pre-treatment and 600 μM H2O2 exposure. Another member of the 
galectin family of proteins, galectin-7, was found to be up-regulated in response to 
quercetin (1 mM) pre-treatment and 5 mM H2O2 exposure in mitotic H9c2 cells (Chen et al, 
2013). The role of Galectin-1 in flavonoid mediated cytoprotection remains unclear, but it 
can be inferred that as gelectins play a role in differentiation, it is possible they may 
influence the protein kinases ERK1/2 and PKB, which were shown to be inhibited as a result 
of quercetin pre-treatment (Gillenwater et al, 1998). If indeed gelectin-1 has an effect on 
ERK1/2 and PKB then it may be intrinsically linked to the flavonoid mediated cytoprotective 
mechanism. Further investigation into the role of galectins is needed to fully understand 
their place in the cytoprotective mechanism mediated by flavonoids.     
iii) PEBP-1 
PEBP-1 (Phosphatidylethanolamine-binding protein 1), also known as Raf-1 kinase 
inhibitory protein (RKIP) is a known negative regulator of MAPK signalling pathways, 
partially MEK/ERK1/2 pathways (Zeng et al, 2013). This negative regulation is a result of 
direct binding of PEBP-1 to Raf-1 at two activation sites.  It has therefore been shown to be 
a regulator of cellular migration, an inhibitor of non-apoptosis cell death and also displays 
tumour suppressive activity (Hassan et al, 2011). To the authors knowledge, this present 
study represents the first incidence of PEBP-1 observed in relation to flavonoid mediated 
cytoprotection. The up-regulation of PEBP-1 after flavonoid pre-treatment and 600 μM 
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H2O2 exposure links with the observed inhibition of MAPK signalling proteins. Along with 
CBR1, PEBP-1 seems to be a potential cause of the inhibition of ERK1/2, PKB, JNK and MAPK 
p38 observed after flavonoid pre-treatment. The cause of the up-regulation of PEBP-1 in 
response to flavonoid pre-treatment and 600 μM H2O2 exposure is unclear, although PEBP-
1 is known to be negatively regulated by PKC phosphorylation, which may be influenced by 
quercetin pre-treatment (Zeng et al, 2013).  
iv) PRKC apoptosis WT1 regulator protein (PAWR) 
PAWR, also known as prostate apoptosis response-4 (Par-4), is a protein implicated to be 
involved in the regulation of apoptosis, identified in prostate cancer cells. It is suggested 
that PAWR induces apoptosis by inhibition of NF-κB and activation of the pro-death Fas 
signalling pathway (Chakraborty et al, 2001). Relatively little else is known about the 
mechanism of action or role of PAWR, save that it may be able to mediate the activation of 
the ERK1/2 cell signalling pathway (Pereira et al, 2013). It has been shown that in CF-7 cells 
increased PAWR expression resulted in reduced ERK phosphorylation (Pereira et al, 2013). 
This suggests that the involvement of PAWR in flavonoid mediated cytoprotection is 
through its activity as an inhibitor of ERK1/2, along with several other proteins identified in 
the present study. Although only identified in one incidence, the involvement of PAWR is 
plausible in its capacity as a negative regulator of ERK1/2.  
v) Annexin-III 
Annexin-III was shown to be up-regulated in response to exposure to 100 μM quercetin in 
differentiated H9c2 cells when compared to 30 μM quercetin treated cells. Annexin-III is a 
member of the annexin family of calcium-dependent membrane-binding proteins. 
Members of this family are involved in cytoskeletal interactions, membrane fusion and cell 
signalling pathways in its capacity as a substrate for protein kinases (Barton et al, 1991). 
Annexin-III has been previously shown to be up-regulated in response to intracellular ROS 
generated by treatment with glucuronic acid (Kim et al, 2003). Annexin proteins were also 
identified as being up-regulated in response to quercetin pre-treatments and exposure to 
H2O2 (Chen et al, 2013). The induction of annexin-3 expression by quercetin exposure may 
result from the generation of intracellular ROS by quercetin metabolism (Metodiewa et al, 
1999). The increased expression of annexin-3, and heat shock proteins, has been shown to 
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be related to the stimulation of phosphorylation of MAPK signals such as the pro-apoptotic 
signals JNK and p38 MAPK and other MAPK proteins such as ERK1/2 (Kim et al, 2003). In 
the present study annexin-3 was observed after 24 h exposure to 100 μM quercetin, which 
was shown to have no cytotoxic effect in chapter 5. Although, this increased expression of 
annexin-3 may be a precursor to the cytotoxic effects and increased JNK, p38 MAPK, 
ERK1/2 and PKB phosphorylation observed after ≥ 48 h quercetin exposure. Further 
investigation is necessary to determine the precise role in flavonoid induced cytotoxicity. 
vi) Calumenin 
Calumenin is a universally expressed multiple EF-hand Ca2+ binding protein, of the CREC 
(Cab45, reticulocalbin, ERC-45, calumenin) family, with several functions. Calumenin is 
known to be expressed at particularly high levels in cardiac cells (Lee et al, 2013). 
Calumenin expression is increased in response to stress to the sarcoplasmic reticulum (SR), 
which can be caused by ischaemia, oxidative stress and exposure to ROS. The expression of 
calumenin has been shown to be similar to other molecular chaperones of the SR, which 
are known to have protective effects against ischaemic cell death (Lee et al, 2013). In 
neonatal rat cardiomyocytes, which are similar to the differentiated H9c2 cells used in the 
present study, increased calumenin expression was shown to have a protective effect 
against sarcoplasmic reticular stress, which can results from ischaemic attack. The 
increased expression of calumenin as a response to 24 h quercetin (30 μM) exposure may 
potentially lead to the protective effects observed in previous chapters. Calumenin is 
suggested to down-regulate pro-apoptotic cell signals (Lee et al, 2013). Exposure to 
quercetin may stimulate moderate sarcoplasmic reticular stress, leading to overexpression 
of calumenin and other SR chaperone proteins, which then allows cells to react to a 
subsequent incident of oxidative stress, this may explain partially the cytoprotective effect 
of flavonoid pre-treatment. Further investigation into the action of flavonoids on ER 
resident chaperone proteins may further expand the understanding of flavonoid mediated 
cytoprotection.  
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vii) Glutamate receptor (ionotropic kainate 4) 
Glutamate receptor (ionotropic kainate 4) or GRIK4 is a member of the ionotropic kainite 
receptor family of proteins, which are known to be activators of ERK1/2 and other 
members of the MAPK family (Fuller et al, 2001). Furthermore, flavonoids are known to be 
able to bind and activate other proteins including GABAA and GABAC receptors (Goutman 
et al, 2013). The increased expression of this protein in response to 24 h quercetin (30 μM) 
exposure may lead to the increased expression of upstream regulator proteins. This in turn 
may influence the phosphorylation state of MEK and PI3K family proteins (Fuller et al, 2001). 
This may relate to the modulation of MEK and PI3K family proteins by flavonoids during 
their cytoprotective and cytotoxic effects.  
viii) Summary 
From these findings it is clear that the mechanisms of flavonoid mediated cytoprotection 
and cytotoxicity are complex and interrelated. Several known regulators of the cell 
signalling proteins investigated in this study were identified using proteomic methods. This 
present study is the first to identify these proteins as being involved in the cytoprotective 
and cytotoxic mechanisms of flavonoids.   
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Conclusions 
and further 
work 
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7.1 Results summary and further work 
This present study for the first time used differentiated H9c2 cells to investigate the 
cytoprotective and cytotoxic effects of exposure to flavonoids. Mitotic H9c2 cells which 
have been used in previous studies, have a great many metabolic and morphological 
differences to differentiated H9c2 cells, which provide a better model for in vivo 
cardiomyocytes (Gutiérrez-Venegas et al, 2010; Angeloni et al, 2012; Angeloni et al, 2007; 
Sun et al, 2012; Kim et al, 2010; Mojzisová et al, 2009; Pereira et al, 2011; Dangel et al, 
1996; Branco et al, 2013). This body of work further demonstrated these differences by 
investigating protein expression with proteomic methods for the first time. It was shown 
that differentiated H9c2 cell express tropomyosin alpha-1, alpha-4 and beta chain in a 
significantly greater concentration than mitotic H9c2 cells. Actin and vimentin were also 
shown to be expressed in a significantly greater concentration than mitotic H9c2 cells. The 
increased sensitivity of differentiated H9c2 cells to oxidative stress was also demonstrated. 
Considering these differences, as well as the other reported differences between mitotic 
and differentiated H9c2 cells, future studies using H9c2 cells as a model for in vivo 
cardiomyocytes should consider using the differentiated H9c2 cells as the model cell.  
From the investigation into flavonoid mediated cytoprotection concluded that quercetin 
was shown to have a cytoprotective effect, specifically able to protect differentiated H9c2 
cells from H2O2 treatment with a pre-treatment time of 1 h as well as 24 h with 
concentrations of quercetin about 30 µM. A pre-treatment of 24 h with 100 µM myricetin 
was necessary to protect differentiated H9c2 cells from H2O2 treatment induced cell death. 
Kaempferol was not observed to induce a significant protective effect after 24 h pre-
treatment with a 1-100 µM range of concentrations. Protection from hypoxia induced cell 
death was achieved with 24 h pre-treatment with a concentration of 100 µM quercetin. Of 
the two quercetin metabolites tested 3’-O-methyl quercetin was found to exhibit a similar 
protective effect to quercetin against cell death caused by H2O2 exposure, whereas quercetin-
3-glucorinde showed no protective effect. As previously stated in chapter 4, the evidence 
for the plasma levels of flavonoid achievable in vivo suggest that the observations of 
cytoprotection in this present study may not translate to observable cardioprotection 
resulting from dietary flavonoids in humans (Labbé et al, 2009). However, the results 
presented in chapter 4 highlight that quercetin has potent cellular effects under laboratory 
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condition, particularly with regard to MAPK and PI3K signalling. Further research is required 
into the intracellular accumulation of flavonoids and their metabolites, this will lead to an 
enhanced understanding of the conditions necessary for flavonoids to provoke a 
cytoprotective effect under laboratory conditions as well as in vivo. This present study 
proposes that a major mechanism of flavonoid mediated cytoprotection in differentiated 
H9c2 cells is inhibition of cell signalling molecules, which is supported by observations 
made in several other studies (Gutiérrez-Venegas et al, 2010; Mansuri et al, 2014; Sun et 
al, 2012; Angeloni et al, 2007). However, specific kinase inhibitors were unable to mimic the 
cytoprotective effect of quercetin, necessitating further studies into the relationship between 
kinase inhibition and cytoprotection. As quercetin is a non-specific inhibitor it may be able to 
inhibit multiple kinases at the same time, therefore a study into the effect of multiple 
inhibitors used concomitantly on differentiated H9c2 cells may provide more insight into this 
mechanism.   
Chapter 5 showed that, as well as having a cytoprotective effect, quercetin and 3’-O-methyl 
quercetin had a cytotoxic effect on differentiated H9c2 cells after 48 h exposure. Prolonged 
exposure to 100 µM quercetin was also shown to coincide with significant phosphorylation of 
ERK1/2, PKB, p38 MAPK and JNK after 72 h, as well as causing significant activation of Caspase-
3 after 48 h. Investigation into intracellular ROS generation revealed significant levels after 48 
and 72 h exposure to 100 µM quercetin. These observations agree with previous studies that 
have shown the activation of these kinases by ROS, and the pro-oxidant intracellular 
metabolism of quercetin (Kamata and Hirata, 1999; Clerk et al, 1998; Pham et al, 2000; 
Takeishi et al, 1999; Metodiewa et al, 1999). As with the concentration of flavonoid 
required to invoke a cytoprotective effect, the concentrations of flavonoid it induce 
cytotoxicity are greater than those than can be achieved in vivo from dietary sources (Labbé 
et al, 2009). This observation further demonstrates the need for further research into the 
intracellular accumulation of flavonoids and the concentration of flavonoid retained by 
cells. As this study showed that at high concentrations intracellular ROS generation 
resulting from quercetin exposure likely leads to cytotoxicity.      
 The proteomic investigation into the effect of quercetin treatment on protein expression 
after oxidative stress revealed that several proteins associated with cell signal regulation 
are expressed. Specifically CBR-1, Geletin-1, PEBP-1 and PAWR were shown to have 
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increased expression in differentiated H9c2 cells after exposure to oxidative stress from 
H2O2. Of these proteins CBR-1 and PEBP-1 are known to have MAPK regulatory functions, 
and PAWR is thought to have a similar function (Kim et al, 2014; Zeng et al, 2013; Pereira 
et al, 2013). These results show that quercetin may influence a number of MAPK regulatory 
mechanisms downstream of ERK1/2.  
Three proteins were shown to be expressed after exposure of differentiated H9c2 cells to 
100 and 30 µM quercetin. Calumenin has particular importance to this present study as it 
is reported to be expressed in response to SR stress, leading to a protective effect (Lee et 
al, 2013). This result suggests that exposure to quercetin (30 µM) may lead to SR stress, 
and induce a protective effect during subsequent episodes of oxidative stress. Although 
this was only observed after exposure to 30 µM quercetin, which is greater than the 
maximum plasma concentration of flavonoids achievable from dietary sources, this 
observation draws attention to another potential mechanism for flavonoid induced 
cytoprotection. Further studies investigating protein expression in H9c2 cells utilising lower 
concentrations of flavonoid, in particular concentrations that could be achieved in vivo, 
would further illustrate the effects of flavonoid on protein expression that may lead to a 
cytoprotective effect.  
To be translatable to understanding flavonoid mediated cardioprotection in vivo, future 
studies should focus on investigating the effects of concentrations of flavonoid that are 
achievable via dietary consumption. More studies into the intracellular accumulation of 
flavonoids are required to reveal the exact concentrations of flavonoid achievable in vivo 
heart cells. As this present study and previous studies have shown, flavonoids are able to 
have potent effects in model cell lines at concentrations above 30 µM (Gutiérrez-Venegas 
et al, 2010; Mansuri et al, 2014; Sun et al, 2012; Angeloni et al, 2007). Using an animal model 
to study the effects of dietary flavonoids will further develop the understanding of this 
mechanism, as well as the general mechanism of flavonoid mediated protection from CVD.  
 As flavonoids are ubiquitous in the diet, and numerous flavonoids are present in a single 
dietary source, future studies could consider using mixtures of flavonoids to better reflect how 
flavonoids are encountered by in vivo cells. Furthermore, other plant polyphenols such as 
tannins could be introduced to this mixture to simulate the polyphenolic content of wine.  
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7.2 General conclusions 
This present study has provided novel data contributing to the understanding of the 
cardioprotective mechanisms of dietary flavonoids and their metabolites, specifically in the 
model H9c2 cell line. For the first time, investigations in to the protective mechanisms of 
dietary flavonoids were performed using differentiated H9c2 cells as a model for in vivo 
cardiomyocytes. Furthermore the cytotoxic effect of long term exposure to flavonoids and 
flavonoid metabolites was investigated, with flavonoids showing some cytotoxic activity. 
The findings of this study suggest that flavonoids are potent modulators of cell signalling 
molecules under certain conditions, and that this can be both beneficial and fatal to cells. 
This is further demonstrated by the novel proteins identified in this study, many of which 
play a role in the regulation of MAPK or PI3K cell signalling pathways. Although, the 
concentrations required it provoke these effects was greater than concentrations available 
to in vivo cardiomyocytes.  
7.3 Concluding remarks 
In conclusion, this study has shown that flavonoids, particularly quercetin, can provide 
protection against hypoxia and H2O2 induced cell death in differentiated H9c2 cells. This 
protection is most probably due to the modulation of cell signalling molecules of the MAPK 
and PI3K families. Several novel proteins associated with MAPK and PI3K regulation were 
shown to be upregulated in the presence of quercetin. Furthermore, flavonoid induced 
cytotoxicity was shown to occur after extended periods of exposure, most likely due to 
intracellular metabolism of flavonoids forming pro-oxidants and ROS. The data presented 
in this present study will contribute to increasing the body of knowledge concerning the 
protective effects of flavonoids, and their cytotoxic potential. Hopefully this study will lead 
to further investigations into the complex nature of flavonoid induced cytoprotection, 
leading eventually to more effect therapies against ischaemic attacks.    
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Appendix I 
Bruker peptide calibration standard II content 
 
Peptide Average Monoisotopic Mass  
Angiotensin II 1046.5418 
Angiotensin I 1296.6848 
Substance P 1347.7354 
Bombesin 1619.8223 
ACTH (1-17) 2093.0862 
ACTH (18-39) 2465.1983 
Somatostatin 2 3147.4710 
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Appendix 2 
Proteomic gels produced by two-dimensional gel electrophoresis 
 
 
A.1 Proteomic gels of differentiated H9c2 cell lysates. 
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A.2 Proteomic gels of mitotic H9c2 cell lysates. 
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A.3 Proteomic gels of differentiated H9c2 cells exposed for 2 h to 600 µM H2O2 cell lysates. 
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A.4 Proteomic gels of differentiated H9c2 cells 24 h pre-treated with 30 µM quercetin followed by 2 h 
exposure to 600 µM H2O2 cell lysates. 
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A.5 Proteomic gels of differentiated H9c2 cells 24 h pre-treated with 100 µM quercetin followed by 2 h 
exposure to 600 µM H2O2 cell lysates. 
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A.6 Proteomic gels of differentiated H9c2 cells exposed for 24 h to 30 µM quercetin cell lysates. 
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A.7 Proteomic gels of differentiated H9c2 cells exposed for 24 h to 100 µM quercetin cell lysates. 
 
 
 
 
 
 
 
 
  
